0000844856-23-000016.txt : 20230505 0000844856-23-000016.hdr.sgml : 20230505 20230505171554 ACCESSION NUMBER: 0000844856-23-000016 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthier Choices Management Corp. CENTRAL INDEX KEY: 0000844856 STANDARD INDUSTRIAL CLASSIFICATION: TOBACCO PRODUCTS [2100] IRS NUMBER: 841070932 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36469 FILM NUMBER: 23894986 BUSINESS ADDRESS: STREET 1: 3800 NORTH 28TH WAY CITY: HOLLYWOOD STATE: FL ZIP: 33020 BUSINESS PHONE: 305-600-5004 MAIL ADDRESS: STREET 1: 3800 NORTH 28TH WAY CITY: HOLLYWOOD STATE: FL ZIP: 33020 FORMER COMPANY: FORMER CONFORMED NAME: VAPOR CORP. DATE OF NAME CHANGE: 20100108 FORMER COMPANY: FORMER CONFORMED NAME: MILLER DIVERSIFIED CORP DATE OF NAME CHANGE: 19920703 10-Q 1 form10q.htm QUARTERLY REPORT
graphic

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

Or

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 001-36469

HEALTHIER CHOICES MANAGEMENT CORP.
(Exact name of Registrant as specified in its charter)

Delaware
 
84-1070932
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
     
3800 North 28Th Way
   
Hollywood, Florida
 
33020
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: 305-600-5004

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
 
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
 
HCMC
 
OTC Pink Marketplace

As of May 4, 2023, there were 463,266,632,384 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.




TABLE OF CONTENTS

PAGE
   
1
   
1
   
1
   
2
   
3
   
4
   
5
   
15
   
21
   
21
   
23
   
23
   
24
   
24
   
24
   
24
   
24
   
24
   
26
   
 
   
 
   
 
   
 



PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

HEALTHIER CHOICES MANAGEMENT CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS


 
March 31, 2023 (Unaudited)
 
December 31,
2022
ASSETS
         
CURRENT ASSETS
         
Cash
$
19,765,487
 
$
22,911,892
Accounts receivable, net
 
100,633
   
55,815
Notes receivable
 
172,905
   
189,225
Inventories
 
3,967,497
   
3,817,192
Prepaid expenses and vendor deposits
 
577,569
   
322,182
Investment
 
5,314
   
9,771
Other current assets
 
944,470
   
1,224,171
Restricted cash
 
1,728,232
   
1,778,232
TOTAL CURRENT ASSETS
 
27,262,107
   
30,308,480
           
Property, plant, and equipment, net of accumulated depreciation
 
3,096,599
   
3,112,908
Intangible assets, net of accumulated amortization
 
4,774,609
   
5,005,511
Goodwill
 
5,747,000
   
5,747,000
Right of use asset – operating lease, net
 
11,003,033
   
10,604,935
Other assets
 
475,425
   
476,196
           
TOTAL ASSETS
$
52,358,773
 
$
55,255,030
           
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
         
CURRENT LIABILITIES
         
Accounts payable and accrued expenses
$
4,977,089
 
$
5,715,234
Contingent consideration
 
797,000
   
774,900
Contract liabilities
 
200,372
   
198,606
Line of credit
 
453,232
   
453,232
Current portion of loan payment
 
543,945
   
536,542
Operating lease liability, current
 
2,036,415
   
2,228,852
TOTAL CURRENT LIABILITIES
 
9,008,053
   
9,907,366
           
Loan payable, net of current portion
 
2,239,044
   
2,378,061
Operating lease liability, net of current
 
8,657,428
   
8,041,504
TOTAL LIABILITIES
 
19,904,525
   
20,326,931
           
COMMITMENTS AND CONTINGENCIES (SEE NOTE 13)
 
   
           
CONVERTIBLE PREFERRED STOCK
         
Series E redeemable convertible preferred stock, $1,000 par value per share, 14,722 shares authorized, 13,497 shares and 14,722 shares issued and outstanding as of  March 31, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $13.5 million and $14.7 million as of March 31, 2023 and December 31, 2022, respectively
 
13,496,525
   
14,722,075
STOCKHOLDERS’ EQUITY
         
Series D convertible preferred stock, $1,000 par value per share, 5,000 shares authorized; 800 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $0.8 million
 
800,000
   
800,000
Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 346,441,632,384 and 339,741,632,384 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
 
34,644,163
   
33,974,163
Additional paid-in capital
 
29,034,802
   
29,045,802
Accumulated deficit
 
(45,521,242)
   
(43,613,941)
TOTAL STOCKHOLDERS’ EQUITY
 
18,957,723
   
20,206,024
           
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
$
52,358,773
 
$
55,255,030

See notes to unaudited condensed consolidated financial statements


1


HEALTHIER CHOICES MANAGEMENT CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

 
Three Months Ended March 31,
 
2023
 
2022
SALES
         
Vapor sales, net
$
38
 
$
249,563
Grocery sales, net
 
13,559,706
   
4,798,990
TOTAL SALES, NET
 
13,559,744
   
5,048,553
           
Cost of sales vapor
 
653
   
111,684
Cost of sales grocery
 
8,644,700
   
2,964,355
GROSS PROFIT
 
4,914,391
   
1,972,514
           
OPERATING EXPENSES
 
6,897,438
   
3,327,420
           
LOSS FROM OPERATIONS
 
(1,983,047)
   
(1,354,906)
           
OTHER INCOME (EXPENSE)
         
(Loss) gain on investment
 
(4,457)
   
3,514
Other (expense) income, net
 
(17,450)
   
16,874
Interest income, net
 
97,653
   
16,603
Total other income (expense), net
 
75,746
   
36,991
           
Net loss
$
(1,907,301)
 
$
(1,317,915)
           
Induced conversions of Preferred Stock
 
(61,000)
   
-
           
Net loss attributable to common stockholders
$
(1,968,301)
 
$
-
           
NET LOSS PER SHARE-BASIC AND DILUTED
$
0.00
 
$
0.00
           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC AND DILUTED
 
341,671,076,830
   
339,741,632,384

See notes to unaudited condensed consolidated financial statements

2


HEALTHIER CHOICES MANAGEMENT CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2023 and 2022
(Unaudited)
 
Series E Convertible Preferred Stock
   
Convertible
Preferred Stock
   
Common Stock
   
Additional
Paid-In
   
Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Deficit
   
Total
 
Balance – January 1, 2023
   
14,722
   
$
14,722,075
     
800
   
$
800,000
     
339,741,632,384
   
$
33,974,163
   
$
29,045,802
   
$
(43,613,941
)
 
$
20,206,024
 
Series E convertible preferred stock redeemed
   
(556
)
   
(555,550
)
   
-
     
-
     
-
     
-
     
-
     
-
     
-
 
Conversion of series E convertible preferred stock
   
(670
)
   
(670,000
)
   
-
     
-
     
6,700,000,000
     
670,000
     
-
     
-
     
670,000
 
Induced conversions of preferred stock
   
-
     
-
     
-
     
-
     
-
     
-
     
(61,000
)
   
-
     
(61,000
)
Stock-based compensation expense
   
-
     
-
     
-
     
-
     
-
     
-
     
50,000
     
-
     
50,000
 
Net loss
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(1,907,301
)
   
(1,907,301
)
Balance – March 31, 2023
   
13,497
   
$
13,496,525
     
800
   
$
800,000
     
346,441,632,384
   
$
34,644,163
   
$
29,034,802
   
$
(45,521,242
)
 
$
18,957,723
 



Series E Convertible Preferred Stock
 
Convertible
Preferred Stock
 
Common Stock
 
Additional
Paid-In
 
Accumulated
     
 
Shares
   
Amount
 
Shares
 
Amount
 
Shares
 
Amount
 
Capital
 
Deficit
 
Total
 
Balance – January 1, 2022
   
-
     
-
     
800
   
$
800,000
     
339,741,632,384
   
$
33,974,163
   
$
30,855,824
   
$
(36,396,330
)
 
$
29,233,657
 
Net loss
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
(1,317,915
)
   
(1,317,915
)
Balance – March 31, 2022
   
-
     
-
     
800
   
$
800,000
     
339,741,632,384
   
$
33,974,163
   
$
30,855,824
   
$
(37,714,245
)
 
$
27,915,742
 

See notes to unaudited condensed consolidated financial statements

3


HEALTHIER CHOICES MANAGEMENT CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 
Three Months Ended March 31,
 
2023
 
2022
OPERATING ACTIVITIES
         
Net loss
$
(1,907,301)
 
$
(1,317,915)
Adjustments to reconcile net loss to net cash used in operating activities:
         
Depreciation and amortization
 
373,462
   
193,322
Loss (gain) on investment
 
4,457
   
(3,514)
Amortization of right-of-use asset
 
695,192
   
177,643
Write-down of obsolete and slow-moving inventory
 
523,087
   
115,842
Stock-based compensation expense
 
50,000
   
-
   Change in contingent consideration
 
22,100
   
-
Changes in operating assets and liabilities:
         
Accounts receivable
 
(44,818)
   
(9,031)
Inventories
 
(673,392)
   
(160,312)
Prepaid expenses and vendor deposits
 
(255,387)
   
157,641
Other current assets
 
279,701
   
-
Other assets
 
771
   
(27,446)
Accounts payable and accrued expenses
 
(744,145)
   
415,957
Contract liabilities
 
1,766
   
(61,965)
Lease liability
 
(669,803)
   
(159,851)
NET CASH USED IN OPERATING ACTIVITIES
 
(2,344,310)
   
(679,629)
           
INVESTING ACTIVITIES
         
Acquisition of Mother Earth's Storehouse
 
-
   
(5,150,000)
Collection of note receivable
 
16,320
   
13,772
Purchases of property and equipment
 
(126,251)
   
(127,275)
NET CASH USED IN INVESTING ACTIVITIES
 
(109,931)
   
(5,263,503)
           
FINANCING ACTIVITIES
         
Proceeds from line of credit
 
-
   
35,196
Principal payments on loan payable
 
(131,614)
   
(638)
Payment of induced conversions of preferred stock
 
(55,000)
   
-
Payment for series E preferred stock redemption
 
(555,550)
   
-
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES
 
(742,164)
   
34,558
           
NET DECREASE IN CASH AND RESTRICTED CASH
 
(3,196,405)
   
(5,908,574)
CASH AND RESTRICTED CASH— BEGINNING OF PERIOD
 
24,690,124
   
26,496,404
CASH AND RESTRICTED CASH — END OF PERIOD
$
21,493,719
 
$
20,587,830
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
         
Cash paid for interest
$
44,478
 
$
1,428
Cash paid for income tax
$
-
 
$
-
NON-CASH INVESTING AND FINANCING ACTIVITIES
         
Issuance of common stock in connection with series E preferred stock conversion
$
670,000
 
$
-
Right-of-use assets obtained in exchange for operating lease liabilities
$
1,093,290
 
$
1,797,667
Accrued payment of induced conversions of preferred stock
$
6,000
 
$
-

See notes to unaudited condensed consolidated financial statements

4


HEALTHIER CHOICES MANAGEMENT CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. ORGANIZATION

Organization

Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives.

Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio. 

Through its wholly owned subsidiaries, the Company operates:

Ada’s Natural Market, a natural and organic grocery store offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.

Paradise Health & Nutrition’s three stores that likewise offer fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.

Mother Earth’s Storehouse, a two-store organic and health food and vitamin chain in New York’s Hudson Valley, a business that has been in existence for over 40 years.

Greens Natural Foods’ eight stores in New York and New Jersey, offering a selection of 100% organic produce and all-natural, non-GMO groceries & bulk foods; a wide selection of local products; an organic juice and smoothie bar; a fresh foods department, which offers fresh and healthy “grab & go” foods; a full selection of vitamins & supplements; as well as health and beauty products

Through its wholly owned subsidiary, Healthy Choice Wellness, LLC, the Company operates:

Licensing agreements for Healthy Choice Wellness Centers located at the Casbah Spa and Salon in Fort Lauderdale, FL, Boston Direct Health in Boston, MA and Green Care Medical Services in Chicago, IL.

These centers offer multiple vitamin drip mixes and intramuscular shots for clients to choose from that are designed to help boost immunity, fight fatigue and stress, reduce inflammation, enhance weight loss, and efficiently deliver antioxidants and anti-aging mixes. Additionally, there are IV vitamin mixes and shots for health, beauty, and re-hydration.

Through its wholly owned subsidiary, Healthy U Wholesale, Inc, the Company sells vitamins and supplements, as well as health, beauty, and personal care products on its website www.TheVitaminStore.com.

Additionally, the Company markets its patented the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally.

Spin-Off

The Company has commenced steps to spin off ("Spin-Off") its grocery segment and wellness business into a new publicly traded company (hereinafter referred to as “NewCo”). NewCo will continue the path of growth in the wellness verticals started by HCMC and explore other growth opportunities that comport with HCMC’s healthier lifestyle mission. Following the Spin-Off, HCMC will retain its entire patent suite, the Q-Cup® brand, and continue to develop its patent suite through R&D as well as continuing its path of enforcing its patent rights against infringers and attempting to monetize said patents through licensing deals.

At the time of the Spin-Off, HCMC will distribute all the outstanding shares of Common Stock held by it on a pro rata basis to holders of HCMC’s common stock. Shares of HCMC’s common stock outstanding as of the record date for the Spin-Off (the “Record Date”), will entitle the holder thereof to receive a certain number of shares of Common Stock in NewCo. The distribution will be made in book-entry form by a distribution agent. Fractional shares of Common Stock will not be distributed in the Spin-Off and any fractional amounts will be rounded down. Please see more disclosure in Note 12 Stockholder Equity.
5



Note 2. LIQUIDITY

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.

The Company currently and historically has reported net losses and cash outflows from operations. As of March 31, 2023, the Company had cash of approximately $19.8 million and working capital of $18.3 million. In the past, the Company financed its operations primarily through issuances of common stock and convertible preferred stock. The Company believes current cash on hand is sufficient to meet its obligations and capital requirements for at least the next twelve months from the date of filing.


Note 3. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-X and do not include all the information and disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The Company has made estimates and judgments affecting the amounts reported in the Company’s unaudited condensed consolidated financial statements and the accompanying notes. The actual results experienced by the Company may differ materially from the Company’s estimates. The condensed consolidated financial information is unaudited but reflects all normal adjustments that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company’s audited 2022 financial statements contained in the above referenced Form 10-K. Results of the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2022 Annual Report.


Reclassification

Certain amounts in the condensed consolidated financial statements and related notes have been reclassified to conform to the current year presentation. Such reclassifications do not impact the Company's previously reported financial position or net income (loss). $75,000 inventory shrink was originally presented in the statement of cash flow under change in operating assets inventory in cash used in operating activities for three months ended March 31, 2022, it was reclassified to write-down of obsolete and slow-moving inventory under cash used in operating activities in the statement of cash flow.
6



Note 4. CONCENTRATIONS

Cash and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash is concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. The Company did not have any cash equivalent as of March 31, 2023, and  December 31, 2022.

A summary of the financial institution that had cash in excess of FDIC limits of $250,000 on March 31, 2023 and December 31, 2022 is presented below:

March 31, 2023
 
December 31, 2022
 
Total cash in excess of FDIC limits of $250,000
 
$
18,646,360
   
$
21,682,144
 

The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company has not experienced any losses in such accounts.

The following table provides a reconciliation of cash and restricted cash to amounts shown in unaudited condensed consolidated statements of cash flow

 
March 31, 2023
   
March 31, 2022
 
Cash
 
$
19,765,487
   
$
20,587,830
 
Restricted cash
   
1,728,232
     
-
 
Total cash and restricted cash
 
$
21,493,719
   
$
20,587,830
 

Restricted Cash
 
The Company's restricted cash consisted of cash balances which were restricted as to withdrawal or usage under the August 18, 2022 securities purchase agreement for the purpose of funding any amounts due under the Series E Certificate of Designation upon the redemption of the Series E Preferred Stock. The balance also included cash held  in the collateral account to cover the cash draw from the line of credit.

7


Note 5. SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES

In accordance with FASB ASC 280, "Disclosures about Segment of an enterprise and related information", the Company determined it has two reportable segments: grocery and vapor. There are no inter-segment revenues.

The Company's general and administrative costs are not segment specific. As a result, all operating expenses are not managed on segment basis.

The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 
Three Months Ended March 31,
 
   
2023
   
2022
 
Vapor
 
$
38
   
$
249,563
 
Grocery
   
13,559,706
     
4,798,990
 
Total revenue
 
$
13,559,744
   
$
5,048,553
 
                 
Retail Vapor
 
$
38
   
$
249,563
 
Retail Grocery
   
11,613,730
     
4,283,288
 
Food service/restaurant
   
1,943,914
     
509,810
 
Online/eCommerce
   
2,062
     
5,892
 
Total revenue
 
$
13,559,744
   
$
5,048,553
 
                 
Loss from operations - Vapor
   
(6,672
)
   
(18,967
)
(Loss) income from operations - Grocery
   
(276,842
)
   
163,936
 
Corporate items
   
(1,699,533
)
   
(1,499,875
)
Total loss from operations
 
$
(1,983,047
)
 
$
(1,354,906
)



Note 6. NOTES RECEIVABLE AND OTHER INCOME

On September 6, 2018, the Company entered into a secured, 36-month promissory note (the “Note”) with VPR Brands L.P. for $582,260. The Note bears an interest rate of 7.00%, which payments thereunder are $4,141 weekly. The Company records all proceeds related to the interest of the Note as interest income as proceeds are received.

On August 31, 2022, the Company amended and restated the Note (the "Amended Note") with VPR Brands L.P. to extend the maturity date for one year. The outstanding balance for the Amended Note is $211,355. The Amended Note bears an interest rate of 7.00%, which payments thereunder are $1,500 weekly, with such payments commencing as of September 3, 2022. The Amended Note has a balloon payment of $145,931 for all remaining accrued interest and principal balance due in the final week of the 1-year extension of the Amended Note.

A summary of the Amended Note as of March 31, 2023 and December 31, 2022 is presented below:

Description
 
March 31, 2023
 
December 31, 2022
Promissory Note
 
$
172,905
 
$
189,225


8


Note 7. ACQUISITION

On October 14, 2022, the Company through its wholly owned subsidiary, Healthy Choice Markets IV, LLC, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Dean’s Natural Food Market of Shrewsbury, Inc., a New Jersey corporation, Green’s Natural Foods, Inc., a Delaware corporation, Dean’s Natural Food Market of Chester, LLC, a New Jersey limited liability company, Dean’s Natural Food Market of Basking Ridge, LLC, a New Jersey limited liability company, and Dean’s Natural Food Market, Inc., a New Jersey corporation (collectively, the “Sellers”), and shareholders of the Sellers. Pursuant to the Purchase Agreement, the Company acquired certain assets and assumed certain liabilities of an organic and natural health food and vitamin chain with eight store locations in New York and northern and central New Jersey (the “Stores”).

The cash purchase price under the Asset Purchase Agreement was $5,142,000, with $3,000,000 seller financing in the form of promissory note. In addition, the seller is entitled to a contingent earn-out based on a certain revenue threshold within the one-year period of the closing.

The Company recorded $1,108,000 of contingent consideration based on the estimated financial performance for the one year following closing.  The contingent consideration was discounted at an interest rate of 3.8%, which represents the Company's weighted average discount rate.  Contingent consideration related to the acquisition is recorded at fair value (level 3) with changes in fair value recorded in other expense (income), net.

The following table summarizes the change in fair value of contingent consideration from acquisition date to March 31, 2023:

 
Fair Market Value - Level 3
 
Balance as of October 14, 2022
 
$
1,108,000
 
Remeasurement
   
(333,100
)
Balance as of December 31, 2022
 
$
774,900
 
Remeasurement
   
22,100
 
Balance as of March 31, 2023
 
$
797,000
 

The following table summarizes the purchase price allocation based on fair values of the net assets acquired at the acquisition date:

 
October 14, 2022
 
Purchase Consideration
     
Cash consideration paid
 
$
5,142,000
 
Promissory note
   
3,000,000
 
Contingent consideration issued to Green's Natural seller
   
1,108,000
 
Total Purchase Consideration
 
$
9,250,000
 
         
Purchase price allocation
       
Inventory
 
$
1,642,000
 
Property and equipment
   
1,478,000
 
Intangible assets
   
3,251,000
 
Right of use asset - Operating lease
   
6,427,000
 
Other liabilities
   
(211,000
)
Operating lease liability
   
(6,427,000
)
Goodwill
   
3,090,000
 
Net assets acquired
 
$
9,250,000
 
         
Finite-lived intangible assets
       
Trade Names (8 years)
 
$
1,133,000
 
Customer Relationships (6 years)
   
1,103,000
 
Non-Compete Agreement (5 years)
   
1,015,000
 
Total intangible assets
 
$
3,251,000
 

9


The acquisition is structured as asset purchase in a business combination, and goodwill is tax-deductible, and amortizable over 15 years for tax purpose.

Revenue and Earnings

The following table represents the combined pro forma revenue and net loss for the three months ended March 31, 2022:

   
For Three Months Ended
 March 31, 2022
Sales
 
$
13,156,447
Net loss
 
$
(1,585,281)

The combined proforma revenue and net loss for the three month period ended March 31, 2022 were prepared as though acquisition occurred as of January 1, 2022.


Note 8. PROPERTY, PLANT, AND EQUIPMENT

Property, plant, and equipment consist of the following:
   
March 31, 2023
   
December 31, 2022
Displays
 
$
312,146
   
$
312,146
Building
   
575,000
     
575,000
Furniture and fixtures
   
572,224
     
560,256
Leasehold improvements
   
1,910,719
     
1,910,719
Computer hardware & equipment
   
177,652
     
160,210
Other
   
684,443
     
587,602
     
4,232,184
     
4,105,933
Less: accumulated depreciation and amortization
   
(1,135,585)
     
(993,025)
Total property, plant, and equipment
 
$
3,096,599
   
$
3,112,908

The Company incurred approximately $142,560 and $49,936 of depreciation expense for the three months ended March 31, 2023 and 2022, respectively.

10



Note 9. INTANGIBLE ASSETS

Intangible assets, net are as follows:

March 31, 2023
 
Useful Lives (Years)
 
Gross
Carrying Amount
 
Accumulated
Amortization
 
Net
Carrying Amount
Trade names
   
8-10 years
 
$
2,569,000
 
$
(800,880)
 
$
1,768,120
Customer relationships
   
4-6 years
   
2,669,000
   
(1,107,722)
   
1,561,278
Patents
   
10 years
   
384,665
   
(169,587)
   
215,078
Non-compete
   
4-5 years
   
1,602,000
   
(371,867)
   
1,230,133
Intangible assets, net
       
$
7,224,665
 
$
(2,450,056)
 
$
4,774,609

December 31, 2022
 
Useful Lives (Years)
 
Gross
Carrying Amount
 
Accumulated
Amortization
 
Net
Carrying Amount
Trade names
   
8-10 years
 
 $
2,569,000
   
(725,723)
 
 $
1,843,277
Customer relationships
   
4-6 years
   
2,669,000
   
(1,033,306)
   
1,635,694
Patents
   
10 years
   
384,665
   
(159,658)
   
225,007
Non-compete
   
4-5 years
   
1,602,000
   
(300,467)
   
1,301,533
Intangible assets, net
       
$
7,224,665
 
$
(2,219,154)
 
$
5,005,511

Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately  $230,902 and $143,386 for the three months ended March 31, 2023 and 2022, respectively. Future annual estimated amortization expense is as follows:

Years ending December 31,
     
2023 (remaining nine months)
 
$
692,706
 
2024
   
923,608
 
2025
   
918,108
 
2026
   
840,127
 
2027
   
695,498
 
Thereafter
   
704,562
 
Total
 
$
4,774,609
 

11

Note 10. CONTRACT LIABILITIES

A summary of the contract liabilities activity at March 31, 2023 and December 31, 2022 is presented below:


 
March 31, 2023
   
December 31, 2022
 
Beginning balance as January 1,
 
$
198,606
   
$
23,178
 
Issued
   
695,438
     
859,383
 
Redeemed
   
(640,160
)
   
(628,012
)
Breakage recognized
   
(53,512
)
   
(55,943
)
Ending balance
 
$
200,372
   
$
198,606
 

Note 11. DEBT

The following table provides a breakdown of the Company's debt as of March 31, 2023 and December 31, 2022 is presented below:

_
 
March 31, 2023
   
December 31, 2022
 
Promissory note
 
$
2,782,847
   
$
2,913,788
 
Other debt
   
142
     
815
 
Total debt
 
$
2,782,989
   
$
2,914,603
 
Current portion of long-term debt
   
(543,945
)
   
(536,542
)
Long-term debt
 
$
2,239,044
   
$
2,378,061
 
 

Note 12. STOCKHOLDERS’ EQUITY

Series E Convertible Preferred Stock

On August 18, 2022, the Company entered into a Securities Purchase Agreement ("Series E Preferred Stock") pursuant to which the Company sold and issued 14,722 shares of its Series E Redeemable Convertible Preferred Stock to institutional investors for $1,000 per share or an aggregate subscription of $13.25 million. The number of shares issued to each participant is based on subscription amount multiplied by conversion rate of 1.1111. The Company also incurred offering costs of approximately $410,000, which covers legal and consulting fee.
The HCMC Series E Preferred Stock shall have voting rights on as converted basis at the Company’s next stockholders’ meeting. However, as long as any shares of HCMC Series E Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the HCMC Series E Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the HCMC Series E Preferred Stock or alter or amend the Certificate of Designation, (b) increase the number of authorized shares of HCMC Series E Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing. Each share of Series E Preferred Stock shall be convertible, at any time and from time to time at the option of the Holder thereof, into that number of shares of Common Stock (subject to the beneficial ownership limitations). The initial conversion price for the HCMC Series E Preferred Stock shall equal $0.0001.
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of HCMC Series E Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to $1,000 per share of Series E Preferred Stock.

Unless earlier converted or extended as set forth below, a holder may require the redemption of all or a portion of the stated value of the HCMC Series E Preferred Stock either (1) six months after closing or (2) the time at which the balance is due and payable upon an event of default.

On March 1, 2023, the Company entered into a First Amendment to HCMC Series E Preferred Stock with each purchaser ("Purchaser") identified as those who participated in the HCMC Series E Preferred Stock, dated as of August 18, 2022.  The parties amended the HCMC Preferred Stock related to the conversion payment whereby upon conversion of the Series E Preferred Stock prior to the record date for the Spin-Off, the Company will pay the Purchaser ten percent (10%) of the stated value of the Series E Preferred Stock converted. The record date is May 1, 2023.
12


As of March 31, 2023, 6,700,000,000 shares of common stock were issued as a result of the Series E preferred stock conversion. 556 shares of Series E preferred stock was redeemed and approximately $556,000 was paid for redemption.

Pursuant to the Securities Purchase Agreement, purchasers of the Series E Convertible Preferred Stock will also be required to purchase Series A Convertible Preferred Stock of NewCo resulting from spin off of HCMC’s grocery and wellness businesses in the same subscription amounts that the Purchasers paid for the HCMC Series E Preferred Stock.

Stock Options

During the three months ended March 31, 2023 and 2022, no stock options of the Company were exercised into common stock.

During the three months ended March 31, 2023 and 2022, the Company recognized stock-based compensation of approximately $50,000 and $0, respectively in connection with amortization of restricted stock and stock options. Stock based compensation is included as part of selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations.

Income (Loss) Per Share

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 
As of March 31,
 
   
2023
   
2022
 
Preferred stock
   
136,215,000,000
     
1,250,000,000
 
Stock options
   
67,587,000,000
     
67,587,000,000
 
Restricted stock
   
5,500,000,000
     
-
 
Total
   
209,302,000,000
     
68,837,000,000
 
 
Note 13. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints in 2019 and we exchanged additional support information with the plaintiff for one of the lawsuits in 2021. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.

On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia.  The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed a notice of appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. The appeal brief was filed on February 28, 2022.

On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $575,000 in attorneys’ fees to be paid by the Company. The Company has fully provisioned this amount as of December 31, 2022. HCMC appealed this ruling on June 22, 2022. Refer to Note 14 Subsequent Event.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of March 31, 2023. With respect to legal costs, we record such costs as incurred.

13



Note 14. SUBSEQUENT EVENTS

On April 12, 2023, the U.S. Court of Appeals for the Federal Circuit ruled in favor of HCMC on two separate appeals it had filed in its patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. pending in the district court for the Northern District of Georgia.

In the first appeal, HCMC appealed the ruling of the District Court dismissing HCMC’s patent infringement action and denying HCMC’s motion to amend its pleading. In the second appeal, HCMC appealed the District Court’s award of attorneys’ fees to Philip Morris. In its decisions, the Federal Circuit ruled for HCMC by reversing both of those decisions and remanded the case back to the District Court for further proceedings.

As of the date of filing, 9,150,000,000 shares of common stock were subsequently issued since March 31, 2023 as a result of HCMC Series E Preferred Stock conversions.

On April 23, 2023, the Board of Directors of HCMC approved the Second Amendment to the 2015 Equity Incentive Plan which increased the number of shares of HCMC common stock authorized for issuance under the Amended Plan to 225,000,000,000 shares. The board of directors also approved the issuance of an additional 107,675,000,000 shares of restricted common stock to the employees and executive officers of HCMC. The grants of restricted common stock will commence vesting at 12.5% of the award on February 1, 2024 and will vest in 2.5% increments on the last day of each calendar quarter thereafter through September 30, 2025.

14

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF CONDENSED CONSOLIDATED OPERATIONS

The following discussion and analysis should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements. The terms “we,” “us,” “our,” and the “Company” refer to Healthier Choices Management Corp. and its wholly-owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC (“Paradise Health and Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s Storehouse”), Healthy Choices Markets 3 Real Estate LLC, Healthy Choice Markets IV, LLC (“Green's Natural Foods”), HCMC Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC, The Vitamin Store, LLC, Healthy U Wholesale, Inc., and The Vape Store, Inc. (“Vape Store”). All intercompany accounts and transactions have been eliminated in consolidation.

Company Overview

Healthier Choices Management Corp. is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives.
Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio.
Through its wholly owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC, and Healthy Choice Markets 3, LLC, and Healthy Choice Markets IV, LLC respectively, the Company operates:
Ada’s Natural Market, a natural and organic grocery store offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.
Paradise Health & Nutrition’s three stores that likewise offer fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.
Mother Earth’s Storehouse, a two store organic and health food and vitamin chain in New York’s Hudson Valley, which has been in existence for over 40 years.
Green's Natural Foods’ eight stores in New York and New Jersey, offering a selection of 100% organic produce and all-natural, non-GMO groceries & bulk foods; a wide selection of local products; an organic juice and smoothie bar; a fresh foods department, which offers fresh and healthy “grab & go” foods; a full selection of vitamins & supplements; as well as health and beauty products (www.Greensnaturalfoods.com).
Through its wholly owned subsidiary, Healthy Choice Wellness, LLC, the Company has licensing agreements for Healthy Choice Wellness Centers at the Casbah Spa and Salon in Fort Lauderdale, FL, and Boston Direct Health in Boston, MA. These centers offer multiple IV drip “cocktails” for clients to choose from that are designed to help boost immunity, fight fatigue and stress, reduce inflammation, enhance weight loss, and efficiently deliver antioxidants and anti-aging mixes. Additionally, there are cocktails for health, beauty, and re-hydration. (www.HealthyChoiceWellness.com).

Through its wholly owned subsidiary, Healthy U Wholesale Inc., the Company sells vitamins and supplements, as well as health, beauty and personal care products on its website www.TheVitaminStore.com.
Additionally, the Company markets its patented Q-Unit™ and Q-Cup® technology. Information on these products and the technology is available on the Company’s website at www.theQcup.com.
15


Liquidity

The unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company incurred a loss from operations of approximately $2.0 million for the three months ended March 31, 2023. As of March 31, 2023, cash totaled approximately $19.8 million. The Company expects to continue incurring losses for the foreseeable future but we anticipate that our current cash and additional cash to be generated from operations will be sufficient to cover our projected operating expenses for the foreseeable future. Management does not believe there are any substantial doubts about the Company’s ability to continue as a going concern within a year and a day from the issuance of these unaudited consolidated financial statements.

Factors Affecting Our Performance

We believe the following factors affect our performance:

Retail: We believe the operating performance of our retail stores will affect our revenue and financial performance. The Company has four natural and organic groceries and dietary supplement stores located in Florida, as well as ten located in New York and New Jersey. The Company has closed retail vape stores, as management has shifted its retail sales focus to the wholesale and online channel. The adverse industry trends and increasing federal and state regulations that, if implemented, may negatively impact future wholesale and online operations in vapor segment.

Increased Competition: Food retail is a large and competitive industry. Our competition varies and includes national, regional, and local conventional supermarkets, national superstores, alternative food retailers, natural foods stores, smaller specialty stores, and farmers’ markets. In addition, we compete with restaurants and other dining options in the food-at-home and food-away-from-home markets. The opening and closing of competitive stores, as well as restaurants and other dining options, in regions where we operate will affect our results. In addition, changing consumer preferences with respect to food choices and to dining out or at home can impact us. We also expect increased product supply and downward pressure on prices to continue and impact our operating results in the future.
16



Results of Operations

The following table sets forth our unaudited condensed consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 that is used in the following discussions of our results of operations:

 
Three Months Ended March 31,
 
2023 to 2022
 
2023
 
2022
 
Change $
SALES
               
Vapor sales, net
$
38
 
$
249,563
 
$
(249,525)
Grocery sales, net
 
13,559,706
   
4,798,990
   
8,760,716
TOTAL SALES, NET
 
13,559,744
   
5,048,553
   
8,511,191
                 
Cost of sales vapor
 
653
   
111,684
   
(111,031)
Cost of sales grocery
 
8,644,700
   
2,964,355
   
5,680,345
GROSS PROFIT
 
4,914,391
   
1,972,514
   
2,941,877
                 
OPERATING EXPENSES
               
Selling, general and administrative
 
6,897,438
   
3,327,420
   
3,570,018
LOSS FROM OPERATIONS
 
(1,983,047)
   
(1,354,906)
   
(628,141)
                 
OTHER INCOME (EXPENSE)
               
(Loss) gain on investment
 
(4,457)
   
3,514
   
(7,971)
Other (expense) income, net
 
(17,450)
   
16,874
   
(34,324)
Interest income
 
97,653
   
16,603
   
81,050
Total other income (expense), net
 
75,746
   
36,991
   
38,755
                 
NET LOSS
$
(1,907,301)
 
$
(1,317,915)
 
$
(589,386)
17


Net vapor sales decreased approximately $0.2 million to $0.0 thousand for the three months ended March 31, 2023 as compared to $0.2 million for the same period in 2022. The decrease in sales is primarily due to closing all retail vape store, as management has shifted its retail sales focus to the wholesale and online channel. The sales for the three months ended March 31, 2023, were significantly impacted by technical issues associated with the processing of credit card payments. Management is continuing to work with the third-party provider to address the matter.

Net grocery sales increased $8.8 million to $13.6 million for the three months ended March 31, 2023 as compared to $4.8 million for the same period in 2022. The $8.8 million increase in grocery sales was primarily due to the acquisition of Mother Earth's Storehouse and Green's Natural Foods.

Vapor cost of goods sold for the three months ended March 31, 2023 and 2022 were $1.0 thousand and $0.1 million, respectively, a decrease of $0.1 million. The decrease is primarily due to closing retail vape stores, as management has shifted its retail sales focus to the wholesale and online channel. Gross (loss) profit was $(0.6) thousand and $0.1 million for three months ended March 31, 2023 and 2022, respectively.

Grocery cost of goods sold for the three months ended March 31, 2023 and 2022 were $8.6 million and $3.0 million, respectively. The increase of $5.6 million is primarily due to the acquisition of Mother Earth's Storehouse and Green's Natural Foods stores. Gross profit was $4.9 million and $1.8 million for the three months ended March 31, 2023 and 2022, respectively. Gross margin as a percentage of sales decreased approximately 2.0% as compared to the same period in prior year as a result of increased inventory shrink and inventory reserve.

Total operating expenses increased $3.6 million to $6.9 million for the three months ended March 31, 2023 compared to $3.3 million for the same period in 2022. The increase is due to the acquisition of Mother Earth's Storehouse and Green's Natural Foods stores, and increases in professional fees of $0.1 million, and stock compensation expense  of $0.05 million.

Total net other income increased $39,000 to $76,000 for the three months ended March 31, 2023 compared to $37,000 for the same period in 2022. The increase in net other income is mainly attributable to increase in interest income as a result of an increase in interest rates, offset by increase in remeasurement on contingent liability.

Liquidity and Capital Resources

 
Three Months Ended March 31,
 
2023
 
2022
Net cash (used in) provided by
         
 Operating activities
$
(2,344,310)
 
$
(679,629)
 Investing activities
 
(109,931)
   
(5,263,503)
Financing activities
 
(742,164)
   
34,558
 
$
(3,196,405)
 
$
(5,908,574)
18


Our net cash used in operating activities of approximately $2.3 million for the three months ended March 31, 2023 resulted from a net loss of $1.9 million, offset by a non-cash adjustment of $1.7 million and a net cash usage of $2.1 million from changes in operating assets and liabilities. Our net cash used in operating activities of $0.7 million for the three months ended March 31, 2022 resulted from a net loss of $1.3 million and a net cash provided by operation of $0.2 million from changes in operating assets and liabilities, offset by a non-cash adjustment of $0.5 million.

The net cash used in investing activities of $0.1 million for the three months ended March 31, 2023 resulted from collection on a note receivable and purchases of property and equipment. The net cash used in investing activities of $5,264,000 for the three months ended March 31, 2022 resulted from the acquisition of Mother Earth's Storehouse, collection of a note receivable, and purchases of property and equipment.

The net cash used in financing activities of $742,000 for the three months ended March 31, 2023 is due to Series E Preferred Stock redemption and exercise and principle payment on loan payable. The net cash provided by financing activities of $35,000 for the three months ended March 31, 2022 is due to proceeds received from the line of credit.

At March 31, 2023 and December 31, 2022, we did not have any material financial guarantees or other contractual commitments with vendors that are reasonably likely to have an adverse effect on liquidity.

Our cash balances are kept liquid to support our growing acquisition and infrastructure needs for operational expansion. Most of our cash is concentrated in several financial institutions and is generally in excess of the FDIC insurance limit. The Company has not experienced any losses on its cash. The following table presents the Company’s cash position as of March 31, 2023 and December 31, 2022.

 
March 31, 2023
 
December 31, 2022
Cash
$
19,765,487
 
$
22,911,892
Total assets
$
52,358,773
 
$
55,255,030
Percentage of total assets
 
37.75%
   
41.47%

The Company reported a net loss of $1.9 million for the three months ended March 31, 2023. The Company also had positive working capital of $18.3 million. The Company expects to continue incurring losses for the foreseeable future, but we do not believe there are any substantial doubts about the Company’s ability to continue as a going concern. The Company's current cash and cash generated from operations will be sufficient to meet the projected operating expenses for the foreseeable future through at least the next twelve months from the issuance of these unaudited condensed consolidated financial statements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

19


Critical Accounting Policies and Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and contingencies at the date of the condensed consolidated financial statements.

We base our estimates on our historical experience, knowledge of our business and industry, current and expected economic conditions, the attributes of our products, the regulatory environment, and in certain cases, the results of outside appraisals. We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.

There have been no material changes to the Company’s critical accounting policies and estimates as compared to the critical accounting policies and estimates described in the 2022 Annual Report, which we believe are the most critical to our business and the understanding of our results of operations and affect the more significant judgments and estimates that we use in the preparation of our condensed consolidated financial statements.

Seasonality

We do not consider our business to be seasonal.

Cautionary Note Regarding Forward-Looking Statements

This report includes forward-looking statements including statements regarding retail expansion, the future demand for our products, the transition to vaporizer and other products, competition, the adequacy of our cash resources and our authorized Common Stock, and our continued ability to raise capital.

The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include our future common stock price, the timing of future Series D preferred stock exercises and stock sales, customer acceptance of our products, and proposed federal and state regulation. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.


20


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.


ITEM 4. CONTROLS AND PROCEDURES

We are required to report under Section 404(a) of Sarbanes-Oxley regarding the effectiveness of our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

Our management, including our Principal Executive Officer and Principal Financial Officer, did not carry out an evaluation on internal controls as of March 31, 2023 in regard to the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act. As an evaluation was not carried out, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report.

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, the Company evaluated the effectiveness of the design and operation of its internal control over financial reporting based on the framework established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).  Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s internal control over financial reporting was ineffective as of March 31, 2023 and noted the material weaknesses as follows:

Failure to have properly documented and designed disclosure controls and procedures and testing of the operating effectiveness of our internal control over financial reporting.

Failure to perform periodic and year-end inventory observations in a timely manner and adequate controls to sufficiently perform required rollback procedures of inventory counts to the year-end.

Weakness around our purchase orders and inventory procedures, inclusive of year-end physical inventory observation procedures as well as physical count procedures.

Segregation of duties due to lack of personnel.

Information technology general controls (ITGCs) were not designed effectively to ensure that appropriate access security controls, change management and data center and network operations ITGCs were in place.

Our management concluded that considering internal control deficiencies that, in the aggregate, rise to the level of material weaknesses, we did not maintain effective internal control over financial reporting as of March 31, 2023 based on the criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
21


Planned Remediation

Management continues to work to improve its controls related to our material weaknesses listed above. In order to achieve the timely implementation of the above, management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

Continuing to increase headcount across the Company, with a particular focus on hiring individuals with strong internal control backgrounds and inventory expertise.

Increasing its focus on the Company’s purchase order process in order to better manage inventory thereby improving cash management and ultimately leading to more reliable and precise financial reporting.

Establishing policies and procedures in the IT area to mitigate data breach, unauthorized access, and address segregation of duties.

We are currently working to improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material weaknesses will not be considered to be remediated until the applicable remediated controls are operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Changes in Internal Controls over Financing Reporting

Except as detailed above, during the quarter ended March 31, 2023, there were no significant changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.





22

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints in 2019 and we exchanged additional support information with the plaintiff for one of the lawsuits in 2021. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.

On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia. The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed a notice of appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. The appeal brief was filed on February 28, 2022.

On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $575,000 in attorneys’ fees to be paid by the Company. HCMC appealed this ruling on June 22, 2022.

On April 12, 2023, the U.S. Court of Appeals for the Federal Circuit ruled in favor of HCMC on two separate appeals it had filed in its patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. pending in the district court for the Northern District of Georgia.

In the first appeal, HCMC appealed the ruling of the District Court dismissing HCMC’s patent infringement action and denying HCMC’s motion to amend its pleading. In the second appeal, HCMC appealed the District Court’s award of attorneys’ fees to Philip Morris. In its decisions, the Federal Circuit ruled for HCMC by reversing both of those decisions and remanded the case back to the District Court for further proceedings.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of March 31, 2023. With respect to legal costs, we record such costs as incurred.
23


ITEM 1A. RISK FACTORS.

Not Applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not Applicable.

ITEM 5. OTHER INFORMATION.

Not Applicable.

ITEM 6. EXHIBITS.

See the exhibits listed in the accompanying “Index to Exhibits.”

24


INDEX TO EXHIBITS

Exhibit
     
Incorporated by Reference
 
Filed or Furnished
No.
 
Exhibit Description
 
Form
 
Date
 
Number
 
Herewith
31.1
               
Filed
31.2
               
Filed
32.1
               
Furnished *
32.2
               
Furnished *
101.INS
 
XBRL Instance Document
             
Filed
101.SCH
 
XBRL Taxonomy Extension Schema Document
             
Filed
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
             
Filed
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
             
Filed
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
             
Filed
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
             
Filed
104
 
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
             
Filed

*
This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.
25



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
HEALTHIER CHOICES MANAGEMENT CORP.
     
Date: May 5, 2023
By:
/s/ Jeffrey Holman
   
Jeffrey Holman
   
Chief Executive Officer
     
Date: May 5, 2023
By:
/s/ John Ollet
   
John Ollet
   
Chief Financial Officer

26
EX-31.1 2 ex31_1.htm EXHIBIT 31.1  
Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Jeffrey Holman, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Healthier Choices Management Corp.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2023

 
/s/ Jeffrey Holman
 
Jeffrey Holman
 
Chief Executive Officer
 
(Principal Executive Officer)

EX-31.2 3 ex31_2.htm EXHIBIT 31.2  
Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, John Ollet, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Healthier Choices Management Corp.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 5, 2023

 
/s/ John Ollet
 
John Ollet
 
Chief Financial Officer
 
(Principal Financial Officer)

EX-32.1 4 ex32_1.htm EXHIBIT 32.1  
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Healthier Choices Management Corp. (the “Company”) on Form 10-Q for the quarter ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, Jeffrey Holman, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.
The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2.
The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 5, 2023

 
/s/ Jeffrey Holman
 
Jeffrey Holman
 
Chief Executive Officer
 
(Principal Executive Officer)

EX-32.2 5 ex32_2.htm EXHIBIT 32.2  
Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Healthier Choices Management Corp. (the “Company”) on Form 10-Q for the quarter ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof, I, John Ollet, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.
The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2.
The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 5, 2023

 
/s/ John Ollet
 
John Ollet
 
Chief Financial Officer
 
(Principal Financial Officer)

EX-101.SCH 6 hcmc-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - ACQUISITION link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - CONTRACT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - ORGANIZATION (Policies) link:presentationLink link:calculationLink link:definitionLink 070300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - CONTRACT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - LIQUIDITY (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - INTANGIBLE ASSETS, Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 090902 - Disclosure - INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - CONTRACT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - STOCKHOLDERS' EQUITY, Rights Offering (Details) link:presentationLink link:calculationLink link:definitionLink 091202 - Disclosure - STOCKHOLDERS' EQUITY, Exchange Agreement and Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 091204 - Disclosure - STOCKHOLDERS' EQUITY, Series E Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 091206 - Disclosure - STOCKHOLDERS' EQUITY, Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 091208 - Disclosure - STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hcmc-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 hcmc-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 hcmc-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Award Type [Axis] BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable and accrued expenses Accounts receivable, net Receivable Type [Axis] Accounts, Notes, Loans and Financing Receivable [Line Items] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in capital Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Amortization expense Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive securities excluded from computation of diluted loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] ASSETS Assets [Abstract] TOTAL ASSETS Assets TOTAL CURRENT ASSETS Assets, Current CURRENT ASSETS Building [Member] Ending balance Beginning balance Contingent consideration Cash Consideration paid Purchase price Business Combination, Consideration Transferred Remeasurement Change in contingent consideration Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other ACQUISITIONS [Abstract] Finite-Lived Intangible Assets [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract] Business Acquisition [Axis] Net loss Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Acquiree [Domain] Acquisitions [Abstract] Business Combinations [Abstract] Sales Business Acquisition, Pro Forma Revenue Business Acquisition [Line Items] Pro Forma Information [Abstract] Business Acquisition, Pro Forma Information [Abstract] Supplemental Pro Forma Information ACQUISITION Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Purchase Price Allocation [Abstract] Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract] Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash and Restricted Cash [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] CASH AND RESTRICTED CASH - END OF PERIOD CASH AND RESTRICTED CASH - BEGINNING OF PERIOD Total cash and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents NET DECREASE IN CASH AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash Cash and cash equivalents Cash NON-CASH INVESTING AND FINANCING ACTIVITIES FDIC insured amount Changes in Contract Liabilities Activity [Roll Forward] Class of Stock [Line Items] Class of Stock [Domain] COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES (SEE NOTE 12) COMMITMENTS AND CONTINGENCIES Common Stock [Member] Common Stock [Member] Common stock, par value (in dollars per share) Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 346,441,632,384 and 339,741,632,384 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Computer Hardware & Equipment [Member] CONCENTRATIONS Contract liabilities Deferred Revenue [Abstract] Ending balance as of March 31, Beginning balance Contract with Customer, Liability Summary of Net Changes in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] CONTRACT LIABILITIES [Abstract] Series E convertible preferred stock redeemed Convertible Preferred Stock Converted to Other Securities Convertible Preferred Stock [Member] Corporate [Member] Corporate, Non-Segment [Member] Cost of sales Credit Facility [Domain] Credit Facility [Axis] Customer Relationships [Member] Customer Relationships [Member] Disaggregated Revenue Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Table] DEBT [Abstract] Schedule of Long-term Debt Instruments [Table] DEBT Debt Instrument [Axis] Debt Instrument [Line Items] Face amount Debt Instrument, Name [Domain] Increment percentage on salary each subsequent year Depreciation and amortization Depreciation expense Derivative liabilities, warrants Derivative Liability, Current NET LOSS PER SHARE-BASIC (in dollars per share) NET LOSS PER SHARE-DILUTED (in dollars per share) Stock Options [Member] Share-Based Payment Arrangement, Option [Member] Compensation Expense Recognized [Abstract] Restricted Stock [Abstract] STOCKHOLDERS' EQUITY [Abstract] Equity Component [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Market Value - Level 3 [Member] Fair Value, Inputs, Level 3 [Member] 2025 2023 (remaining nine months) Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets [Line Items] 2024 Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Future Annual Estimated Amortization Expense [Abstract] 2026 2027 Gross carrying amount Amortization period Useful lives Intangible assets, net of accumulated amortization Net carrying amount Furniture and Fixtures [Member] Grantee Status [Domain] Grantee Status [Axis] Loss (gain) on investment (Loss) gain on investment Gain (Loss) on Investments Net gain on debt settlements Gain on debt settlements Loss on extinguishment of debt INTANGIBLE ASSETS Goodwill Goodwill INTANGIBLE ASSETS [Abstract] GROSS PROFIT Gross Profit Impairment of intangible assets Impairment of Intangible Assets, Finite-Lived CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Cash paid for income tax Income Taxes Paid, Net Contract liabilities Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Convertible Preferred Stock [Roll Forward] Contract assets Increase (Decrease) in Contract with Customer, Asset Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Accrued expenses Inventories Changes in operating assets, inventories Increase (Decrease) in Inventories Changes in operating assets and liabilities: Accounts receivable Increase (Decrease) in Receivables Increase (Decrease) in Stockholders' Equity [Roll Forward] Accrued interest on loan Interest income, net Cash paid for interest Website [Member] Internet Domain Names [Member] Write-down of obsolete and slow-moving inventory Inventory Write-down Inventories Leasehold Improvements [Member] LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Liabilities and Equity TOTAL LIABILITIES Liabilities TOTAL CURRENT LIABILITIES Liabilities, Current CURRENT LIABILITIES Line of credit Attorney fees paid Litigation Settlement, Amount Awarded to Other Party Current portion of loan payment NOTES RECEIVABLE AND OTHER INCOME Debt Long-Term Debt Current portion of long-term debt Long-Term Debt, Current Maturities Debt [Abstract] Long-Term Debt, by Current and Noncurrent [Abstract] Loan payable, net of current portion Long-term debt Long-Term Debt, Excluding Current Maturities Loss Contingency Nature [Axis] Damages sought Loss Contingencies [Line Items] Loss Contingencies [Table] Legal Proceedings [Abstract] Loss Contingency, Information about Litigation Matters [Abstract] Loss Contingency, Nature [Domain] Number of lawsuits Loss Contingency, Pending Claims, Number FINANCING ACTIVITIES NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities INVESTING ACTIVITIES OPERATING ACTIVITIES Net loss Net loss Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Acquisition non cash expense Non-Compete Agreement [Member] Non-Compete [Member] Total other income (expense), net Nonoperating Income (Expense) OTHER INCOME (EXPENSE) Nonoperating Income (Expense) [Abstract] Note receivable Notes receivable Promissory note Notes Payable to Bank, Noncurrent Number of operating segments Number of Operating Segments Number of stores Number of Stores Operating lease liability, net of current Amortization of right-of-use asset Operating Lease, Right-of-Use Asset, Amortization Expense Operating lease liability, current Right of use asset - operating lease, net LOSS FROM OPERATIONS Total loss Operating Income (Loss) OPERATING EXPENSES Operating Segments [Member] ORGANIZATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] ORGANIZATION [Abstract] Other assets Other current assets Other [Member] Other Machinery and Equipment [Member] Other (expense) income, net Patents [Member] Payment of induced conversions of Preferred Stock Payment of induced conversions of preferred stock Payment for series E preferred stock redemption Payments for Repurchase of Redeemable Preferred Stock Purchases of property and equipment Payments to Acquire Intangible Assets Cash purchase price Acquisition of Mother Earth's Storehouse Payments to Acquire Businesses, Gross Direct financing costs Issuance of note receivable Payments to Acquire Notes Receivable Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Induced conversions of Preferred Stock Preferred Stock Conversions, Inducements Preferred Stock [Member] Series D convertible preferred stock, aggregate liquidation preference Preferred Stock, Liquidation Preference, Value Conversion rate Aggregate subscription price Number of preferred shares sold and issued (in shares) Series D convertible preferred stock, issued (in shares) Preferred Stock, Shares Issued Conversion price (in dollars per share) Preferred stock, stated value (in dollars per share) Series D convertible preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Series D convertible preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Series D convertible preferred stock, $1,000 par value per share, 5,000 shares authorized; 800 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $0.8 million Preferred Stock, Value, Issued Series D convertible preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Liquidation preference (in dollars per share) Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Reclassification [Abstract] Prior Period Adjustment [Abstract] Proceeds from Rights Offering Net proceeds Proceeds from Issuance of Common Stock Proceeds from issuance of preferred stock Proceeds from line of credit Proceeds from loan and security agreement Collection of note receivable Proceeds Proceeds from exercise of stock options PROPERTY, PLANT, AND EQUIPMENT Property, Plant and Equipment [Line Items] Property, plant, and equipment Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Axis] PROPERTY, PLANT, AND EQUIPMENT [Abstract] Property, plant, and equipment, net of accumulated depreciation Total property, plant, and equipment Property and equipment, gross Property, Plant and Equipment, Type [Domain] Property and Equipment [Abstract] Bad debt expense Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Interest rate Receivable with Imputed Interest, Effective Yield (Interest Rate) Loan amount Receivable with Imputed Interest, Face Amount Receivable [Domain] Remaining balance Receivables with Imputed Interest [Abstract] NOTES RECEIVABLE AND OTHER INCOME [Abstract] Reclassification [Table] Reclassification [Line Items] Principal payments on loan payable Repayments of Short-Term Debt Principal payment on the line of credit Repayments of Lines of Credit Restricted Stock [Member] Restricted cash Restricted Cash, Current Restricted cash Accumulated deficit Accumulated Deficit [Member] SALES, NET Revenue SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES Revenue from Contract with Customer [Text Block] DISAGGREGATION OF REVENUES [Abstract] SALES Line of Credit [Member] CONCENTRATIONS [Abstract] Stock vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Future Annual Estimated Amortization Expense Base salary Intangible Assets, Net Breakdown of Debt Schedule of Finite-Lived Intangible Assets [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Common Share Equivalent Excluded from Calculation of Dilutive Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Purchase Price Allocation for Mother Earth's Storehouse, Inc. Change in Fair Value of Contingent Consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Property, Plant and Equipment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Stock by Class [Table] Segment Reporting Information [Line Items] Segments [Domain] Segment Information [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Vesting on February 1, 2024 [Member] Share-Based Payment Arrangement, Tranche One [Member] Last Day of Each Calendar Quarter Thereafter Through September 30, 2025 [Member] Share-Based Payment Arrangement, Tranche Two [Member] Granted (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Forfeited (in shares) Stock-based compensation expense Stock-based compensation Common stock available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Award Type [Domain] Balance (in shares) Balance (in shares) Shares, Outstanding Subscription price (in dollars per share) Common stock at a price per share (in dollars per share) Investment BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Segments [Axis] Class of Stock [Axis] Equity Components [Axis] Statement [Line Items] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Statement [Table] CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY [Abstract] Authorized repurchase of common stock Stock Repurchase Program, Authorized Amount Conversion of series E convertible preferred stock (in shares) Issuance of common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Common stock shares issued from offering (in shares) Issuance of common stock (in shares) Issuance of common stock in connection with cashless exercise of Series A warrants (in shares) Cancellation of awarded stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Issuance of awarded stock for officers and board member (in shares) Issuance of common stock Indebtedness aggregate amount Stock redeemed Stock options exercised Stock redeemed (in shares) Stock options exercised (in shares) Issuance of awarded stock for officers and board member Cancellation of awarded stock Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Conversion of series E convertible preferred stock Stock Issued During Period, Value, Conversion of Convertible Securities Balance Balance TOTAL STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY SUBSEQUENT EVENTS Subsequent Events [Text Block] Subsequent Event [Table] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Event [Line Items] SUBSEQUENT EVENTS [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Series E redeemable convertible preferred stock, $1,000 par value per share, 14,722 shares authorized, 13,497 shares and 14,722 share issued and outstanding as of March 31, 2023 and December 31, 2022; aggregate liquidation preference of $13.5 million and $14.7 million as of March 31, 2023 and December 31, 2022, respectively Temporary Equity, Carrying Amount, Attributable to Parent Issuance of Series E Convertible Preferred stock in connection with the Securities Purchase Agreement, net of offering costs Temporary Equity, Stock Issued During Period, Value, New Issues Series E convertible preferred stock, aggregate liquidation preference Temporary Equity, Liquidation Preference Series E convertible preferred stock, issued (in shares) Temporary Equity, Shares Issued Balance Balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Series E convertible preferred stock, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Series E convertible preferred stock, authorized (in shares) Temporary Equity, Shares Authorized CONVERTIBLE PREFERRED STOCK Temporary Equity [Abstract] Series E convertible preferred stock, outstanding (in shares) Balance (in shares) Balance (in shares) Temporary Equity, Shares Outstanding Total Cash in excess of FDIC limits of $250,000 Trademarks [Member] Trademarks [Member] Trademarks and Trade Names [Member] Vesting [Axis] Vesting [Domain] Warrants [Member] Warrant [Member] WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-DILUTED (in shares) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC (in shares) Board Member [Member] Board of Directors Chairman [Member] Counterparty Name [Axis] Chief Operating Officer [Member] Chief Executive Officer [Member] Chief Financial Officer [Member] Consolidation Items [Axis] Consolidation Items [Domain] Director [Member] Litigation Case [Axis] Litigation Case [Domain] Maximum [Member] Minimum [Member] Officers [Member] Product and Service [Domain] Product and Service [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Counterparty Name [Domain] Reclassification, Adjustment [Member] Revision of Prior Period, Adjustment [Member] Revision of Prior Period [Domain] Revision of Prior Period [Axis] Title of Individual [Axis] Title of Individual [Domain] Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding The entire disclosure of contract balances and changes in contract balances. Contract with Customer, Asset and Liability [Text Block] CONTRACT LIABILITIES Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finite-Lived Intangible Asset, Expected Amortization, after Year Four Thereafter Rights Offering [Abstract] Rights Offering [Abstract] The gross proceeds from the additional capital contribution to the entity. Gross Proceeds from Issuance of Common Stock Gross proceeds Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract] Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract] Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of vendor deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Prepaid Expense and Vendor Deposits, Current Prepaid expenses and vendor deposits Series E Convertible Preferred Stock [Abstract] Series E Convertible Preferred Stock [Abstract] Period of time after closing when a holder may require the redemption of all or a portion of the stated value of the Company's Preferred Stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Preferred Stock, Redemption Period Redemption period The percentage of stated value of preferred stock will be paid to purchaser upon conversion. Percentage of Stated Value of Preferred Stock will be Paid to Purchaser upon Conversion Percentage of stated value of preferred stock will be paid to purchaser upon conversion Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Series E Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Offering costs are those expenditures made to pay for the accounting, legal and underwriting activities associated with the issuance of securities to investors. Offering Costs Offering costs Period of time between issuance and redemption of gift cards, rewards and points, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Breakage Policy Period Breakage policy period Period in which contract liabilities is expected to be recognized, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Contract Liabilities Expected Recognition Period Contract liabilities expected recognition period Refers to product of gift cards. Gift Cards [Member] Gift Cards [Member] Refers to product of the vapor loyalty rewards. Vapor Loyalty Rewards [Member] Vapor Loyalty Rewards [Member] Refers to product of the grocery loyalty rewards. Grocery Loyalty Rewards [Member] Grocery Loyalty Rewards [Member] Amount of gift cards and loyalty rewards issued as obligation to transfer good or service to customer for which consideration has been received or is receivable. Contract with Customer, Liability, Issued Issued Amount of cost associated with fulfillment of contract with customer. Contract with Customer, Liability, Fulfillment of Contract Fulfillment of contract Amount of expense from redemption of gift cards and loyalty rewards in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Contract with Customer, Liability, Redeemed Redeemed Amount of increase (decrease) in revenue recognized for adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Contract with Customer, Liability, Breakage Recognized Breakage recognized Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Series D Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Number of shares of convertible preferred stock that were converted to other securities. Convertible Preferred Stock Converted to Other Securities, Shares Series E convertible preferred stock redeemed (in shares) Value of convertible preferred stock redeemed during the period. Temporary Equity, Convertible Preferred Stock Redeemed, Value Series E convertible preferred stock redeemed Number of new stock issued in connection with Rights Offering during the period. Stock Issued During Period, Shares, New Issues, Rights Offering Issuance of common stock in connection with the Rights Offering, net of offering expenses (in shares) Equity impact of the value of new stock issued during the period in connection with Rights Offering. Stock Issued During Period, Value, New Issues, Rights Offering Issuance of common stock in connection with the Rights Offering, net of offering expenses Number of new stock classified as temporary equity issued during the period. Temporary Equity, Stock Issued During Period, Shares, New Issues Issuance of Series E Convertible Preferred stock in connection with the Securities Purchase Agreement, net of offering costs (in shares) Number of convertible preferred stock redeemed during the period. Temporary Equity, Convertible Preferred Stock Redeemed, Shares Series E convertible preferred stock redeemed (in shares) Value of convertible preferred stock converted during the period. Temporary Equity, Conversion of Convertible Preferred Stock, Value Conversion of series E convertible preferred stock Number of convertible preferred stock converted during the period. Temporary Equity, Conversion of Convertible Preferred Stock, Shares Conversion of series E convertible preferred stock (in shares) Refers to a substance diffused or suspended in the air, especially one normally liquid or solid. Vapor [Member] Vapor [Member] A grocer is a bulk seller of food and products. Grocery [Member] Grocery [Member] A person that is a dealer primarily engaged in the full-line wholesale distribution and resale of grocery and related nonfood items. Wholesale Grocery [Member] Wholesale Grocery [Member] Refers to food service and restaurants stores that sell vapor products. Food Service and Restaurant [Member] Food Service/Restaurant [Member] Refers to the online stores and other e-commerce platforms that sell vape products. Online and E-commerce [Member] Online/e-Commerce [Member] A grocery retailer primarily sells food. Grocery stores also offer non-perishable foods that are packaged in bottles, boxes, and cans; some also have bakeries, butchers, delis, and fresh produce. Retail Grocery [Member] Retail Grocery [Member] A retail vapor outlet specializing in the selling of electronic cigarette products. Retail Vapor [Member] Retail Vapor [Member] A person that is a dealer primarily engaged in the full-line wholesale distribution of vape products. Wholesale Vapor [Member] Wholesale Vapor [Member] Number of financial institutions in which company concentrates its cash and cash equivalent deposits. Concentration of Deposits, Number of Financial Institutions Number of financial institution Cash and Cash Equivalents in Excess of FDIC Limits [Abstract] Cash and Cash Equivalents in Excess of FDIC Limits [Abstract] Amount of increase (decrease) in prepaid expenses, and vendor deposits. Increase (Decrease) in Prepaid Expense and Vendor Deposits Prepaid expenses and vendor deposits The increase (decrease) during the period lease liability. Increase (Decrease) in Lease liability Lease liability Issuance of common stock in connection with cashless exercise of Series A warrants. Issuance Of Common Stock In Connection With Cashless Exercise Of Series A Warrants Issuance of common stock in connection with series E preferred stock conversion Future cash outflow to pay for induced conversions of preferred stock that have occurred. Accrued Payment of induced conversions of Preferred Stock Accrued payment of induced conversions of Preferred Stock Represents the name of an entity. Philip Morris [Member] Alleged claimed battery defects for an electronic cigarette device. Alleged Claimed Battery Defects For Electronic Cigarette Device [Member] The patent infringement litigation. Patent Infringement Litigation [Member] Patent Infringement Litigation [Member] Medical costs claimed by Plaintiffs. Medical Costs [Member] Person with designation of president and chief operating officer. President and Chief Operating Officer [Member] President and Chief Operating Officer [Member] The amount of investment under litigation. Loss Contingencies, Investment Amount Invested amount The number of users approached by the entity. Number of Users Approached Number of users approached An organic and natural health food grocery store company. Green's Natural Foods [Member] Green's Natural Foods [Member] Greens Natural Foods' [Member] An organic and natural health food grocery store company. Mother Earth's Storehouse [Member] Mother Earth's Storehouse [Member] Dean's Natural Food Market of Shrewsbury, Inc., a New Jersey corporation, Green's Natural Foods, Inc., a Delaware corporation, Dean's Natural Food Market of Chester, LLC, a New Jersey limited liability company, Dean's Natural Food Market of Basking Ridge, LLC, a New Jersey limited liability company, and Dean's Natural Food Market, Inc., a New Jersey corporation (collectively, the "Sellers"). Sellers [Member] Sellers [Member] The weighted average discounted interest rate. Weighted Average Discounted Interest Rate Interest rate The amortization period for the amount of goodwill arising from a business combination that is deductible for tax purposes measured in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Business Acquisition, Goodwill Tax Deductible Amount Amortization Period Amortization period for goodwill for tax purposes Business Combination, Revenue and Earnings [Abstract] Revenue and Earnings [Abstract] Change in Fair Value of Contingent Consideration [Abstract] Change in Fair Value of Contingent Consideration [Abstract] The amount of operating lease right-of-use assets recognized as of the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right-of-use Asset Right of use asset - operating lease Amount of operating lease liabilities assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability Operating lease liability Subsequent Event [Abstract] Subsequent Event [Abstract] Represents the number of appeals filed in patent infringement during the period. Number of Appeals Filed in Patent Infringement Number of appeals filed in patent infringement Two thousand fifteen equity incentive plan is an arrangement where employees own a percentage of their company's shares so that they make money when the company makes a profit. Two Thousand and Fifteen Equity Incentive Plan [Member] 2015 Equity Incentive Plan [Member] Employees and Persons with designation of chief executive officer, chief operating officer and chief financial officer. Employees and Executive Officers [Member] Exchange Agreement [Abstract] Exchange Agreement [Abstract] The percentage of forfeited from current amended award agreement. Percentage of Forfeited from Current Amended Award Agreement Percentage of forfeited from current amended award agreement The percentage of increase in grants from its original award agreement, made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Grants, Increase in Vesting Percentage from its Original Awards In Period Percentage of increase in restricted stock grants from its original award agreement to officers Persons with designation of chief executive officer, chief operating officer, chief financial officer and a director of the company. Officers and Director [Member] On August 18, 2020, the Company agreed to a term loan and security agreement (the "Loan") with Sabby Healthcare Master Fund, LTD and Sabby Volatility Warrant Master Fund, LTD ("collectively, the Lender"). Term Loan and Security Agreement [Member] Loan and Security Agreement [Member] Tabular disclosure of the components of cash and cash equivalents and cash and cash equivalents restricted as to withdrawal or usage. Schedule of Cash and Cash Equivalents and Restricted Cash [Table Text Block] Cash and Restricted Cash Tabular disclosure of the components of cash and cash equivalents in excess of FDIC limit. Cash and Cash Equivalents in Excess of FDIC Limit [Table Text Block] Cash and Cash Equivalents in Excess of FDIC Limit Displays [Member] Displays [Member] Includes equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities, additions or improvements to assets held under a lease arrangement, and long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems. Vape Stores' Disposal [Member] Vape Stores' Disposal [Member] Related to other debt. Other Debt [Member] Other Debt [Member] Promissory notes a signed document containing a written promise to pay a stated sum to a specified person or the bearer at a specified date or on demand. Promissory Notes [Member] Promissory Note [Member] Promissory notes a signed document containing a written promise to pay a stated sum to a specified person or the bearer at a specified date or on demand and Secured note is a type of loan that is backed by the borrower's assets. Promissory Notes and Secured Notes [Member] The cash inflow associated with the balloon payment. Proceeds from Balloon Payment Balloon payment The extension term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Notes Receivable, Extension Term Extension term The payment term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Notes Receivable Payment Term Payment term Tabular disclosure of notes receivable. Schedule Of Accounts Notes Receivable [Text Block] Summary of Amended Notes LIQUIDITY [Abstract] The entire disclosure of liquidity. Liquidity [Text Block] LIQUIDITY The amount of working capital (deficit) as of the balance sheet date. Working capital represents the money available to meet current, short-term obligations. Working Capital (Deficit) Working capital Company Organization [Abstract] The period of time the company has been in existence, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Age of Company Number of years the company has been operating A company offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items. Paradise Health & Nutrition's [Member] Paradise Health & Nutrition's [Member] Disclosure of accounting policy for spin-off. Spin-Off [Policy Text Block] Spin-Off EX-101.PRE 10 hcmc-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 image00001.jpg begin 644 image00001.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2023
May 05, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Document Transition Report false  
Entity File Number 001-36469  
Entity Registrant Name HEALTHIER CHOICES MANAGEMENT CORP.  
Entity Central Index Key 0000844856  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-1070932  
Entity Address, Address Line One 3800 North 28Th Way  
Entity Address, City or Town Hollywood  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33020  
City Area Code 305  
Local Phone Number 600-5004  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol HCMC  
Security Exchange Name NONE  
Entity Common Stock, Shares Outstanding   463,266,632,384
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash $ 19,765,487 $ 22,911,892
Accounts receivable, net 100,633 55,815
Notes receivable 172,905 189,225
Inventories 3,967,497 3,817,192
Prepaid expenses and vendor deposits 577,569 322,182
Investment 5,314 9,771
Other current assets 944,470 1,224,171
Restricted cash 1,728,232 1,778,232
TOTAL CURRENT ASSETS 27,262,107 30,308,480
Property, plant, and equipment, net of accumulated depreciation 3,096,599 3,112,908
Intangible assets, net of accumulated amortization 4,774,609 5,005,511
Goodwill 5,747,000 5,747,000
Right of use asset - operating lease, net 11,003,033 10,604,935
Other assets 475,425 476,196
TOTAL ASSETS 52,358,773 55,255,030
CURRENT LIABILITIES    
Accounts payable and accrued expenses 4,977,089 5,715,234
Contingent consideration 797,000 774,900
Contract liabilities 200,372 198,606
Line of credit 453,232 453,232
Current portion of loan payment 543,945 536,542
Operating lease liability, current 2,036,415 2,228,852
TOTAL CURRENT LIABILITIES 9,008,053 9,907,366
Loan payable, net of current portion 2,239,044 2,378,061
Operating lease liability, net of current 8,657,428 8,041,504
TOTAL LIABILITIES 19,904,525 20,326,931
COMMITMENTS AND CONTINGENCIES (SEE NOTE 12)
CONVERTIBLE PREFERRED STOCK    
Series E redeemable convertible preferred stock, $1,000 par value per share, 14,722 shares authorized, 13,497 shares and 14,722 share issued and outstanding as of March 31, 2023 and December 31, 2022; aggregate liquidation preference of $13.5 million and $14.7 million as of March 31, 2023 and December 31, 2022, respectively 13,496,525 14,722,075
STOCKHOLDERS' EQUITY    
Series D convertible preferred stock, $1,000 par value per share, 5,000 shares authorized; 800 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $0.8 million 800,000 800,000
Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 346,441,632,384 and 339,741,632,384 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 34,644,163 33,974,163
Additional paid-in capital 29,034,802 29,045,802
Accumulated deficit (45,521,242) (43,613,941)
TOTAL STOCKHOLDERS' EQUITY 18,957,723 20,206,024
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY $ 52,358,773 $ 55,255,030
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
CONVERTIBLE PREFERRED STOCK    
Series E convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Series E convertible preferred stock, authorized (in shares) 14,722 14,722
Series E convertible preferred stock, issued (in shares) 13,497 14,722
Series E convertible preferred stock, outstanding (in shares) 13,497 14,722
Series E convertible preferred stock, aggregate liquidation preference $ 13.5 $ 14.7
STOCKHOLDERS' EQUITY    
Series D convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Series D convertible preferred stock, authorized (in shares) 5,000 5,000
Series D convertible preferred stock, issued (in shares) 800 800
Series D convertible preferred stock, outstanding (in shares) 800 800
Series D convertible preferred stock, aggregate liquidation preference $ 0.8 $ 0.8
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 750,000,000,000 750,000,000,000
Common stock, shares issued (in shares) 346,441,632,384 339,741,632,384
Common stock, shares outstanding (in shares) 346,441,632,384 339,741,632,384
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
SALES    
SALES, NET $ 13,559,744 $ 5,048,553
GROSS PROFIT 4,914,391 1,972,514
OPERATING EXPENSES 6,897,438 3,327,420
LOSS FROM OPERATIONS (1,983,047) (1,354,906)
OTHER INCOME (EXPENSE)    
(Loss) gain on investment (4,457) 3,514
Other (expense) income, net (17,450) 16,874
Interest income, net 97,653 16,603
Total other income (expense), net 75,746 36,991
Net loss (1,907,301) (1,317,915)
Induced conversions of Preferred Stock (61,000) 0
Net loss attributable to common stockholders $ (1,968,301) $ 0
NET LOSS PER SHARE-BASIC (in dollars per share) $ 0 $ 0
NET LOSS PER SHARE-DILUTED (in dollars per share) $ 0 $ 0
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC (in shares) 341,671,076,830 339,741,632,384
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-DILUTED (in shares) 341,671,076,830 339,741,632,384
Vapor [Member]    
SALES    
SALES, NET $ 38 $ 249,563
Cost of sales 653 111,684
Grocery [Member]    
SALES    
SALES, NET 13,559,706 4,798,990
Cost of sales $ 8,644,700 $ 2,964,355
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Total
Series E Convertible Preferred Stock [Member]
Balance at Dec. 31, 2021           $ 0  
Balance (in shares) at Dec. 31, 2021           0  
Balance at Mar. 31, 2022           $ 0  
Balance (in shares) at Mar. 31, 2022           0  
Balance at Dec. 31, 2021   $ 800,000 $ 33,974,163 $ 30,855,824 $ (36,396,330) $ 29,233,657  
Balance (in shares) at Dec. 31, 2021   800 339,741,632,384        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock options exercised (in shares)           0  
Induced conversions of Preferred Stock           $ 0  
Net loss $ 0   $ 0 0 (1,317,915) (1,317,915)  
Balance at Mar. 31, 2022   $ 800,000 $ 33,974,163 30,855,824 (37,714,245) 27,915,742  
Balance (in shares) at Mar. 31, 2022   800 339,741,632,384        
Balance at Dec. 31, 2022           $ 14,722,075  
Balance (in shares) at Dec. 31, 2022           14,722  
Increase (Decrease) in Convertible Preferred Stock [Roll Forward]              
Series E convertible preferred stock redeemed           $ (555,550)  
Series E convertible preferred stock redeemed (in shares)           (556)  
Conversion of series E convertible preferred stock           $ (670,000)  
Conversion of series E convertible preferred stock (in shares)           (670)  
Balance at Mar. 31, 2023           $ 13,496,525  
Balance (in shares) at Mar. 31, 2023           13,497  
Balance at Dec. 31, 2022   $ 800,000 $ 33,974,163 29,045,802 (43,613,941) $ 20,206,024  
Balance (in shares) at Dec. 31, 2022   800 339,741,632,384        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Series E convertible preferred stock redeemed $ 0   $ 0 0 0 $ 0  
Series E convertible preferred stock redeemed (in shares) 0   0        
Stock options exercised (in shares)           0  
Conversion of series E convertible preferred stock $ 0   $ 670,000 0 0 $ 670,000  
Conversion of series E convertible preferred stock (in shares) 0   6,700,000,000       6,700,000,000
Induced conversions of Preferred Stock $ 0   $ 0 (61,000) 0 (61,000)  
Stock-based compensation expense 0   0 50,000 0 50,000  
Net loss $ 0   0 0 (1,907,301) (1,907,301)  
Balance at Mar. 31, 2023   $ 800,000 $ 34,644,163 $ 29,034,802 $ (45,521,242) $ 18,957,723  
Balance (in shares) at Mar. 31, 2023   800 346,441,632,384        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
OPERATING ACTIVITIES    
Net loss $ (1,907,301) $ (1,317,915)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 373,462 193,322
Loss (gain) on investment 4,457 (3,514)
Amortization of right-of-use asset 695,192 177,643
Write-down of obsolete and slow-moving inventory 523,087 115,842
Stock-based compensation expense 50,000 0
Change in contingent consideration 22,100 0
Changes in operating assets and liabilities:    
Accounts receivable (44,818) (9,031)
Inventories (673,392) (160,312)
Prepaid expenses and vendor deposits (255,387) 157,641
Other current assets 279,701 0
Other assets 771 (27,446)
Accounts payable and accrued expenses (744,145) 415,957
Contract liabilities 1,766 (61,965)
Lease liability (669,803) (159,851)
NET CASH USED IN OPERATING ACTIVITIES (2,344,310) (679,629)
INVESTING ACTIVITIES    
Acquisition of Mother Earth's Storehouse 0 (5,150,000)
Collection of note receivable 16,320 13,772
Purchases of property and equipment (126,251) (127,275)
NET CASH USED IN INVESTING ACTIVITIES (109,931) (5,263,503)
FINANCING ACTIVITIES    
Proceeds from line of credit 0 35,196
Principal payments on loan payable (131,614) (638)
Payment of induced conversions of preferred stock (55,000) 0
Payment for series E preferred stock redemption (555,550) 0
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (742,164) 34,558
Payment of induced conversions of Preferred Stock 55,000 0
NET DECREASE IN CASH AND RESTRICTED CASH (3,196,405) (5,908,574)
CASH AND RESTRICTED CASH - BEGINNING OF PERIOD 24,690,124 26,496,404
CASH AND RESTRICTED CASH - END OF PERIOD 21,493,719 20,587,830
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid for interest 44,478 1,428
Cash paid for income tax 0 0
NON-CASH INVESTING AND FINANCING ACTIVITIES    
Issuance of common stock in connection with series E preferred stock conversion 670,000 0
Right-of-use assets obtained in exchange for operating lease liabilities 1,093,290 1,797,667
Accrued payment of induced conversions of Preferred Stock $ 6,000 $ 0
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION
3 Months Ended
Mar. 31, 2023
ORGANIZATION [Abstract]  
ORGANIZATION
Note 1. ORGANIZATION

Organization

Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives.

Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio. 

Through its wholly owned subsidiaries, the Company operates:

Ada’s Natural Market, a natural and organic grocery store offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.

Paradise Health & Nutrition’s three stores that likewise offer fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.

Mother Earth’s Storehouse, a two-store organic and health food and vitamin chain in New York’s Hudson Valley, a business that has been in existence for over 40 years.

Greens Natural Foods’ eight stores in New York and New Jersey, offering a selection of 100% organic produce and all-natural, non-GMO groceries & bulk foods; a wide selection of local products; an organic juice and smoothie bar; a fresh foods department, which offers fresh and healthy “grab & go” foods; a full selection of vitamins & supplements; as well as health and beauty products

Through its wholly owned subsidiary, Healthy Choice Wellness, LLC, the Company operates:

Licensing agreements for Healthy Choice Wellness Centers located at the Casbah Spa and Salon in Fort Lauderdale, FL, Boston Direct Health in Boston, MA and Green Care Medical Services in Chicago, IL.

These centers offer multiple vitamin drip mixes and intramuscular shots for clients to choose from that are designed to help boost immunity, fight fatigue and stress, reduce inflammation, enhance weight loss, and efficiently deliver antioxidants and anti-aging mixes. Additionally, there are IV vitamin mixes and shots for health, beauty, and re-hydration.

Through its wholly owned subsidiary, Healthy U Wholesale, Inc, the Company sells vitamins and supplements, as well as health, beauty, and personal care products on its website www.TheVitaminStore.com.

Additionally, the Company markets its patented the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally.

Spin-Off

The Company has commenced steps to spin off ("Spin-Off") its grocery segment and wellness business into a new publicly traded company (hereinafter referred to as “NewCo”). NewCo will continue the path of growth in the wellness verticals started by HCMC and explore other growth opportunities that comport with HCMC’s healthier lifestyle mission. Following the Spin-Off, HCMC will retain its entire patent suite, the Q-Cup® brand, and continue to develop its patent suite through R&D as well as continuing its path of enforcing its patent rights against infringers and attempting to monetize said patents through licensing deals.

At the time of the Spin-Off, HCMC will distribute all the outstanding shares of Common Stock held by it on a pro rata basis to holders of HCMC’s common stock. Shares of HCMC’s common stock outstanding as of the record date for the Spin-Off (the “Record Date”), will entitle the holder thereof to receive a certain number of shares of Common Stock in NewCo. The distribution will be made in book-entry form by a distribution agent. Fractional shares of Common Stock will not be distributed in the Spin-Off and any fractional amounts will be rounded down. Please see more disclosure in Note 12 Stockholder Equity.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
LIQUIDITY
3 Months Ended
Mar. 31, 2023
LIQUIDITY [Abstract]  
LIQUIDITY
Note 2. LIQUIDITY

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.

The Company currently and historically has reported net losses and cash outflows from operations. As of March 31, 2023, the Company had cash of approximately $19.8 million and working capital of $18.3 million. In the past, the Company financed its operations primarily through issuances of common stock and convertible preferred stock. The Company believes current cash on hand is sufficient to meet its obligations and capital requirements for at least the next twelve months from the date of filing.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2023
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
Note 3. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-X and do not include all the information and disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The Company has made estimates and judgments affecting the amounts reported in the Company’s unaudited condensed consolidated financial statements and the accompanying notes. The actual results experienced by the Company may differ materially from the Company’s estimates. The condensed consolidated financial information is unaudited but reflects all normal adjustments that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company’s audited 2022 financial statements contained in the above referenced Form 10-K. Results of the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023.

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2022 Annual Report.

Reclassification

Certain amounts in the condensed consolidated financial statements and related notes have been reclassified to conform to the current year presentation. Such reclassifications do not impact the Company's previously reported financial position or net income (loss). $75,000 inventory shrink was originally presented in the statement of cash flow under change in operating assets inventory in cash used in operating activities for three months ended March 31, 2022, it was reclassified to write-down of obsolete and slow-moving inventory under cash used in operating activities in the statement of cash flow.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
CONCENTRATIONS
3 Months Ended
Mar. 31, 2023
CONCENTRATIONS [Abstract]  
CONCENTRATIONS
Note 4. CONCENTRATIONS

Cash and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash is concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. The Company did not have any cash equivalent as of March 31, 2023, and  December 31, 2022.

A summary of the financial institution that had cash in excess of FDIC limits of $250,000 on March 31, 2023 and December 31, 2022 is presented below:

March 31, 2023
 
December 31, 2022
 
Total cash in excess of FDIC limits of $250,000
 
$
18,646,360
   
$
21,682,144
 

The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company has not experienced any losses in such accounts.

The following table provides a reconciliation of cash and restricted cash to amounts shown in unaudited condensed consolidated statements of cash flow

 
March 31, 2023
   
March 31, 2022
 
Cash
 
$
19,765,487
   
$
20,587,830
 
Restricted cash
   
1,728,232
     
-
 
Total cash and restricted cash
 
$
21,493,719
   
$
20,587,830
 

Restricted Cash
 
The Company's restricted cash consisted of cash balances which were restricted as to withdrawal or usage under the August 18, 2022 securities purchase agreement for the purpose of funding any amounts due under the Series E Certificate of Designation upon the redemption of the Series E Preferred Stock. The balance also included cash held  in the collateral account to cover the cash draw from the line of credit.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES
3 Months Ended
Mar. 31, 2023
DISAGGREGATION OF REVENUES [Abstract]  
SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES
Note 5. SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES

In accordance with FASB ASC 280, "Disclosures about Segment of an enterprise and related information", the Company determined it has two reportable segments: grocery and vapor. There are no inter-segment revenues.

The Company's general and administrative costs are not segment specific. As a result, all operating expenses are not managed on segment basis.

The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 
Three Months Ended March 31,
 
   
2023
   
2022
 
Vapor
 
$
38
   
$
249,563
 
Grocery
   
13,559,706
     
4,798,990
 
Total revenue
 
$
13,559,744
   
$
5,048,553
 
                 
Retail Vapor
 
$
38
   
$
249,563
 
Retail Grocery
   
11,613,730
     
4,283,288
 
Food service/restaurant
   
1,943,914
     
509,810
 
Online/eCommerce
   
2,062
     
5,892
 
Total revenue
 
$
13,559,744
   
$
5,048,553
 
                 
Loss from operations - Vapor
   
(6,672
)
   
(18,967
)
(Loss) income from operations - Grocery
   
(276,842
)
   
163,936
 
Corporate items
   
(1,699,533
)
   
(1,499,875
)
Total loss from operations
 
$
(1,983,047
)
 
$
(1,354,906
)

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES RECEIVABLE AND OTHER INCOME
3 Months Ended
Mar. 31, 2023
NOTES RECEIVABLE AND OTHER INCOME [Abstract]  
NOTES RECEIVABLE AND OTHER INCOME
Note 6. NOTES RECEIVABLE AND OTHER INCOME

On September 6, 2018, the Company entered into a secured, 36-month promissory note (the “Note”) with VPR Brands L.P. for $582,260. The Note bears an interest rate of 7.00%, which payments thereunder are $4,141 weekly. The Company records all proceeds related to the interest of the Note as interest income as proceeds are received.

On August 31, 2022, the Company amended and restated the Note (the "Amended Note") with VPR Brands L.P. to extend the maturity date for one year. The outstanding balance for the Amended Note is $211,355. The Amended Note bears an interest rate of 7.00%, which payments thereunder are $1,500 weekly, with such payments commencing as of September 3, 2022. The Amended Note has a balloon payment of $145,931 for all remaining accrued interest and principal balance due in the final week of the 1-year extension of the Amended Note.

A summary of the Amended Note as of March 31, 2023 and December 31, 2022 is presented below:

Description
 
March 31, 2023
 
December 31, 2022
Promissory Note
 
$
172,905
 
$
189,225
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITION
3 Months Ended
Mar. 31, 2023
ACQUISITIONS [Abstract]  
ACQUISITION
Note 7. ACQUISITION

On October 14, 2022, the Company through its wholly owned subsidiary, Healthy Choice Markets IV, LLC, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Dean’s Natural Food Market of Shrewsbury, Inc., a New Jersey corporation, Green’s Natural Foods, Inc., a Delaware corporation, Dean’s Natural Food Market of Chester, LLC, a New Jersey limited liability company, Dean’s Natural Food Market of Basking Ridge, LLC, a New Jersey limited liability company, and Dean’s Natural Food Market, Inc., a New Jersey corporation (collectively, the “Sellers”), and shareholders of the Sellers. Pursuant to the Purchase Agreement, the Company acquired certain assets and assumed certain liabilities of an organic and natural health food and vitamin chain with eight store locations in New York and northern and central New Jersey (the “Stores”).

The cash purchase price under the Asset Purchase Agreement was $5,142,000, with $3,000,000 seller financing in the form of promissory note. In addition, the seller is entitled to a contingent earn-out based on a certain revenue threshold within the one-year period of the closing.

The Company recorded $1,108,000 of contingent consideration based on the estimated financial performance for the one year following closing.  The contingent consideration was discounted at an interest rate of 3.8%, which represents the Company's weighted average discount rate.  Contingent consideration related to the acquisition is recorded at fair value (level 3) with changes in fair value recorded in other expense (income), net.

The following table summarizes the change in fair value of contingent consideration from acquisition date to March 31, 2023:

 
Fair Market Value - Level 3
 
Balance as of October 14, 2022
 
$
1,108,000
 
Remeasurement
   
(333,100
)
Balance as of December 31, 2022
 
$
774,900
 
Remeasurement
   
22,100
 
Balance as of March 31, 2023
 
$
797,000
 

The following table summarizes the purchase price allocation based on fair values of the net assets acquired at the acquisition date:

 
October 14, 2022
 
Purchase Consideration
     
Cash consideration paid
 
$
5,142,000
 
Promissory note
   
3,000,000
 
Contingent consideration issued to Green's Natural seller
   
1,108,000
 
Total Purchase Consideration
 
$
9,250,000
 
         
Purchase price allocation
       
Inventory
 
$
1,642,000
 
Property and equipment
   
1,478,000
 
Intangible assets
   
3,251,000
 
Right of use asset - Operating lease
   
6,427,000
 
Other liabilities
   
(211,000
)
Operating lease liability
   
(6,427,000
)
Goodwill
   
3,090,000
 
Net assets acquired
 
$
9,250,000
 
         
Finite-lived intangible assets
       
Trade Names (8 years)
 
$
1,133,000
 
Customer Relationships (6 years)
   
1,103,000
 
Non-Compete Agreement (5 years)
   
1,015,000
 
Total intangible assets
 
$
3,251,000
 


The acquisition is structured as asset purchase in a business combination, and goodwill is tax-deductible, and amortizable over 15 years for tax purpose.

Revenue and Earnings

The following table represents the combined pro forma revenue and net loss for the three months ended March 31, 2022:

   
For Three Months Ended
 March 31, 2022
Sales
 
$
13,156,447
Net loss
 
$
(1,585,281)

The combined proforma revenue and net loss for the three month period ended March 31, 2022 were prepared as though acquisition occurred as of January 1, 2022.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT, AND EQUIPMENT
3 Months Ended
Mar. 31, 2023
PROPERTY, PLANT, AND EQUIPMENT [Abstract]  
PROPERTY, PLANT, AND EQUIPMENT
Note 8. PROPERTY, PLANT, AND EQUIPMENT

Property, plant, and equipment consist of the following:
   
March 31, 2023
   
December 31, 2022
Displays
 
$
312,146
   
$
312,146
Building
   
575,000
     
575,000
Furniture and fixtures
   
572,224
     
560,256
Leasehold improvements
   
1,910,719
     
1,910,719
Computer hardware & equipment
   
177,652
     
160,210
Other
   
684,443
     
587,602
     
4,232,184
     
4,105,933
Less: accumulated depreciation and amortization
   
(1,135,585)
     
(993,025)
Total property, plant, and equipment
 
$
3,096,599
   
$
3,112,908

The Company incurred approximately $142,560 and $49,936 of depreciation expense for the three months ended March 31, 2023 and 2022, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2023
INTANGIBLE ASSETS [Abstract]  
INTANGIBLE ASSETS
Note 9. INTANGIBLE ASSETS

Intangible assets, net are as follows:

March 31, 2023
 
Useful Lives (Years)
 
Gross
Carrying Amount
 
Accumulated
Amortization
 
Net
Carrying Amount
Trade names
   
8-10 years
 
$
2,569,000
 
$
(800,880)
 
$
1,768,120
Customer relationships
   
4-6 years
   
2,669,000
   
(1,107,722)
   
1,561,278
Patents
   
10 years
   
384,665
   
(169,587)
   
215,078
Non-compete
   
4-5 years
   
1,602,000
   
(371,867)
   
1,230,133
Intangible assets, net
       
$
7,224,665
 
$
(2,450,056)
 
$
4,774,609

December 31, 2022
 
Useful Lives (Years)
 
Gross
Carrying Amount
 
Accumulated
Amortization
 
Net
Carrying Amount
Trade names
   
8-10 years
 
 $
2,569,000
   
(725,723)
 
 $
1,843,277
Customer relationships
   
4-6 years
   
2,669,000
   
(1,033,306)
   
1,635,694
Patents
   
10 years
   
384,665
   
(159,658)
   
225,007
Non-compete
   
4-5 years
   
1,602,000
   
(300,467)
   
1,301,533
Intangible assets, net
       
$
7,224,665
 
$
(2,219,154)
 
$
5,005,511

Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately  $230,902 and $143,386 for the three months ended March 31, 2023 and 2022, respectively. Future annual estimated amortization expense is as follows:

Years ending December 31,
     
2023 (remaining nine months)
 
$
692,706
 
2024
   
923,608
 
2025
   
918,108
 
2026
   
840,127
 
2027
   
695,498
 
Thereafter
   
704,562
 
Total
 
$
4,774,609
 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
CONTRACT LIABILITIES
3 Months Ended
Mar. 31, 2023
CONTRACT LIABILITIES [Abstract]  
CONTRACT LIABILITIES
Note 10. CONTRACT LIABILITIES
A summary of the contract liabilities activity at March 31, 2023 and December 31, 2022 is presented below:


 
March 31, 2023
   
December 31, 2022
 
Beginning balance as January 1,
 
$
198,606
   
$
23,178
 
Issued
   
695,438
     
859,383
 
Redeemed
   
(640,160
)
   
(628,012
)
Breakage recognized
   
(53,512
)
   
(55,943
)
Ending balance
 
$
200,372
   
$
198,606
 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
DEBT
3 Months Ended
Mar. 31, 2023
DEBT [Abstract]  
DEBT
Note 11. DEBT

The following table provides a breakdown of the Company's debt as of March 31, 2023 and December 31, 2022 is presented below:

_
 
March 31, 2023
   
December 31, 2022
 
Promissory note
 
$
2,782,847
   
$
2,913,788
 
Other debt
   
142
     
815
 
Total debt
 
$
2,782,989
   
$
2,914,603
 
Current portion of long-term debt
   
(543,945
)
   
(536,542
)
Long-term debt
 
$
2,239,044
   
$
2,378,061
 
 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY
3 Months Ended
Mar. 31, 2023
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
Note 12. STOCKHOLDERS’ EQUITY

Series E Convertible Preferred Stock

On August 18, 2022, the Company entered into a Securities Purchase Agreement ("Series E Preferred Stock") pursuant to which the Company sold and issued 14,722 shares of its Series E Redeemable Convertible Preferred Stock to institutional investors for $1,000 per share or an aggregate subscription of $13.25 million. The number of shares issued to each participant is based on subscription amount multiplied by conversion rate of 1.1111. The Company also incurred offering costs of approximately $410,000, which covers legal and consulting fee.
The HCMC Series E Preferred Stock shall have voting rights on as converted basis at the Company’s next stockholders’ meeting. However, as long as any shares of HCMC Series E Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the HCMC Series E Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the HCMC Series E Preferred Stock or alter or amend the Certificate of Designation, (b) increase the number of authorized shares of HCMC Series E Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing. Each share of Series E Preferred Stock shall be convertible, at any time and from time to time at the option of the Holder thereof, into that number of shares of Common Stock (subject to the beneficial ownership limitations). The initial conversion price for the HCMC Series E Preferred Stock shall equal $0.0001.
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of HCMC Series E Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to $1,000 per share of Series E Preferred Stock.

Unless earlier converted or extended as set forth below, a holder may require the redemption of all or a portion of the stated value of the HCMC Series E Preferred Stock either (1) six months after closing or (2) the time at which the balance is due and payable upon an event of default.

On March 1, 2023, the Company entered into a First Amendment to HCMC Series E Preferred Stock with each purchaser ("Purchaser") identified as those who participated in the HCMC Series E Preferred Stock, dated as of August 18, 2022.  The parties amended the HCMC Preferred Stock related to the conversion payment whereby upon conversion of the Series E Preferred Stock prior to the record date for the Spin-Off, the Company will pay the Purchaser ten percent (10%) of the stated value of the Series E Preferred Stock converted. The record date is May 1, 2023.

As of March 31, 2023, 6,700,000,000 shares of common stock were issued as a result of the Series E preferred stock conversion. 556 shares of Series E preferred stock was redeemed and approximately $556,000 was paid for redemption.

Pursuant to the Securities Purchase Agreement, purchasers of the Series E Convertible Preferred Stock will also be required to purchase Series A Convertible Preferred Stock of NewCo resulting from spin off of HCMC’s grocery and wellness businesses in the same subscription amounts that the Purchasers paid for the HCMC Series E Preferred Stock.

Stock Options

During the three months ended March 31, 2023 and 2022, no stock options of the Company were exercised into common stock.

During the three months ended March 31, 2023 and 2022, the Company recognized stock-based compensation of approximately $50,000 and $0, respectively in connection with amortization of restricted stock and stock options. Stock based compensation is included as part of selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations.

Income (Loss) Per Share

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 
As of March 31,
 
   
2023
   
2022
 
Preferred stock
   
136,215,000,000
     
1,250,000,000
 
Stock options
   
67,587,000,000
     
67,587,000,000
 
Restricted stock
   
5,500,000,000
     
-
 
Total
   
209,302,000,000
     
68,837,000,000
 
 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2023
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
Note 13. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints in 2019 and we exchanged additional support information with the plaintiff for one of the lawsuits in 2021. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.

On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia.  The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed a notice of appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. The appeal brief was filed on February 28, 2022.

On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $575,000 in attorneys’ fees to be paid by the Company. The Company has fully provisioned this amount as of December 31, 2022. HCMC appealed this ruling on June 22, 2022. Refer to Note 14 Subsequent Event.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of March 31, 2023. With respect to legal costs, we record such costs as incurred.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2023
SUBSEQUENT EVENTS [Abstract]  
SUBSEQUENT EVENTS
Note 14. SUBSEQUENT EVENTS

On April 12, 2023, the U.S. Court of Appeals for the Federal Circuit ruled in favor of HCMC on two separate appeals it had filed in its patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. pending in the district court for the Northern District of Georgia.

In the first appeal, HCMC appealed the ruling of the District Court dismissing HCMC’s patent infringement action and denying HCMC’s motion to amend its pleading. In the second appeal, HCMC appealed the District Court’s award of attorneys’ fees to Philip Morris. In its decisions, the Federal Circuit ruled for HCMC by reversing both of those decisions and remanded the case back to the District Court for further proceedings.

As of the date of filing, 9,150,000,000 shares of common stock were subsequently issued since March 31, 2023 as a result of HCMC Series E Preferred Stock conversions.

On April 23, 2023, the Board of Directors of HCMC approved the Second Amendment to the 2015 Equity Incentive Plan which increased the number of shares of HCMC common stock authorized for issuance under the Amended Plan to 225,000,000,000 shares. The board of directors also approved the issuance of an additional 107,675,000,000 shares of restricted common stock to the employees and executive officers of HCMC. The grants of restricted common stock will commence vesting at 12.5% of the award on February 1, 2024 and will vest in 2.5% increments on the last day of each calendar quarter thereafter through September 30, 2025.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION (Policies)
3 Months Ended
Mar. 31, 2023
ORGANIZATION [Abstract]  
Spin-Off
Spin-Off

The Company has commenced steps to spin off ("Spin-Off") its grocery segment and wellness business into a new publicly traded company (hereinafter referred to as “NewCo”). NewCo will continue the path of growth in the wellness verticals started by HCMC and explore other growth opportunities that comport with HCMC’s healthier lifestyle mission. Following the Spin-Off, HCMC will retain its entire patent suite, the Q-Cup® brand, and continue to develop its patent suite through R&D as well as continuing its path of enforcing its patent rights against infringers and attempting to monetize said patents through licensing deals.

At the time of the Spin-Off, HCMC will distribute all the outstanding shares of Common Stock held by it on a pro rata basis to holders of HCMC’s common stock. Shares of HCMC’s common stock outstanding as of the record date for the Spin-Off (the “Record Date”), will entitle the holder thereof to receive a certain number of shares of Common Stock in NewCo. The distribution will be made in book-entry form by a distribution agent. Fractional shares of Common Stock will not be distributed in the Spin-Off and any fractional amounts will be rounded down. Please see more disclosure in Note 12 Stockholder Equity.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2023
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Reclassification
Reclassification

Certain amounts in the condensed consolidated financial statements and related notes have been reclassified to conform to the current year presentation. Such reclassifications do not impact the Company's previously reported financial position or net income (loss). $75,000 inventory shrink was originally presented in the statement of cash flow under change in operating assets inventory in cash used in operating activities for three months ended March 31, 2022, it was reclassified to write-down of obsolete and slow-moving inventory under cash used in operating activities in the statement of cash flow.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
CONCENTRATIONS (Tables)
3 Months Ended
Mar. 31, 2023
CONCENTRATIONS [Abstract]  
Cash and Cash Equivalents in Excess of FDIC Limit
A summary of the financial institution that had cash in excess of FDIC limits of $250,000 on March 31, 2023 and December 31, 2022 is presented below:

March 31, 2023
 
December 31, 2022
 
Total cash in excess of FDIC limits of $250,000
 
$
18,646,360
   
$
21,682,144
 
Cash and Restricted Cash
The following table provides a reconciliation of cash and restricted cash to amounts shown in unaudited condensed consolidated statements of cash flow

 
March 31, 2023
   
March 31, 2022
 
Cash
 
$
19,765,487
   
$
20,587,830
 
Restricted cash
   
1,728,232
     
-
 
Total cash and restricted cash
 
$
21,493,719
   
$
20,587,830
 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Tables)
3 Months Ended
Mar. 31, 2023
DISAGGREGATION OF REVENUES [Abstract]  
Disaggregated Revenue
The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 
Three Months Ended March 31,
 
   
2023
   
2022
 
Vapor
 
$
38
   
$
249,563
 
Grocery
   
13,559,706
     
4,798,990
 
Total revenue
 
$
13,559,744
   
$
5,048,553
 
                 
Retail Vapor
 
$
38
   
$
249,563
 
Retail Grocery
   
11,613,730
     
4,283,288
 
Food service/restaurant
   
1,943,914
     
509,810
 
Online/eCommerce
   
2,062
     
5,892
 
Total revenue
 
$
13,559,744
   
$
5,048,553
 
                 
Loss from operations - Vapor
   
(6,672
)
   
(18,967
)
(Loss) income from operations - Grocery
   
(276,842
)
   
163,936
 
Corporate items
   
(1,699,533
)
   
(1,499,875
)
Total loss from operations
 
$
(1,983,047
)
 
$
(1,354,906
)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES RECEIVABLE AND OTHER INCOME (Tables)
3 Months Ended
Mar. 31, 2023
NOTES RECEIVABLE AND OTHER INCOME [Abstract]  
Summary of Amended Notes
A summary of the Amended Note as of March 31, 2023 and December 31, 2022 is presented below:

Description
 
March 31, 2023
 
December 31, 2022
Promissory Note
 
$
172,905
 
$
189,225
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITION (Tables)
3 Months Ended
Mar. 31, 2023
ACQUISITIONS [Abstract]  
Change in Fair Value of Contingent Consideration
The following table summarizes the change in fair value of contingent consideration from acquisition date to March 31, 2023:

 
Fair Market Value - Level 3
 
Balance as of October 14, 2022
 
$
1,108,000
 
Remeasurement
   
(333,100
)
Balance as of December 31, 2022
 
$
774,900
 
Remeasurement
   
22,100
 
Balance as of March 31, 2023
 
$
797,000
 
Purchase Price Allocation for Mother Earth's Storehouse, Inc.
The following table summarizes the purchase price allocation based on fair values of the net assets acquired at the acquisition date:

 
October 14, 2022
 
Purchase Consideration
     
Cash consideration paid
 
$
5,142,000
 
Promissory note
   
3,000,000
 
Contingent consideration issued to Green's Natural seller
   
1,108,000
 
Total Purchase Consideration
 
$
9,250,000
 
         
Purchase price allocation
       
Inventory
 
$
1,642,000
 
Property and equipment
   
1,478,000
 
Intangible assets
   
3,251,000
 
Right of use asset - Operating lease
   
6,427,000
 
Other liabilities
   
(211,000
)
Operating lease liability
   
(6,427,000
)
Goodwill
   
3,090,000
 
Net assets acquired
 
$
9,250,000
 
         
Finite-lived intangible assets
       
Trade Names (8 years)
 
$
1,133,000
 
Customer Relationships (6 years)
   
1,103,000
 
Non-Compete Agreement (5 years)
   
1,015,000
 
Total intangible assets
 
$
3,251,000
 
Supplemental Pro Forma Information
The following table represents the combined pro forma revenue and net loss for the three months ended March 31, 2022:

   
For Three Months Ended
 March 31, 2022
Sales
 
$
13,156,447
Net loss
 
$
(1,585,281)

The combined proforma revenue and net loss for the three month period ended March 31, 2022 were prepared as though acquisition occurred as of January 1, 2022.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT, AND EQUIPMENT (Tables)
3 Months Ended
Mar. 31, 2023
PROPERTY, PLANT, AND EQUIPMENT [Abstract]  
Property, plant, and equipment
Property, plant, and equipment consist of the following:
   
March 31, 2023
   
December 31, 2022
Displays
 
$
312,146
   
$
312,146
Building
   
575,000
     
575,000
Furniture and fixtures
   
572,224
     
560,256
Leasehold improvements
   
1,910,719
     
1,910,719
Computer hardware & equipment
   
177,652
     
160,210
Other
   
684,443
     
587,602
     
4,232,184
     
4,105,933
Less: accumulated depreciation and amortization
   
(1,135,585)
     
(993,025)
Total property, plant, and equipment
 
$
3,096,599
   
$
3,112,908
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS (Tables)
3 Months Ended
Mar. 31, 2023
INTANGIBLE ASSETS [Abstract]  
Intangible Assets, Net
Intangible assets, net are as follows:

March 31, 2023
 
Useful Lives (Years)
 
Gross
Carrying Amount
 
Accumulated
Amortization
 
Net
Carrying Amount
Trade names
   
8-10 years
 
$
2,569,000
 
$
(800,880)
 
$
1,768,120
Customer relationships
   
4-6 years
   
2,669,000
   
(1,107,722)
   
1,561,278
Patents
   
10 years
   
384,665
   
(169,587)
   
215,078
Non-compete
   
4-5 years
   
1,602,000
   
(371,867)
   
1,230,133
Intangible assets, net
       
$
7,224,665
 
$
(2,450,056)
 
$
4,774,609

December 31, 2022
 
Useful Lives (Years)
 
Gross
Carrying Amount
 
Accumulated
Amortization
 
Net
Carrying Amount
Trade names
   
8-10 years
 
 $
2,569,000
   
(725,723)
 
 $
1,843,277
Customer relationships
   
4-6 years
   
2,669,000
   
(1,033,306)
   
1,635,694
Patents
   
10 years
   
384,665
   
(159,658)
   
225,007
Non-compete
   
4-5 years
   
1,602,000
   
(300,467)
   
1,301,533
Intangible assets, net
       
$
7,224,665
 
$
(2,219,154)
 
$
5,005,511
Future Annual Estimated Amortization Expense
Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately  $230,902 and $143,386 for the three months ended March 31, 2023 and 2022, respectively. Future annual estimated amortization expense is as follows:

Years ending December 31,
     
2023 (remaining nine months)
 
$
692,706
 
2024
   
923,608
 
2025
   
918,108
 
2026
   
840,127
 
2027
   
695,498
 
Thereafter
   
704,562
 
Total
 
$
4,774,609
 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
CONTRACT LIABILITIES (Tables)
3 Months Ended
Mar. 31, 2023
CONTRACT LIABILITIES [Abstract]  
Summary of Net Changes in Contract Liabilities
A summary of the contract liabilities activity at March 31, 2023 and December 31, 2022 is presented below:


 
March 31, 2023
   
December 31, 2022
 
Beginning balance as January 1,
 
$
198,606
   
$
23,178
 
Issued
   
695,438
     
859,383
 
Redeemed
   
(640,160
)
   
(628,012
)
Breakage recognized
   
(53,512
)
   
(55,943
)
Ending balance
 
$
200,372
   
$
198,606
 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
DEBT (Tables)
3 Months Ended
Mar. 31, 2023
DEBT [Abstract]  
Breakdown of Debt
The following table provides a breakdown of the Company's debt as of March 31, 2023 and December 31, 2022 is presented below:

_
 
March 31, 2023
   
December 31, 2022
 
Promissory note
 
$
2,782,847
   
$
2,913,788
 
Other debt
   
142
     
815
 
Total debt
 
$
2,782,989
   
$
2,914,603
 
Current portion of long-term debt
   
(543,945
)
   
(536,542
)
Long-term debt
 
$
2,239,044
   
$
2,378,061
 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY (Tables)
3 Months Ended
Mar. 31, 2023
STOCKHOLDERS' EQUITY [Abstract]  
Common Share Equivalent Excluded from Calculation of Dilutive Loss Per Share
The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 
As of March 31,
 
   
2023
   
2022
 
Preferred stock
   
136,215,000,000
     
1,250,000,000
 
Stock options
   
67,587,000,000
     
67,587,000,000
 
Restricted stock
   
5,500,000,000
     
-
 
Total
   
209,302,000,000
     
68,837,000,000
 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION (Details)
3 Months Ended
Mar. 31, 2023
Store
Mother Earth's Storehouse [Member]  
Company Organization [Abstract]  
Number of stores 2
Number of years the company has been operating 40 years
Paradise Health & Nutrition's [Member]  
Company Organization [Abstract]  
Number of stores 3
Greens Natural Foods' [Member]  
Company Organization [Abstract]  
Number of stores 8
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
LIQUIDITY (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
LIQUIDITY [Abstract]      
Cash and cash equivalents $ 19,765,487 $ 22,911,892 $ 20,587,830
Working capital $ 18,300,000    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Reclassification [Abstract]    
Write-down of obsolete and slow-moving inventory $ 523,087 $ 115,842
Changes in operating assets, inventories $ 673,392 160,312
Reclassification, Adjustment [Member]    
Reclassification [Abstract]    
Write-down of obsolete and slow-moving inventory   75,000
Changes in operating assets, inventories   $ (75,000)
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
CONCENTRATIONS (Details)
3 Months Ended
Mar. 31, 2023
USD ($)
FinancialInstitution
Dec. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Cash and Cash Equivalents in Excess of FDIC Limits [Abstract]        
Number of financial institution | FinancialInstitution 1      
FDIC insured amount $ 250,000      
Total Cash in excess of FDIC limits of $250,000 18,646,360 $ 21,682,144    
Cash and Restricted Cash [Abstract]        
Cash 19,765,487 22,911,892 $ 20,587,830  
Restricted cash 1,728,232 1,778,232 0  
Total cash and restricted cash $ 21,493,719 $ 24,690,124 $ 20,587,830 $ 26,496,404
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Details)
3 Months Ended
Mar. 31, 2023
USD ($)
Segment
Mar. 31, 2022
USD ($)
DISAGGREGATION OF REVENUES [Abstract]    
Number of operating segments | Segment 2  
Segment Information [Abstract]    
Revenue $ 13,559,744 $ 5,048,553
Total loss (1,983,047) (1,354,906)
Retail Vapor [Member]    
Segment Information [Abstract]    
Revenue 38 249,563
Retail Grocery [Member]    
Segment Information [Abstract]    
Revenue 11,613,730 4,283,288
Food Service/Restaurant [Member]    
Segment Information [Abstract]    
Revenue 1,943,914 509,810
Online/e-Commerce [Member]    
Segment Information [Abstract]    
Revenue 2,062 5,892
Operating Segments [Member] | Vapor [Member]    
Segment Information [Abstract]    
Revenue 38 249,563
Total loss (6,672) (18,967)
Operating Segments [Member] | Grocery [Member]    
Segment Information [Abstract]    
Revenue 13,559,706 4,798,990
Total loss (276,842) 163,936
Corporate [Member]    
Segment Information [Abstract]    
Total loss $ (1,699,533) $ (1,499,875)
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES RECEIVABLE AND OTHER INCOME (Details) - USD ($)
3 Months Ended
Aug. 31, 2021
Sep. 06, 2018
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Receivables with Imputed Interest [Abstract]          
Proceeds     $ 16,320 $ 13,772  
Promissory Note [Member]          
Receivables with Imputed Interest [Abstract]          
Payment term     36 months    
Loan amount $ 211,355 $ 582,260      
Interest rate 7.00% 7.00%      
Proceeds $ 1,500 $ 4,141      
Balloon payment $ 145,931        
Extension term     1 year    
Remaining balance     $ 172,905   $ 189,225
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITION (Details)
3 Months Ended
Oct. 14, 2022
USD ($)
Mar. 31, 2023
USD ($)
Store
Dec. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Acquisitions [Abstract]        
Cash purchase price   $ 0   $ 5,150,000
Change in Fair Value of Contingent Consideration [Abstract]        
Beginning balance   774,900    
Remeasurement   22,100   0
Ending balance   797,000 $ 774,900  
Purchase Price Allocation [Abstract]        
Goodwill   $ 5,747,000 5,747,000  
Mother Earth's Storehouse [Member]        
Acquisitions [Abstract]        
Number of stores | Store   2    
Green's Natural Foods [Member]        
Acquisitions [Abstract]        
Cash purchase price $ 5,142,000      
Promissory note $ 3,000,000      
Number of stores | Store   8    
Interest rate 3.80%      
Cash Consideration paid $ 9,250,000      
Purchase Price Allocation [Abstract]        
Inventory 1,642,000      
Property and equipment 1,478,000      
Right of use asset - operating lease 6,427,000      
Other liabilities (211,000)      
Operating lease liability (6,427,000)      
Goodwill 3,090,000      
Net assets acquired 9,250,000      
Finite-Lived Intangible Assets [Abstract]        
Intangible assets 3,251,000      
Amortization period for goodwill for tax purposes   15 years    
Pro Forma Information [Abstract]        
Sales       13,156,447
Net loss       $ (1,585,281)
Green's Natural Foods [Member] | Fair Market Value - Level 3 [Member]        
Change in Fair Value of Contingent Consideration [Abstract]        
Beginning balance   $ 774,900 1,108,000  
Remeasurement   22,100 (333,100)  
Ending balance 1,108,000 $ 797,000 $ 774,900  
Green's Natural Foods [Member] | Trademarks [Member]        
Finite-Lived Intangible Assets [Abstract]        
Intangible assets 1,133,000      
Amortization period   8 years    
Green's Natural Foods [Member] | Customer Relationships [Member]        
Finite-Lived Intangible Assets [Abstract]        
Intangible assets 1,103,000      
Amortization period   6 years    
Green's Natural Foods [Member] | Non-Compete Agreement [Member]        
Finite-Lived Intangible Assets [Abstract]        
Intangible assets 1,015,000      
Amortization period   5 years    
Sellers [Member]        
Acquisitions [Abstract]        
Cash Consideration paid $ 1,108,000      
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Property and Equipment [Abstract]      
Property and equipment, gross $ 4,232,184   $ 4,105,933
Less: accumulated depreciation and amortization (1,135,585)   (993,025)
Total property, plant, and equipment 3,096,599   3,112,908
Depreciation expense 142,560 $ 49,936  
Displays [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross 312,146   312,146
Building [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross 575,000   575,000
Furniture and Fixtures [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross 572,224   560,256
Leasehold Improvements [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross 1,910,719   1,910,719
Computer Hardware & Equipment [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross 177,652   160,210
Other [Member]      
Property and Equipment [Abstract]      
Property and equipment, gross $ 684,443   $ 587,602
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS, Intangible Assets, Net (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Intangible Assets, Net [Abstract]    
Gross carrying amount $ 7,224,665 $ 7,224,665
Accumulated amortization (2,450,056) (2,219,154)
Net carrying amount 4,774,609 5,005,511
Trademarks [Member]    
Intangible Assets, Net [Abstract]    
Gross carrying amount 2,569,000 2,569,000
Accumulated amortization (800,880) (725,723)
Net carrying amount $ 1,768,120 $ 1,843,277
Trademarks [Member] | Minimum [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 8 years 8 years
Trademarks [Member] | Maximum [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 10 years 10 years
Customer Relationships [Member]    
Intangible Assets, Net [Abstract]    
Gross carrying amount $ 2,669,000 $ 2,669,000
Accumulated amortization (1,107,722) (1,033,306)
Net carrying amount $ 1,561,278 $ 1,635,694
Customer Relationships [Member] | Minimum [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 4 years 4 years
Customer Relationships [Member] | Maximum [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 6 years 6 years
Patents [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 10 years 10 years
Gross carrying amount $ 384,665 $ 384,665
Accumulated amortization (169,587) (159,658)
Net carrying amount 215,078 225,007
Non-Compete [Member]    
Intangible Assets, Net [Abstract]    
Gross carrying amount 1,602,000 1,602,000
Accumulated amortization (371,867) (300,467)
Net carrying amount $ 1,230,133 $ 1,301,533
Non-Compete [Member] | Minimum [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 4 years 4 years
Non-Compete [Member] | Maximum [Member]    
Intangible Assets, Net [Abstract]    
Useful lives 5 years 5 years
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
INTANGIBLE ASSETS [Abstract]      
Amortization expense $ 230,902 $ 143,386  
Future Annual Estimated Amortization Expense [Abstract]      
2023 (remaining nine months) 692,706    
2024 923,608    
2025 918,108    
2026 840,127    
2027 695,498    
Thereafter 704,562    
Net carrying amount $ 4,774,609   $ 5,005,511
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
CONTRACT LIABILITIES (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Changes in Contract Liabilities Activity [Roll Forward]    
Beginning balance $ 198,606 $ 23,178
Issued 695,438 859,383
Redeemed (640,160) (628,012)
Breakage recognized (53,512) (55,943)
Ending balance as of March 31, $ 200,372 $ 198,606
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.1
DEBT (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Debt [Abstract]    
Debt $ 2,782,989 $ 2,914,603
Current portion of long-term debt (543,945) (536,542)
Long-term debt 2,239,044 2,378,061
Promissory Note [Member]    
Debt [Abstract]    
Debt 2,782,847 2,913,788
Other Debt [Member]    
Debt [Abstract]    
Debt $ 142 $ 815
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY, Series E Convertible Preferred Stock (Details)
3 Months Ended
Aug. 18, 2022
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Mar. 21, 2023
Dec. 31, 2022
$ / shares
shares
Series E Convertible Preferred Stock [Abstract]        
Number of preferred shares sold and issued (in shares) | shares   800   800
Preferred stock, stated value (in dollars per share) | $ / shares   $ 1,000   $ 1,000
Percentage of stated value of preferred stock will be paid to purchaser upon conversion     10.00%  
Series E Convertible Preferred Stock [Member]        
Series E Convertible Preferred Stock [Abstract]        
Number of preferred shares sold and issued (in shares) | shares 14,722      
Preferred stock, stated value (in dollars per share) | $ / shares $ 1,000      
Aggregate subscription price | $ $ 13,250,000      
Conversion rate 1.1111      
Offering costs | $ $ 410,000      
Conversion price (in dollars per share) | $ / shares $ 0.0001      
Liquidation preference (in dollars per share) | $ / shares $ 1,000      
Redemption period   6 months    
Issuance of common stock (in shares) | shares   6,700,000,000    
Stock redeemed (in shares) | shares   556,000    
Stock redeemed | $   $ 556,000    
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY, Stock Options (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Compensation Expense Recognized [Abstract]    
Stock options exercised (in shares) 0 0
Stock-based compensation $ 50,000 $ 0
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract]    
Antidilutive securities excluded from computation of diluted loss per share (in shares) 209,302,000,000 68,837,000,000
Preferred Stock [Member]    
Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract]    
Antidilutive securities excluded from computation of diluted loss per share (in shares) 136,215,000,000 1,250,000,000
Stock Options [Member]    
Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract]    
Antidilutive securities excluded from computation of diluted loss per share (in shares) 67,587,000,000 67,587,000,000
Restricted Stock [Member]    
Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract]    
Antidilutive securities excluded from computation of diluted loss per share (in shares) 5,500,000,000 0
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details)
User in Millions
3 Months Ended
Feb. 22, 2022
USD ($)
Mar. 31, 2023
USD ($)
Lawsuit
Nov. 30, 2020
USD ($)
User
Alleged Claimed Battery Defects For Electronic Cigarette Device [Member]      
Legal Proceedings [Abstract]      
Number of lawsuits | Lawsuit   2  
Philip Morris [Member]      
Legal Proceedings [Abstract]      
Number of users approached | User     14
Invested amount     $ 3,000,000,000
Philip Morris [Member] | Patent Infringement Litigation [Member]      
Legal Proceedings [Abstract]      
Attorney fees paid $ 575,000    
Medical Costs [Member] | Alleged Claimed Battery Defects For Electronic Cigarette Device [Member]      
Legal Proceedings [Abstract]      
Damages sought   $ 400,000  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details)
3 Months Ended
May 05, 2023
shares
Apr. 23, 2023
shares
Apr. 12, 2023
Appeal
Oct. 14, 2022
USD ($)
Mar. 31, 2023
shares
Sellers [Member]          
Subsequent Event [Abstract]          
Purchase price | $       $ 1,108,000  
Series E Convertible Preferred Stock [Member]          
Subsequent Event [Abstract]          
Issuance of common stock (in shares)         6,700,000,000
Subsequent Event [Member]          
Subsequent Event [Abstract]          
Number of appeals filed in patent infringement | Appeal     2    
Subsequent Event [Member] | Series E Convertible Preferred Stock [Member]          
Subsequent Event [Abstract]          
Issuance of common stock (in shares) 9,150,000,000        
Subsequent Event [Member] | 2015 Equity Incentive Plan [Member]          
Subsequent Event [Abstract]          
Common stock available for grant (in shares)   225,000,000,000      
Subsequent Event [Member] | 2015 Equity Incentive Plan [Member] | Vesting on February 1, 2024 [Member]          
Subsequent Event [Abstract]          
Stock vesting percentage   12.50%      
Subsequent Event [Member] | 2015 Equity Incentive Plan [Member] | Last Day of Each Calendar Quarter Thereafter Through September 30, 2025 [Member]          
Subsequent Event [Abstract]          
Stock vesting percentage   2.50%      
Subsequent Event [Member] | 2015 Equity Incentive Plan [Member] | Restricted Stock [Member] | Employees and Executive Officers [Member]          
Subsequent Event [Abstract]          
Granted (in shares)   107,675,000,000      
XML 60 form10q_htm.xml IDEA: XBRL DOCUMENT 0000844856 2023-01-01 2023-03-31 0000844856 2023-05-05 0000844856 2023-03-31 0000844856 2022-12-31 0000844856 hcmc:VaporMember 2023-01-01 2023-03-31 0000844856 hcmc:GroceryMember 2022-01-01 2022-03-31 0000844856 hcmc:VaporMember 2022-01-01 2022-03-31 0000844856 hcmc:GroceryMember 2023-01-01 2023-03-31 0000844856 2022-01-01 2022-03-31 0000844856 2021-12-31 0000844856 2022-03-31 0000844856 us-gaap:CommonStockMember 2021-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000844856 us-gaap:CommonStockMember 2022-12-31 0000844856 us-gaap:RetainedEarningsMember 2021-12-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000844856 us-gaap:RetainedEarningsMember 2022-12-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000844856 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000844856 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000844856 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000844856 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000844856 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000844856 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000844856 us-gaap:RetainedEarningsMember 2023-03-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000844856 us-gaap:CommonStockMember 2023-03-31 0000844856 us-gaap:CommonStockMember 2022-03-31 0000844856 us-gaap:RetainedEarningsMember 2022-03-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000844856 hcmc:MotherEarthsStorehouseMember 2023-03-31 0000844856 hcmc:ParadiseHealthNutritionSMember 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember 2023-03-31 0000844856 hcmc:MotherEarthsStorehouseMember 2023-01-01 2023-03-31 0000844856 srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:VaporMember 2022-01-01 2022-03-31 0000844856 hcmc:OnlineAndECommerceMember 2022-01-01 2022-03-31 0000844856 hcmc:OnlineAndECommerceMember 2023-01-01 2023-03-31 0000844856 hcmc:FoodServiceAndRestaurantMember 2022-01-01 2022-03-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:GroceryMember 2023-01-01 2023-03-31 0000844856 hcmc:RetailVaporMember 2022-01-01 2022-03-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:VaporMember 2023-01-01 2023-03-31 0000844856 hcmc:RetailVaporMember 2023-01-01 2023-03-31 0000844856 hcmc:RetailGroceryMember 2023-01-01 2023-03-31 0000844856 hcmc:FoodServiceAndRestaurantMember 2023-01-01 2023-03-31 0000844856 hcmc:RetailGroceryMember 2022-01-01 2022-03-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:GroceryMember 2022-01-01 2022-03-31 0000844856 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000844856 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000844856 hcmc:PromissoryNotesMember 2023-01-01 2023-03-31 0000844856 hcmc:PromissoryNotesMember 2018-09-06 0000844856 hcmc:PromissoryNotesMember 2021-08-31 0000844856 hcmc:PromissoryNotesMember 2018-09-06 2018-09-06 0000844856 hcmc:PromissoryNotesMember 2021-08-31 2021-08-31 0000844856 hcmc:PromissoryNotesMember 2022-12-31 0000844856 hcmc:PromissoryNotesMember 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember 2022-10-14 2022-10-14 0000844856 hcmc:GreenSNaturalFoodsMember 2022-10-14 0000844856 hcmc:SellersMember 2022-10-14 2022-10-14 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:FairValueInputsLevel3Member 2022-10-14 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:FairValueInputsLevel3Member 2022-10-15 2022-12-31 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:CustomerRelationshipsMember 2022-10-14 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:NoncompeteAgreementsMember 2022-10-14 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:TrademarksAndTradeNamesMember 2022-10-14 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:NoncompeteAgreementsMember 2023-01-01 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember us-gaap:TrademarksAndTradeNamesMember 2023-01-01 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember 2023-01-01 2023-03-31 0000844856 hcmc:GreenSNaturalFoodsMember 2022-01-01 2022-03-31 0000844856 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000844856 us-gaap:BuildingMember 2022-12-31 0000844856 us-gaap:ComputerEquipmentMember 2022-12-31 0000844856 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000844856 us-gaap:FurnitureAndFixturesMember 2023-03-31 0000844856 hcmc:DisplaysMember 2023-03-31 0000844856 hcmc:DisplaysMember 2022-12-31 0000844856 us-gaap:BuildingMember 2023-03-31 0000844856 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000844856 us-gaap:OtherMachineryAndEquipmentMember 2022-12-31 0000844856 us-gaap:OtherMachineryAndEquipmentMember 2023-03-31 0000844856 us-gaap:ComputerEquipmentMember 2023-03-31 0000844856 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0000844856 us-gaap:PatentsMember 2022-01-01 2022-12-31 0000844856 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2023-01-01 2023-03-31 0000844856 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2022-01-01 2022-12-31 0000844856 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2023-01-01 2023-03-31 0000844856 srt:MaximumMember us-gaap:TradeNamesMember 2022-01-01 2022-12-31 0000844856 srt:MaximumMember us-gaap:TradeNamesMember 2023-01-01 2023-03-31 0000844856 srt:MinimumMember us-gaap:TradeNamesMember 2022-01-01 2022-12-31 0000844856 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2022-01-01 2022-12-31 0000844856 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0000844856 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0000844856 us-gaap:PatentsMember 2023-01-01 2023-03-31 0000844856 srt:MinimumMember us-gaap:TradeNamesMember 2023-01-01 2023-03-31 0000844856 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2023-01-01 2023-03-31 0000844856 us-gaap:TradeNamesMember 2022-12-31 0000844856 us-gaap:PatentsMember 2022-12-31 0000844856 us-gaap:TradeNamesMember 2023-03-31 0000844856 us-gaap:NoncompeteAgreementsMember 2022-12-31 0000844856 us-gaap:CustomerRelationshipsMember 2022-12-31 0000844856 us-gaap:CustomerRelationshipsMember 2023-03-31 0000844856 us-gaap:NoncompeteAgreementsMember 2023-03-31 0000844856 us-gaap:PatentsMember 2023-03-31 0000844856 2022-01-01 2022-12-31 0000844856 hcmc:OtherDebtMember 2022-12-31 0000844856 hcmc:OtherDebtMember 2023-03-31 0000844856 hcmc:PromissoryNotesMember 2022-12-31 0000844856 hcmc:PromissoryNotesMember 2023-03-31 0000844856 hcmc:SeriesEConvertiblePreferredStockMember 2022-08-18 0000844856 hcmc:SeriesEConvertiblePreferredStockMember 2022-08-18 2022-08-18 0000844856 hcmc:SeriesEConvertiblePreferredStockMember 2023-01-01 2023-03-31 0000844856 2023-03-21 0000844856 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000844856 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000844856 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000844856 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000844856 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000844856 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0000844856 hcmc:AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember 2023-03-31 0000844856 hcmc:AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember hcmc:MedicalCostsMember 2023-01-01 2023-03-31 0000844856 hcmc:PhilipMorrisMember 2020-11-30 0000844856 hcmc:PhilipMorrisMember hcmc:PatentInfringementLitigationMember 2022-02-22 2022-02-22 0000844856 us-gaap:SubsequentEventMember 2023-04-12 2023-04-12 0000844856 hcmc:SeriesEConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-05-05 2023-05-05 0000844856 hcmc:TwoThousandAndFifteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2023-04-23 0000844856 us-gaap:RestrictedStockMember hcmc:EmployeesAndExecutiveOfficersMember hcmc:TwoThousandAndFifteenEquityIncentivePlanMember us-gaap:SubsequentEventMember 2023-04-23 2023-04-23 0000844856 hcmc:TwoThousandAndFifteenEquityIncentivePlanMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-04-23 2023-04-23 0000844856 hcmc:TwoThousandAndFifteenEquityIncentivePlanMember us-gaap:SubsequentEventMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-04-23 2023-04-23 shares iso4217:USD iso4217:USD shares hcmc:Store hcmc:FinancialInstitution hcmc:Segment pure hcmc:Lawsuit hcmc:User hcmc:Appeal false --12-31 2023 Q1 0000844856 NONE 75000 10-Q true 2023-03-31 false 001-36469 HEALTHIER CHOICES MANAGEMENT CORP. DE 84-1070932 3800 North 28Th Way Hollywood FL 33020 305 600-5004 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.0001 per share HCMC 463266632384 19765487 22911892 100633 55815 172905 189225 3967497 3817192 577569 322182 5314 9771 944470 1224171 1728232 1778232 27262107 30308480 3096599 3112908 4774609 5005511 5747000 5747000 11003033 10604935 475425 476196 52358773 55255030 4977089 5715234 797000 774900 200372 198606 453232 453232 543945 536542 2036415 2228852 9008053 9907366 2239044 2378061 8657428 8041504 19904525 20326931 1000 1000 14722 14722 13497 13497 14722 14722 13500000 14700000 13496525 14722075 1000 1000 5000 5000 800 800 800 800 800000 800000 800000 800000 0.0001 0.0001 750000000000 750000000000 346441632384 346441632384 339741632384 339741632384 34644163 33974163 29034802 29045802 -45521242 -43613941 18957723 20206024 52358773 55255030 38 249563 13559706 4798990 13559744 5048553 653 111684 8644700 2964355 4914391 1972514 6897438 3327420 -1983047 -1354906 -4457 3514 -17450 16874 97653 16603 75746 36991 -1907301 -1317915 61000 0 -1968301 0 0 0 0 0 341671076830 341671076830 339741632384 339741632384 14722 14722075 800 800000 339741632384 33974163 29045802 -43613941 20206024 556 555550 0 0 0 0 0 0 0 670 670000 0 0 6700000000 670000 0 0 670000 0 0 61000 0 61000 0 0 50000 0 50000 0 0 0 -1907301 -1907301 13497 13496525 800 800000 346441632384 34644163 29034802 -45521242 18957723 0 0 800 800000 339741632384 33974163 30855824 -36396330 29233657 0 0 0 -1317915 -1317915 0 0 800 800000 339741632384 33974163 30855824 -37714245 27915742 -1907301 -1317915 373462 193322 -4457 3514 695192 177643 523087 115842 50000 0 22100 0 44818 9031 673392 160312 255387 -157641 -279701 0 -771 27446 -744145 415957 1766 -61965 669803 159851 -2344310 -679629 0 5150000 16320 13772 126251 127275 -109931 -5263503 0 35196 131614 638 55000 0 555550 0 -742164 34558 -3196405 -5908574 24690124 26496404 21493719 20587830 44478 1428 0 0 670000 0 1093290 1797667 6000 0 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 1. ORGANIZATION</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Organization</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio. </div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Through its wholly owned subsidiaries, the Company operates:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ada’s Natural Market, a natural and organic grocery store offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health &amp; beauty products and natural household items.</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Paradise Health &amp; Nutrition’s three stores that likewise offer fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health &amp; beauty products and natural household items.</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mother Earth’s Storehouse, a two-store organic and health food and vitamin chain in New York’s Hudson Valley, a business that has been in existence for over 40 years.</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Greens Natural Foods’ eight stores in New York and New Jersey, offering a selection of 100% organic produce and all-natural, non-GMO groceries &amp; bulk foods; a wide selection of local products; an organic juice and smoothie bar; a fresh foods department, which offers fresh and healthy “grab &amp; go” foods; a full selection of vitamins &amp; supplements; as well as health and beauty products</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Through its wholly owned subsidiary, Healthy Choice Wellness, LLC, the Company operates:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing agreements for Healthy Choice Wellness Centers located at the Casbah Spa and Salon in Fort Lauderdale, FL, Boston Direct Health in Boston, MA and Green Care Medical Services in Chicago, IL.</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These centers offer multiple vitamin drip mixes and intramuscular shots for clients to choose from that are designed to help boost immunity, fight fatigue and stress, reduce inflammation, enhance weight loss, and efficiently deliver antioxidants and anti-aging mixes. Additionally, there are IV vitamin mixes and shots for health, beauty, and re-hydration.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Through its wholly owned subsidiary, Healthy U Wholesale, Inc, the Company sells vitamins and supplements, as well as health, beauty, and personal care products on its website www.TheVitaminStore.com.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additionally, the Company markets its patented the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Spin-Off</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company has commenced steps to spin off ("Spin-Off") its grocery segment and wellness business into a new publicly traded company (hereinafter referred to as “NewCo”). NewCo will continue the path of growth in the wellness verticals started by HCMC and explore other growth opportunities that comport with HCMC’s healthier lifestyle mission. Following the Spin-Off, HCMC will retain its entire patent suite, the Q-Cup® brand, and continue to develop its patent suite through R&amp;D as well as continuing its path of enforcing its patent rights against infringers and attempting to monetize said patents through licensing deals.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the time of the Spin-Off, HCMC will distribute all the outstanding shares of Common Stock held by it on a pro rata basis to holders of HCMC’s common stock. Shares of HCMC’s common stock outstanding as of the record date for the Spin-Off (the “Record Date”), will entitle the holder thereof to receive a certain number of shares of Common Stock in NewCo. The distribution will be made in book-entry form by a distribution agent. Fractional shares of Common Stock will not be distributed in the Spin-Off and any fractional amounts will be rounded down. Please see more disclosure in Note 12 Stockholder Equity.</div> 3 2 P40Y 8 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Spin-Off</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company has commenced steps to spin off ("Spin-Off") its grocery segment and wellness business into a new publicly traded company (hereinafter referred to as “NewCo”). NewCo will continue the path of growth in the wellness verticals started by HCMC and explore other growth opportunities that comport with HCMC’s healthier lifestyle mission. Following the Spin-Off, HCMC will retain its entire patent suite, the Q-Cup® brand, and continue to develop its patent suite through R&amp;D as well as continuing its path of enforcing its patent rights against infringers and attempting to monetize said patents through licensing deals.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the time of the Spin-Off, HCMC will distribute all the outstanding shares of Common Stock held by it on a pro rata basis to holders of HCMC’s common stock. Shares of HCMC’s common stock outstanding as of the record date for the Spin-Off (the “Record Date”), will entitle the holder thereof to receive a certain number of shares of Common Stock in NewCo. The distribution will be made in book-entry form by a distribution agent. Fractional shares of Common Stock will not be distributed in the Spin-Off and any fractional amounts will be rounded down. Please see more disclosure in Note 12 Stockholder Equity.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 2. LIQUIDITY</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company currently and historically has reported net losses and cash outflows from operations. </span>As of March 31, 2023, the Company had cash of approximately <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span>19.8<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million </span>and working capital of $18.3 million. In the past, the Company financed its operations primarily through issuances of common stock and convertible preferred stock. The Company believes current cash on hand is sufficient to meet its obligations and capital requirements for at least the next twelve months from the date of filing.</div> 19800000 18300000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 3. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-X and do not include all the information and disclosures required by generally accepted accounting principles in the United States of America (“GAAP”). The Company has made estimates and judgments affecting the amounts reported in the Company’s unaudited condensed consolidated financial statements and the accompanying notes. The actual results experienced by the Company may differ materially from the Company’s estimates. The condensed consolidated financial information is unaudited but reflects all normal adjustments that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2023. The condensed consolidated balance sheet as of December 31, 2022 was derived from the Company’s audited 2022 financial statements contained in the above referenced Form 10-K. Results of the three months ended March 31, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Significant Accounting Policies</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2022 Annual Report.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Reclassification</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certain amounts in the condensed consolidated financial statements and related notes have been reclassified to conform to the current year presentation. Such reclassifications do not impact the Company's previously reported financial position or net income (loss). $75,000 inventory shrink was originally presented in the statement of cash flow under change in operating assets inventory in cash used in operating activities for three months ended March 31, 2022, it was reclassified to <span style="-sec-ix-hidden:Fact_e3e3a10e63a2480fa55f6eb5b59c4c40">write-down of obsolete and slow-moving inventory</span> <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">under cash used in operating activities in the statement of cash flow.</span></div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Reclassification</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certain amounts in the condensed consolidated financial statements and related notes have been reclassified to conform to the current year presentation. Such reclassifications do not impact the Company's previously reported financial position or net income (loss). $75,000 inventory shrink was originally presented in the statement of cash flow under change in operating assets inventory in cash used in operating activities for three months ended March 31, 2022, it was reclassified to <span style="-sec-ix-hidden:Fact_e3e3a10e63a2480fa55f6eb5b59c4c40">write-down of obsolete and slow-moving inventory</span> <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">under cash used in operating activities in the statement of cash flow.</span></div> -75000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 4. CONCENTRATIONS</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Cash and Restricted Cash</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash is concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. The Company did not have any cash equivalent as of March 31, 2023, and  December 31, 2022.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the financial institution that had cash in excess of FDIC limits of $250,000 on March 31, 2023 and December 31, 2022 is presented below:</div> <div style="text-align: justify;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Total cash in excess of FDIC limits of $</span>250,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">18,646,360</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,682,144</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company has not experienced any losses in such accounts.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table provides a reconciliation of cash and restricted cash to amounts shown in unaudited c</span>ondensed consolidated statements of cash flow<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">: </span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">19,765,487</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,587,830</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted cash</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,728,232</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total cash and restricted cash</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">21,493,719</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,587,830</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Restricted Cash</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company's restricted cash consisted of cash balances which were restricted as to withdrawal or usage under the August 18, 2022 securities purchase agreement for the purpose of funding any amounts due under the Series E Certificate of Designation upon the redemption of the Series E Preferred Stock. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The balance also included cash held  in the collateral account to cover the cash draw from the line of credit.</span></div> 1 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the financial institution that had cash in excess of FDIC limits of $250,000 on March 31, 2023 and December 31, 2022 is presented below:</div> <div style="text-align: justify;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Total cash in excess of FDIC limits of $</span>250,000</div> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">18,646,360</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,682,144</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 250000 250000 18646360 21682144 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table provides a reconciliation of cash and restricted cash to amounts shown in unaudited c</span>ondensed consolidated statements of cash flow<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">: </span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">19,765,487</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,587,830</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted cash</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,728,232</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total cash and restricted cash</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">21,493,719</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,587,830</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 19765487 20587830 1728232 0 21493719 20587830 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 5. SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES</div> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In accordance with FASB ASC 280, "Disclosures about Segment of an enterprise and related information", the Company determined it has two reportable segments: grocery and vapor. There are no inter-segment revenues.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company's general and administrative costs are not segment specific. As a result, all operating expenses are not managed on segment basis.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">38</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">249,563</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,559,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,798,990</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,559,744</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,048,553</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">38</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">249,563</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,613,730</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,283,288</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Food service/restaurant</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,943,914</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">509,810</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Online/eCommerce</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,062</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,892</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,559,744</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,048,553</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss from operations - Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(6,672</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(18,967</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Loss) income from operations - Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(276,842</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,936</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate items</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,699,533</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,499,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total loss from operations</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,983,047</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,354,906</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> 2 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">38</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">249,563</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,559,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,798,990</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,559,744</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,048,553</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">38</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">249,563</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,613,730</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,283,288</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Food service/restaurant</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,943,914</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">509,810</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Online/eCommerce</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,062</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,892</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,559,744</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,048,553</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss from operations - Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(6,672</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(18,967</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Loss) income from operations - Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(276,842</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,936</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate items</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,699,533</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,499,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total loss from operations</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,983,047</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,354,906</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> 38 249563 13559706 4798990 13559744 5048553 38 249563 11613730 4283288 1943914 509810 2062 5892 13559744 5048553 -6672 -18967 -276842 163936 -1699533 -1499875 -1983047 -1354906 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 6. NOTES RECEIVABLE AND OTHER INCOME</div> <div style="text-align: justify;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On September 6, 2018, the Company entered into a secured, </span>36<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-month promissory note </span>(the “Note”) <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">with VPR Brands L.P. for $</span>582,260<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The Note bears an interest rate of </span>7.00%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, which payments thereunder are $</span>4,141<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> weekly. The Company records all proceeds related to the interest of the Note as interest income as proceeds are received.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On August 31, 2022, the Company amended and restated the Note (the "Amended Note") with VPR Brands L.P. to extend the </span>maturity date for one year. T<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">he outstanding balance for the Amended Note is $</span>211,355<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The Amended Note bears an interest rate of </span>7.00%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, which payments thereunder are $</span>1,500<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> weekly, with such payments commencing as of September 3, 2022. The Amended Note has a balloon payment of $</span>145,931<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for all remaining accrued interest and principal balance due in the final week of the </span>1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-year extension of the Amended Note.</span></div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">A summary of the Amended Note as of March 31, 2023 and December 31, 2022 is presented below:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 63.03%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td style="width: 1.57%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 17.32%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td style="width: 1.57%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 16.52%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> </tr> <tr> <td style="width: 63.03%; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory Note</div> </td> <td style="width: 1.57%; vertical-align: bottom;"> </td> <td style="width: 1.57%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 15.75%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">172,905</div> </td> <td style="width: 1.57%; vertical-align: bottom;"> </td> <td style="width: 1.57%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 14.95%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">189,225</div> </td> </tr> </table> P36M 582260 0.07 4141 211355 0.07 1500 145931 P1Y <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">A summary of the Amended Note as of March 31, 2023 and December 31, 2022 is presented below:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 63.03%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td style="width: 1.57%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 17.32%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td style="width: 1.57%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 16.52%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2022</div> </td> </tr> <tr> <td style="width: 63.03%; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory Note</div> </td> <td style="width: 1.57%; vertical-align: bottom;"> </td> <td style="width: 1.57%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 15.75%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">172,905</div> </td> <td style="width: 1.57%; vertical-align: bottom;"> </td> <td style="width: 1.57%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 14.95%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">189,225</div> </td> </tr> </table> 172905 189225 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 7. ACQUISITION</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On October 14, 2022, the Company through its wholly owned subsidiary, Healthy Choice Markets IV, LLC, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Dean’s Natural Food Market of Shrewsbury, Inc., a New Jersey corporation, Green’s Natural Foods, Inc., a Delaware corporation, Dean’s Natural Food Market of Chester, LLC, a New Jersey limited liability company, Dean’s Natural Food Market of Basking Ridge, LLC, a New Jersey limited liability company, and Dean’s Natural Food Market, Inc., a New Jersey corporation (collectively, the “Sellers”), and shareholders of the Sellers. Pursuant to the Purchase Agreement, the Company acquired certain assets and assumed certain liabilities of an organic and natural health food and vitamin chain with eight store locations in New York and northern and central New Jersey (the “Stores”).</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The cash purchase price under the Asset Purchase Agreement was $</span>5,142,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, with $</span>3,000,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> seller financing in the form of promissory note. </span>In addition, the seller is entitled to a contingent earn-out based on a certain revenue threshold within the one-year period of the closing.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company recorded $1,108,000 of contingent consideration based on the estimated financial performance for the one year following closing.  The contingent consideration was discounted at an interest rate of 3.8%, which represents the Company's weighted average discount rate.  Contingent consideration related to the acquisition is recorded at fair value (level 3) with changes in fair value recorded in other expense (income), net.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the change in fair value of contingent consideration from acquisition date to March 31, 2023:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair Market Value - Level 3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Balance as of October 14, 2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,108,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Remeasurement</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(333,100</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Balance as of December 31, 2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">774,900</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Remeasurement</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,100</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Balance as of March 31, 2023</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">797,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the purchase price allocation based on fair values of the net assets acquired at the acquisition date:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">October 14, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Purchase Consideration</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash consideration paid</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,142,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory note</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contingent consideration issued to Green's Natural seller</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,108,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Purchase Consideration</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,250,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Purchase price allocation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventory</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,642,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,478,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,251,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right of use asset - Operating lease</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,427,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(211,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liability</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,427,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Goodwill</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,090,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net assets acquired</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,250,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Finite-lived intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade Names (<span style="text-indent: 0pt;">8</span> years)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,133,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer Relationships (<span style="text-indent: 0pt;">6</span> years)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,103,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-Compete Agreement (<span style="text-indent: 0pt;">5</span> years)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,015,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,251,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The acquisition is structured as asset purchase in a business combination, and goodwill is tax-deductible, and amortizable over 15 years for tax purpose.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue and Earnings</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table represents the combined pro forma revenue and net loss for the three months ended March 31, 2022:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 72.44%; vertical-align: middle; background-color: #CCEEFF;"> </td> <td style="width: 3.05%; vertical-align: middle; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 24.52%; vertical-align: middle; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For Three Months Ended</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> March 31, 2022</div> </td> </tr> <tr> <td style="width: 72.44%; vertical-align: middle;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sales</div> </td> <td style="width: 3.05%; vertical-align: middle;"> </td> <td style="width: 2.49%; vertical-align: middle;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 22.02%; vertical-align: middle;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,156,447</div> </td> </tr> <tr> <td style="width: 72.44%; vertical-align: middle; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss</div> </td> <td style="width: 3.05%; vertical-align: middle; background-color: #CCEEFF;"> </td> <td style="width: 2.49%; vertical-align: middle; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 22.02%; vertical-align: middle; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,585,281)</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The combined proforma revenue and net loss for the three month period ended March 31, 2022 were prepared as though acquisition occurred as of January 1, 2022.</div> 8 5142000 3000000 1108000 0.038 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the change in fair value of contingent consideration from acquisition date to March 31, 2023:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair Market Value - Level 3</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Balance as of October 14, 2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,108,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Remeasurement</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(333,100</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Balance as of December 31, 2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">774,900</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Remeasurement</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,100</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Balance as of March 31, 2023</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">797,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1108000 -333100 774900 22100 797000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the purchase price allocation based on fair values of the net assets acquired at the acquisition date:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">October 14, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Purchase Consideration</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: middle;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash consideration paid</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,142,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory note</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contingent consideration issued to Green's Natural seller</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,108,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Purchase Consideration</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,250,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Purchase price allocation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventory</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,642,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,478,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,251,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right of use asset - Operating lease</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,427,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(211,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liability</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,427,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Goodwill</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,090,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net assets acquired</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,250,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Finite-lived intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade Names (<span style="text-indent: 0pt;">8</span> years)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,133,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer Relationships (<span style="text-indent: 0pt;">6</span> years)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,103,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-Compete Agreement (<span style="text-indent: 0pt;">5</span> years)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,015,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,251,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 5142000 3000000 1108000 9250000 1642000 1478000 3251000 6427000 211000 6427000 3090000 9250000 P8Y 1133000 P6Y 1103000 P5Y 1015000 3251000 P15Y <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table represents the combined pro forma revenue and net loss for the three months ended March 31, 2022:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 72.44%; vertical-align: middle; background-color: #CCEEFF;"> </td> <td style="width: 3.05%; vertical-align: middle; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 24.52%; vertical-align: middle; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For Three Months Ended</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> March 31, 2022</div> </td> </tr> <tr> <td style="width: 72.44%; vertical-align: middle;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sales</div> </td> <td style="width: 3.05%; vertical-align: middle;"> </td> <td style="width: 2.49%; vertical-align: middle;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 22.02%; vertical-align: middle;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,156,447</div> </td> </tr> <tr> <td style="width: 72.44%; vertical-align: middle; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss</div> </td> <td style="width: 3.05%; vertical-align: middle; background-color: #CCEEFF;"> </td> <td style="width: 2.49%; vertical-align: middle; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 22.02%; vertical-align: middle; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,585,281)</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The combined proforma revenue and net loss for the three month period ended March 31, 2022 were prepared as though acquisition occurred as of January 1, 2022.</div> 13156447 -1585281 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Note 8. PROPERTY, PLANT, AND EQUIPMENT</span></div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Property, plant, and equipment consist of the following:</span></div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 68.08%; vertical-align: bottom;"> </td> <td style="width: 0.13%; vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="width: 15.53%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="width: 14.99%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Displays</div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </div> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">312,146</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </div> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">312,146</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">575,000</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">575,000</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">572,224</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">560,256</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,910,719</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,910,719</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer hardware &amp; equipment</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">177,652</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">160,210</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #CCEEFF;">Other</span></div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 13.05%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">684,443</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 12.23%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">587,602</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,232,184</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,105,933</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #CCEEFF;">Less: accumulated depreciation and amortization</span></div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 13.05%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,135,585)</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 12.23%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(993,025)</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total property, plant, and equipment</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 13.05%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,096,599</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 12.23%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,112,908</div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company incurred approximately $</span>142,560<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and $</span>49,936<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of depreciation expense for the </span>three months ended<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span>March 31, 2023<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2022<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, respectively.</span></div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Property, plant, and equipment consist of the following:</span></div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 68.08%; vertical-align: bottom;"> </td> <td style="width: 0.13%; vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="width: 15.53%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="width: 14.99%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Displays</div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </div> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">312,146</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </div> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">312,146</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">575,000</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">575,000</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">572,224</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">560,256</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,910,719</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,910,719</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer hardware &amp; equipment</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">177,652</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">160,210</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #CCEEFF;">Other</span></div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 13.05%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">684,443</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 12.23%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">587,602</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom;"> </td> <td style="width: 13.05%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,232,184</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom;"> </td> <td style="width: 12.23%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,105,933</div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #CCEEFF;">Less: accumulated depreciation and amortization</span></div> </div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 13.05%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,135,585)</div> </div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 12.23%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(993,025)</div> </div> </td> </tr> <tr> <td style="width: 68.08%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total property, plant, and equipment</div> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.48%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 13.05%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,096,599</div> </td> <td style="width: 1.14%; vertical-align: bottom; white-space: nowrap;"> </td> <td style="width: 0.13%; vertical-align: bottom;"> </td> <td style="width: 2.76%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 12.23%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,112,908</div> </td> </tr> </table> 312146 312146 575000 575000 572224 560256 1910719 1910719 177652 160210 684443 587602 4232184 4105933 1135585 993025 3096599 3112908 142560 49936 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 9. INTANGIBLE ASSETS</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets, net are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 30%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">March 31, 2023</span></div> </td> <td style="width: 2.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 21.11%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 15.28%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 11.81%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="width: 2.36%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 19.31%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 13.33%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,569,000</div> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 1.39%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.42%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(800,880)</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 12.78%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,768,120</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="width: 2.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.31%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-6 years</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 13.33%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,669,000</div> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.42%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,107,722)</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.78%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,561,278</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="width: 2.36%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 19.31%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 13.33%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">384,665</div> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 10.42%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(169,587)</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 12.78%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">215,078</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="width: 2.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.31%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-5 years</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 13.33%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,602,000</div> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.42%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(371,867)</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.78%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,230,133</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intangible assets, net</div> </td> <td style="width: 2.36%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 19.31%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 13.33%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7,224,665</div> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 1.39%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.42%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(2,450,056)</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 12.78%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,774,609</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 29.86%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">December 31, 2022</span></div> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 21.53%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 11.53%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.86%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 19.58%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> $</div> </td> <td style="width: 12.36%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,569,000</div> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 1.53%; vertical-align: bottom;"> </td> <td style="width: 10%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(725,723)</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> $</div> </td> <td style="width: 12.64%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,843,277</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.58%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-6 years</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.36%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,669,000</div> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.53%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,033,306)</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.64%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,635,694</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 19.58%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 12.36%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">384,665</div> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 1.53%; vertical-align: bottom;"> </td> <td style="width: 10%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(159,658)</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 12.64%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">225,007</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.58%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-5 years</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.36%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,602,000</div> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.53%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(300,467)</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.64%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,301,533</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets, net</div> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 19.58%; vertical-align: bottom;"> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 12.36%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,224,665</div> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 1.53%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,219,154)</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 12.64%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,005,511</div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately  $230,902 and $143,386 for the three months ended March 31, 2023 and 2022, respectively. Future annual estimated amortization expense is as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Years ending December 31,</span></div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2023 (remaining nine months)</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">692,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2024</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">923,608</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2025</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">918,108</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2026</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">840,127</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2027</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">695,498</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">704,562</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,774,609</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets, net are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 30%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">March 31, 2023</span></div> </td> <td style="width: 2.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 21.11%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 15.28%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 11.81%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="width: 2.36%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 19.31%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 13.33%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,569,000</div> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 1.39%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.42%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(800,880)</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 12.78%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,768,120</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="width: 2.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.31%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-6 years</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 13.33%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,669,000</div> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.42%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,107,722)</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.78%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,561,278</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="width: 2.36%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 19.31%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 13.33%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">384,665</div> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 10.42%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(169,587)</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 12.78%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">215,078</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="width: 2.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.31%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-5 years</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 13.33%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,602,000</div> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.39%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.42%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(371,867)</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.78%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,230,133</div> </td> </tr> <tr> <td style="width: 30%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intangible assets, net</div> </td> <td style="width: 2.36%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 19.31%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 13.33%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7,224,665</div> </td> <td style="width: 1.39%; vertical-align: bottom;"> </td> <td style="width: 1.39%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.42%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(2,450,056)</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 1.81%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 12.78%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,774,609</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 29.86%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">December 31, 2022</span></div> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 21.53%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 11.53%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.86%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Carrying Amount</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 19.58%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> $</div> </td> <td style="width: 12.36%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,569,000</div> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 1.53%; vertical-align: bottom;"> </td> <td style="width: 10%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(725,723)</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> $</div> </td> <td style="width: 12.64%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,843,277</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.58%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-6 years</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.36%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,669,000</div> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.53%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,033,306)</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.64%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,635,694</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 19.58%; vertical-align: bottom;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 12.36%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">384,665</div> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 1.53%; vertical-align: bottom;"> </td> <td style="width: 10%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(159,658)</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 12.64%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">225,007</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 19.58%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-5 years</div> </td> <td style="width: 1.67%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.36%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,602,000</div> </td> <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.53%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(300,467)</div> </td> <td style="width: 1.81%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.22%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 12.64%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,301,533</div> </td> </tr> <tr> <td style="width: 29.86%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets, net</div> </td> <td style="width: 2.22%; vertical-align: bottom;"> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 19.58%; vertical-align: bottom;"> </td> <td style="width: 1.67%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 12.36%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,224,665</div> </td> <td style="width: 1.94%; vertical-align: bottom;"> </td> <td style="width: 1.53%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 10%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,219,154)</div> </td> <td style="width: 1.81%; vertical-align: bottom;"> </td> <td style="width: 2.22%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 12.64%; vertical-align: bottom; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,005,511</div> </td> </tr> </table> P8Y P10Y 2569000 800880 1768120 P4Y P6Y 2669000 1107722 1561278 P10Y 384665 169587 215078 P4Y P5Y 1602000 371867 1230133 7224665 2450056 4774609 P8Y P10Y 2569000 725723 1843277 P4Y P6Y 2669000 1033306 1635694 P10Y 384665 159658 225007 P4Y P5Y 1602000 300467 1301533 7224665 2219154 5005511 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately  $230,902 and $143,386 for the three months ended March 31, 2023 and 2022, respectively. Future annual estimated amortization expense is as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Years ending December 31,</span></div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2023 (remaining nine months)</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">692,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2024</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">923,608</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2025</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">918,108</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2026</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">840,127</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2027</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">695,498</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">704,562</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,774,609</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 230902 143386 692706 923608 918108 840127 695498 704562 4774609 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 10. CONTRACT LIABILITIES</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the contract liabilities activity at March 31, 2023 and December 31, 2022 is presented below:</div> <div><br/> </div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance as January 1,</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">198,606</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,178</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issued</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">695,438</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">859,383</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Redeemed</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(640,160</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(628,012</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Breakage recognized</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(53,512</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(55,943</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">200,372</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">198,606</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the contract liabilities activity at March 31, 2023 and December 31, 2022 is presented below:</div> <div><br/> </div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance as January 1,</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">198,606</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,178</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issued</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">695,438</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">859,383</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Redeemed</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(640,160</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(628,012</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Breakage recognized</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(53,512</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(55,943</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">200,372</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">198,606</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 198606 23178 695438 859383 640160 628012 -53512 -55943 200372 198606 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 11. DEBT</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table provides a breakdown of the Company's debt as of March 31, 2023 and December 31, 2022 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 1pt;">_</span></div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory note</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,782,847</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,913,788</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">142</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">815</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,782,989</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,914,603</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of long-term debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(543,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(536,542</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,239,044</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,378,061</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table provides a breakdown of the Company's debt as of March 31, 2023 and December 31, 2022 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 1pt;">_</span></div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">March 31, 2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory note</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,782,847</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,913,788</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">142</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">815</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,782,989</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,914,603</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of long-term debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(543,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(536,542</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,239,044</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,378,061</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 2782847 2913788 142 815 2782989 2914603 543945 536542 2239044 2378061 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 12. STOCKHOLDERS’ EQUITY</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series E Convertible Preferred Stock</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 18, 2022, the Company entered into a Securities Purchase Agreement <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">("Series E Preferred Stock") </span>pursuant to which the Company sold and issued 14,722 shares of its Series E Redeemable Convertible Preferred Stock to institutional investors for $1,000 per share or an aggregate subscription of $13.25 million. The number of shares issued to each participant is based on subscription amount multiplied by conversion rate of 1.1111. The Company also incurred offering costs of approximately $410,000, which covers legal and consulting fee.</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The HCMC Series E Preferred Stock shall have voting rights on as converted basis at the Company’s next stockholders’ meeting. However, as long as any shares of HCMC Series E Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the HCMC Series E Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the HCMC Series E Preferred Stock or alter or amend the Certificate of Designation, (b) increase the number of authorized shares of HCMC Series E Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing. </span>Each share of Series E Preferred Stock shall be convertible, at any time and from time to time at the option of the Holder thereof, into that number of shares of Common Stock (subject to the beneficial ownership limitations). The initial conversion price for the HCMC Series E Preferred Stock shall equal $0.0001.</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of HCMC Series E Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to $1,000 per share of Series E Preferred Stock.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unless earlier converted or extended as set forth below, a holder may require the redemption of all or a portion of the stated value of the HCMC Series E Preferred Stock either (1) six months after closing or (2) the time at which the balance is due and payable upon an event of default.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On March 1, 2023, the Company entered into a First Amendment to HCMC Series E Preferred Stock with each purchaser ("Purchaser") identified as those who participated in the HCMC Series E Preferred Stock, dated as of August 18, 2022.  The parties amended the HCMC Preferred Stock related to the conversion payment whereby upon conversion of the Series E Preferred Stock prior to the record date for the Spin-Off, the Company will pay the Purchaser ten percent (10%) of the stated value of the Series E Preferred Stock converted. The record date is May 1, 2023.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">As of March 31, 2023, 6,700,000,000 shares of common stock were issued as a result of the Series E preferred stock conversion. 556 shares of Series E preferred stock was redeemed and approximately $556,000 was paid for redemption.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Securities Purchase Agreement, purchasers of the Series E Convertible Preferred Stock will also be required to purchase Series A Convertible Preferred Stock of NewCo resulting from spin off of HCMC’s grocery and wellness businesses in the same subscription amounts that the Purchasers paid for the HCMC Series E Preferred Stock.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Stock Options</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the three months ended March 31, 2023 and 2022, no stock options of the Company were exercised into common stock.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">During the three months ended </span>March 31, 2023<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2022<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company recognized stock-based compensation of approximately </span>$50,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>$0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, respectively </span>in connection with amortization of restricted stock and stock options<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Stock based compensation is included as part of selling, general and administrative expense in the accompanying </span>unaudited condensed<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> consolidated statements of operations.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Income (Loss) Per Share</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of March 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred stock</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">136,215,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,250,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock options</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">67,587,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted stock</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5,500,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">209,302,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,837,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div> 14722 1000 13250000 1.1111 410000 0.0001 1000 P6M 0.10 0.10 6700000000 556000 556000 0 0 50000 0 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of March 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2023</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred stock</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">136,215,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,250,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock options</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">67,587,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Restricted stock</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5,500,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">209,302,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,837,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 136215000000 1250000000 67587000000 67587000000 5500000000 0 209302000000 68837000000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 13. COMMITMENTS AND CONTINGENCIES</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Legal Proceedings</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints in 2019 and we exchanged additional support information with the plaintiff for one of the lawsuits in 2021. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia.  The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed a notice of appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. The appeal brief was filed on February 28, 2022.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $</span>575,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in attorneys’ fees to be paid by the Company. </span>The Company has fully provisioned this amount as of December 31, 2022. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">HCMC appealed this ruling on June 22, 2022. Refer to Note 14 Subsequent Event.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is </span>no<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of </span>March 31, 2023<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. With respect to legal costs, we record such costs as incurred.</span></div> 2 400000 14000000 3000000000 575000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Note </span>14.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> SUBSEQUENT EVENTS</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 12, 2023, the U.S. Court of Appeals for the Federal Circuit ruled in favor of HCMC on two separate appeals it had filed in its patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. pending in the district court for the Northern District of Georgia<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the first appeal, HCMC appealed the ruling of the District Court dismissing HCMC’s patent infringement action and denying HCMC’s motion to amend its pleading. In the second appeal, HCMC appealed the District Court’s award of attorneys’ fees to Philip Morris. In its decisions, the Federal Circuit ruled for HCMC by reversing both of those decisions and remanded the case back to the District Court for further proceedings.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of the date of filing, 9,150,000,000 shares of common stock were subsequently issued since March 31, 2023 as a result of HCMC Series E Preferred Stock conversions.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On April 23, 2023, the Board of Directors of HCMC approved the Second Amendment to the 2015 Equity Incentive Plan which increased the number of shares of HCMC common stock authorized for issuance under the Amended Plan to 225,000,000,000 shares. The board of directors also approved the issuance of an additional 107,675,000,000 shares of restricted common stock to the employees and executive officers of HCMC. The grants of restricted common stock will commence vesting at 12.5% of the award on February 1, 2024 and will vest in 2.5% increments on the last day of each calendar quarter thereafter through September 30, 2025. </div> 2 9150000000 225000000000 107675000000 0.125 0.025 19800000 -1900000 -1300000 2 400000 EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 136 228 1 false 51 0 false 10 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://healthiercmc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Sheet http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 060100 - Disclosure - ORGANIZATION Sheet http://healthiercmc.com/role/Organization ORGANIZATION Notes 7 false false R8.htm 060200 - Disclosure - LIQUIDITY Sheet http://healthiercmc.com/role/Liquidity LIQUIDITY Notes 8 false false R9.htm 060300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 060400 - Disclosure - CONCENTRATIONS Sheet http://healthiercmc.com/role/Concentrations CONCENTRATIONS Notes 10 false false R11.htm 060500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES Sheet http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenues SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES Notes 11 false false R12.htm 060600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME Notes http://healthiercmc.com/role/NotesReceivableAndOtherIncome NOTES RECEIVABLE AND OTHER INCOME Notes 12 false false R13.htm 060700 - Disclosure - ACQUISITION Sheet http://healthiercmc.com/role/Acquisition ACQUISITION Notes 13 false false R14.htm 060800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT Sheet http://healthiercmc.com/role/PropertyPlantAndEquipment PROPERTY, PLANT, AND EQUIPMENT Notes 14 false false R15.htm 060900 - Disclosure - INTANGIBLE ASSETS Sheet http://healthiercmc.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 15 false false R16.htm 061000 - Disclosure - CONTRACT LIABILITIES Sheet http://healthiercmc.com/role/ContractLiabilities CONTRACT LIABILITIES Notes 16 false false R17.htm 061100 - Disclosure - DEBT Sheet http://healthiercmc.com/role/Debt DEBT Notes 17 false false R18.htm 061200 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://healthiercmc.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 18 false false R19.htm 061300 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://healthiercmc.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 061400 - Disclosure - SUBSEQUENT EVENTS Sheet http://healthiercmc.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 070100 - Disclosure - ORGANIZATION (Policies) Sheet http://healthiercmc.com/role/OrganizationPolicies ORGANIZATION (Policies) Policies 21 false false R22.htm 070300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 080400 - Disclosure - CONCENTRATIONS (Tables) Sheet http://healthiercmc.com/role/ConcentrationsTables CONCENTRATIONS (Tables) Tables http://healthiercmc.com/role/Concentrations 23 false false R24.htm 080500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Tables) Sheet http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesTables SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Tables) Tables http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenues 24 false false R25.htm 080600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Tables) Notes http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables NOTES RECEIVABLE AND OTHER INCOME (Tables) Tables http://healthiercmc.com/role/NotesReceivableAndOtherIncome 25 false false R26.htm 080700 - Disclosure - ACQUISITION (Tables) Sheet http://healthiercmc.com/role/AcquisitionTables ACQUISITION (Tables) Tables http://healthiercmc.com/role/Acquisition 26 false false R27.htm 080800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables) Sheet http://healthiercmc.com/role/PropertyPlantAndEquipmentTables PROPERTY, PLANT, AND EQUIPMENT (Tables) Tables http://healthiercmc.com/role/PropertyPlantAndEquipment 27 false false R28.htm 080900 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://healthiercmc.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://healthiercmc.com/role/IntangibleAssets 28 false false R29.htm 081000 - Disclosure - CONTRACT LIABILITIES (Tables) Sheet http://healthiercmc.com/role/ContractLiabilitiesTables CONTRACT LIABILITIES (Tables) Tables http://healthiercmc.com/role/ContractLiabilities 29 false false R30.htm 081100 - Disclosure - DEBT (Tables) Sheet http://healthiercmc.com/role/DebtTables DEBT (Tables) Tables http://healthiercmc.com/role/Debt 30 false false R31.htm 081200 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://healthiercmc.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://healthiercmc.com/role/StockholdersEquity 31 false false R32.htm 090100 - Disclosure - ORGANIZATION (Details) Sheet http://healthiercmc.com/role/OrganizationDetails ORGANIZATION (Details) Details http://healthiercmc.com/role/OrganizationPolicies 32 false false R33.htm 090200 - Disclosure - LIQUIDITY (Details) Sheet http://healthiercmc.com/role/LiquidityDetails LIQUIDITY (Details) Details http://healthiercmc.com/role/Liquidity 33 false false R34.htm 090300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies 34 false false R35.htm 090400 - Disclosure - CONCENTRATIONS (Details) Sheet http://healthiercmc.com/role/ConcentrationsDetails CONCENTRATIONS (Details) Details http://healthiercmc.com/role/ConcentrationsTables 35 false false R36.htm 090500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Details) Sheet http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Details) Details http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesTables 36 false false R37.htm 090600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Details) Notes http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails NOTES RECEIVABLE AND OTHER INCOME (Details) Details http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables 37 false false R38.htm 090700 - Disclosure - ACQUISITION (Details) Sheet http://healthiercmc.com/role/AcquisitionDetails ACQUISITION (Details) Details http://healthiercmc.com/role/AcquisitionTables 38 false false R39.htm 090800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details) Sheet http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails PROPERTY, PLANT, AND EQUIPMENT (Details) Details http://healthiercmc.com/role/PropertyPlantAndEquipmentTables 39 false false R40.htm 090900 - Disclosure - INTANGIBLE ASSETS, Intangible Assets, Net (Details) Sheet http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails INTANGIBLE ASSETS, Intangible Assets, Net (Details) Details 40 false false R41.htm 090902 - Disclosure - INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) Sheet http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) Details 41 false false R42.htm 091000 - Disclosure - CONTRACT LIABILITIES (Details) Sheet http://healthiercmc.com/role/ContractLiabilitiesDetails CONTRACT LIABILITIES (Details) Details http://healthiercmc.com/role/ContractLiabilitiesTables 42 false false R43.htm 091100 - Disclosure - DEBT (Details) Sheet http://healthiercmc.com/role/DebtDetails DEBT (Details) Details http://healthiercmc.com/role/DebtTables 43 false false R44.htm 091204 - Disclosure - STOCKHOLDERS' EQUITY, Series E Convertible Preferred Stock (Details) Sheet http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails STOCKHOLDERS' EQUITY, Series E Convertible Preferred Stock (Details) Details 44 false false R45.htm 091206 - Disclosure - STOCKHOLDERS' EQUITY, Stock Options (Details) Sheet http://healthiercmc.com/role/StockholdersEquityStockOptionsDetails STOCKHOLDERS' EQUITY, Stock Options (Details) Details 45 false false R46.htm 091208 - Disclosure - STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) Sheet http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) Details 46 false false R47.htm 091300 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://healthiercmc.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://healthiercmc.com/role/CommitmentsAndContingencies 47 false false R48.htm 091400 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://healthiercmc.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://healthiercmc.com/role/SubsequentEvents 48 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName, us-gaap:InventoryWriteDown - form10q.htm 11 form10q.htm ex31_1.htm ex31_2.htm ex32_1.htm ex32_2.htm hcmc-20230331.xsd hcmc-20230331_cal.xml hcmc-20230331_def.xml hcmc-20230331_lab.xml hcmc-20230331_pre.xml image00001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10q.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 476, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 136, "dts": { "calculationLink": { "local": [ "hcmc-20230331_cal.xml" ] }, "definitionLink": { "local": [ "hcmc-20230331_def.xml" ] }, "inline": { "local": [ "form10q.htm" ] }, "labelLink": { "local": [ "hcmc-20230331_lab.xml" ] }, "presentationLink": { "local": [ "hcmc-20230331_pre.xml" ] }, "schema": { "local": [ "hcmc-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 478, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 7 }, "keyCustom": 36, "keyStandard": 192, "memberCustom": 20, "memberStandard": 26, "nsprefix": "hcmc", "nsuri": "http://healthiercmc.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://healthiercmc.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060400 - Disclosure - CONCENTRATIONS", "menuCat": "Notes", "order": "10", "role": "http://healthiercmc.com/role/Concentrations", "shortName": "CONCENTRATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES", "menuCat": "Notes", "order": "11", "role": "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenues", "shortName": "SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME", "menuCat": "Notes", "order": "12", "role": "http://healthiercmc.com/role/NotesReceivableAndOtherIncome", "shortName": "NOTES RECEIVABLE AND OTHER INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060700 - Disclosure - ACQUISITION", "menuCat": "Notes", "order": "13", "role": "http://healthiercmc.com/role/Acquisition", "shortName": "ACQUISITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT", "menuCat": "Notes", "order": "14", "role": "http://healthiercmc.com/role/PropertyPlantAndEquipment", "shortName": "PROPERTY, PLANT, AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060900 - Disclosure - INTANGIBLE ASSETS", "menuCat": "Notes", "order": "15", "role": "http://healthiercmc.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ContractWithCustomerAssetAndLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061000 - Disclosure - CONTRACT LIABILITIES", "menuCat": "Notes", "order": "16", "role": "http://healthiercmc.com/role/ContractLiabilities", "shortName": "CONTRACT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ContractWithCustomerAssetAndLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061100 - Disclosure - DEBT", "menuCat": "Notes", "order": "17", "role": "http://healthiercmc.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061200 - Disclosure - STOCKHOLDERS' EQUITY", "menuCat": "Notes", "order": "18", "role": "http://healthiercmc.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061300 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "19", "role": "http://healthiercmc.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061400 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "20", "role": "http://healthiercmc.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:SpinOffPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070100 - Disclosure - ORGANIZATION (Policies)", "menuCat": "Policies", "order": "21", "role": "http://healthiercmc.com/role/OrganizationPolicies", "shortName": "ORGANIZATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:SpinOffPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "22", "role": "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:CashAndCashEquivalentsInExcessOfFDICLimitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080400 - Disclosure - CONCENTRATIONS (Tables)", "menuCat": "Tables", "order": "23", "role": "http://healthiercmc.com/role/ConcentrationsTables", "shortName": "CONCENTRATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:CashAndCashEquivalentsInExcessOfFDICLimitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Tables)", "menuCat": "Tables", "order": "24", "role": "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesTables", "shortName": "SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ScheduleOfAccountsNotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Tables)", "menuCat": "Tables", "order": "25", "role": "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables", "shortName": "NOTES RECEIVABLE AND OTHER INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ScheduleOfAccountsNotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080700 - Disclosure - ACQUISITION (Tables)", "menuCat": "Tables", "order": "26", "role": "http://healthiercmc.com/role/AcquisitionTables", "shortName": "ACQUISITION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "27", "role": "http://healthiercmc.com/role/PropertyPlantAndEquipmentTables", "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080900 - Disclosure - INTANGIBLE ASSETS (Tables)", "menuCat": "Tables", "order": "28", "role": "http://healthiercmc.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081000 - Disclosure - CONTRACT LIABILITIES (Tables)", "menuCat": "Tables", "order": "29", "role": "http://healthiercmc.com/role/ContractLiabilitiesTables", "shortName": "CONTRACT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:TemporaryEquityParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:TemporaryEquityParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081100 - Disclosure - DEBT (Tables)", "menuCat": "Tables", "order": "30", "role": "http://healthiercmc.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081200 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "menuCat": "Tables", "order": "31", "role": "http://healthiercmc.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331_BusinessAcquisitionAxis_MotherEarthsStorehouseMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfStores", "reportCount": 1, "unitRef": "U004", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090100 - Disclosure - ORGANIZATION (Details)", "menuCat": "Details", "order": "32", "role": "http://healthiercmc.com/role/OrganizationDetails", "shortName": "ORGANIZATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331_BusinessAcquisitionAxis_MotherEarthsStorehouseMember", "decimals": null, "lang": "en-US", "name": "hcmc:AgeOfCompany", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090200 - Disclosure - LIQUIDITY (Details)", "menuCat": "Details", "order": "33", "role": "http://healthiercmc.com/role/LiquidityDetails", "shortName": "LIQUIDITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "-5", "lang": null, "name": "hcmc:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "34", "role": "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20220101to20220331_RestatementAxis_RestatementAdjustmentMember", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInInventories", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "INF", "first": true, "lang": null, "name": "hcmc:ConcentrationOfDepositsNumberOfFinancialInstitutions", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090400 - Disclosure - CONCENTRATIONS (Details)", "menuCat": "Details", "order": "35", "role": "http://healthiercmc.com/role/ConcentrationsDetails", "shortName": "CONCENTRATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "INF", "first": true, "lang": null, "name": "hcmc:ConcentrationOfDepositsNumberOfFinancialInstitutions", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U006", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090500 - Disclosure - SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Details)", "menuCat": "Details", "order": "36", "role": "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails", "shortName": "SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U006", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfNotesReceivable", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090600 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Details)", "menuCat": "Details", "order": "37", "role": "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails", "shortName": "NOTES RECEIVABLE AND OTHER INCOME (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_PromissoryNotesMember", "decimals": null, "lang": "en-US", "name": "hcmc:NotesReceivablePaymentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090700 - Disclosure - ACQUISITION (Details)", "menuCat": "Details", "order": "38", "role": "http://healthiercmc.com/role/AcquisitionDetails", "shortName": "ACQUISITION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20221014to20221014_BusinessAcquisitionAxis_GreenSNaturalFoodsMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090800 - Disclosure - PROPERTY, PLANT, AND EQUIPMENT (Details)", "menuCat": "Details", "order": "39", "role": "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails", "shortName": "PROPERTY, PLANT, AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090900 - Disclosure - INTANGIBLE ASSETS, Intangible Assets, Net (Details)", "menuCat": "Details", "order": "40", "role": "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails", "shortName": "INTANGIBLE ASSETS, Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090902 - Disclosure - INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details)", "menuCat": "Details", "order": "41", "role": "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails", "shortName": "INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20221231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091000 - Disclosure - CONTRACT LIABILITIES (Details)", "menuCat": "Details", "order": "42", "role": "http://healthiercmc.com/role/ContractLiabilitiesDetails", "shortName": "CONTRACT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20211231", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091100 - Disclosure - DEBT (Details)", "menuCat": "Details", "order": "43", "role": "http://healthiercmc.com/role/DebtDetails", "shortName": "DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "us-gaap:PreferredStockSharesOutstanding", "us-gaap:PreferredStockSharesOutstanding", "span", "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091204 - Disclosure - STOCKHOLDERS' EQUITY, Series E Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "44", "role": "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY, Series E Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230321", "decimals": "INF", "lang": null, "name": "hcmc:PercentageOfStatedValueOfPreferredStockWillBePaidToPurchaserUponConversion", "reportCount": 1, "unique": true, "unitRef": "U007", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091206 - Disclosure - STOCKHOLDERS' EQUITY, Stock Options (Details)", "menuCat": "Details", "order": "45", "role": "http://healthiercmc.com/role/StockholdersEquityStockOptionsDetails", "shortName": "STOCKHOLDERS' EQUITY, Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091208 - Disclosure - STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details)", "menuCat": "Details", "order": "46", "role": "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails", "shortName": "STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331_LitigationCaseAxis_AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unique": true, "unitRef": "U008", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091300 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "47", "role": "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230331_LitigationCaseAxis_AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyPendingClaimsNumber", "reportCount": 1, "unique": true, "unitRef": "U008", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20221014to20221014_BusinessAcquisitionAxis_SellersMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091400 - Disclosure - SUBSEQUENT EVENTS (Details)", "menuCat": "Details", "order": "48", "role": "http://healthiercmc.com/role/SubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230412to20230412_SubsequentEventTypeAxis_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "hcmc:NumberOfAppealsFiledInPatentInfringement", "reportCount": 1, "unique": true, "unitRef": "U010", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060100 - Disclosure - ORGANIZATION", "menuCat": "Notes", "order": "7", "role": "http://healthiercmc.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060200 - Disclosure - LIQUIDITY", "menuCat": "Notes", "order": "8", "role": "http://healthiercmc.com/role/Liquidity", "shortName": "LIQUIDITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060300 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "9", "role": "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "c20230101to20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 51, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hcmc_AccruedPaymentOfInducedConversionsOfPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for induced conversions of preferred stock that have occurred.", "label": "Accrued Payment of induced conversions of Preferred Stock", "terseLabel": "Accrued payment of induced conversions of Preferred Stock" } } }, "localname": "AccruedPaymentOfInducedConversionsOfPreferredStock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_AgeOfCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time the company has been in existence, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Age of Company", "terseLabel": "Number of years the company has been operating" } } }, "localname": "AgeOfCompany", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "durationItemType" }, "hcmc_AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alleged claimed battery defects for an electronic cigarette device.", "label": "Alleged Claimed Battery Defects For Electronic Cigarette Device [Member]" } } }, "localname": "AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_BreakagePolicyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and redemption of gift cards, rewards and points, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Breakage Policy Period", "terseLabel": "Breakage policy period" } } }, "localname": "BreakagePolicyPeriod", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "hcmc_BusinessAcquisitionGoodwillTaxDeductibleAmountAmortizationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amortization period for the amount of goodwill arising from a business combination that is deductible for tax purposes measured in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Business Acquisition, Goodwill Tax Deductible Amount Amortization Period", "terseLabel": "Amortization period for goodwill for tax purposes" } } }, "localname": "BusinessAcquisitionGoodwillTaxDeductibleAmountAmortizationPeriod", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "durationItemType" }, "hcmc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liability", "negatedLabel": "Operating lease liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of operating lease right-of-use assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right-of-use Asset", "terseLabel": "Right of use asset - operating lease" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_BusinessCombinationRevenueAndEarningsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Revenue and Earnings [Abstract]", "terseLabel": "Revenue and Earnings [Abstract]" } } }, "localname": "BusinessCombinationRevenueAndEarningsAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "hcmc_CashAndCashEquivalentsInExcessOfFDICLimitTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents in excess of FDIC limit.", "label": "Cash and Cash Equivalents in Excess of FDIC Limit [Table Text Block]", "terseLabel": "Cash and Cash Equivalents in Excess of FDIC Limit" } } }, "localname": "CashAndCashEquivalentsInExcessOfFDICLimitTableTextBlock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "hcmc_CashAndCashEquivalentsInExcessOfFDICLimitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents in Excess of FDIC Limits [Abstract]", "terseLabel": "Cash and Cash Equivalents in Excess of FDIC Limits [Abstract]" } } }, "localname": "CashAndCashEquivalentsInExcessOfFDICLimitsAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "hcmc_ChangeInFairValueOfContingentConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Fair Value of Contingent Consideration [Abstract]", "terseLabel": "Change in Fair Value of Contingent Consideration [Abstract]" } } }, "localname": "ChangeInFairValueOfContingentConsiderationAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "hcmc_CommonShareEquivalentsExcludedFromCalculationOfDilutiveLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract]", "terseLabel": "Common Share Equivalents Excluded from Calculation of Dilutive Loss Per Share [Abstract]" } } }, "localname": "CommonShareEquivalentsExcludedFromCalculationOfDilutiveLossPerShareAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "hcmc_CompanyOrganizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Company Organization [Abstract]" } } }, "localname": "CompanyOrganizationAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "hcmc_ConcentrationOfDepositsNumberOfFinancialInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of financial institutions in which company concentrates its cash and cash equivalent deposits.", "label": "Concentration of Deposits, Number of Financial Institutions", "terseLabel": "Number of financial institution" } } }, "localname": "ConcentrationOfDepositsNumberOfFinancialInstitutions", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails" ], "xbrltype": "integerItemType" }, "hcmc_ContractLiabilitiesExpectedRecognitionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period in which contract liabilities is expected to be recognized, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Contract Liabilities Expected Recognition Period", "terseLabel": "Contract liabilities expected recognition period" } } }, "localname": "ContractLiabilitiesExpectedRecognitionPeriod", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "hcmc_ContractWithCustomerAssetAndLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Text Block]", "verboseLabel": "CONTRACT LIABILITIES" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTextBlock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilities" ], "xbrltype": "textBlockItemType" }, "hcmc_ContractWithCustomerLiabilityBreakageRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Breakage Recognized", "terseLabel": "Breakage recognized" } } }, "localname": "ContractWithCustomerLiabilityBreakageRecognized", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ContractWithCustomerLiabilityFulfillmentOfContract": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost associated with fulfillment of contract with customer.", "label": "Contract with Customer, Liability, Fulfillment of Contract", "negatedLabel": "Fulfillment of contract" } } }, "localname": "ContractWithCustomerLiabilityFulfillmentOfContract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ContractWithCustomerLiabilityIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gift cards and loyalty rewards issued as obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability, Issued", "terseLabel": "Issued" } } }, "localname": "ContractWithCustomerLiabilityIssued", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ContractWithCustomerLiabilityRedeemed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense from redemption of gift cards and loyalty rewards in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Liability, Redeemed", "negatedLabel": "Redeemed" } } }, "localname": "ContractWithCustomerLiabilityRedeemed", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ConvertiblePreferredStockConvertedToOtherSecuritiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of convertible preferred stock that were converted to other securities.", "label": "Convertible Preferred Stock Converted to Other Securities, Shares", "terseLabel": "Series E convertible preferred stock redeemed (in shares)" } } }, "localname": "ConvertiblePreferredStockConvertedToOtherSecuritiesShares", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_DisplaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Displays [Member]", "terseLabel": "Displays [Member]" } } }, "localname": "DisplaysMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "hcmc_EmployeesAndExecutiveOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and Persons with designation of chief executive officer, chief operating officer and chief financial officer.", "label": "Employees and Executive Officers [Member]" } } }, "localname": "EmployeesAndExecutiveOfficersMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_ExchangeAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exchange Agreement [Abstract]", "terseLabel": "Exchange Agreement [Abstract]" } } }, "localname": "ExchangeAgreementAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "hcmc_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_FoodServiceAndRestaurantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to food service and restaurants stores that sell vapor products.", "label": "Food Service and Restaurant [Member]", "verboseLabel": "Food Service/Restaurant [Member]" } } }, "localname": "FoodServiceAndRestaurantMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GiftCardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to product of gift cards.", "label": "Gift Cards [Member]", "terseLabel": "Gift Cards [Member]" } } }, "localname": "GiftCardsMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GreenSNaturalFoodsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An organic and natural health food grocery store company.", "label": "Green's Natural Foods [Member]", "terseLabel": "Green's Natural Foods [Member]", "verboseLabel": "Greens Natural Foods' [Member]" } } }, "localname": "GreenSNaturalFoodsMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "hcmc_GroceryLoyaltyRewardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to product of the grocery loyalty rewards.", "label": "Grocery Loyalty Rewards [Member]", "terseLabel": "Grocery Loyalty Rewards [Member]" } } }, "localname": "GroceryLoyaltyRewardsMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GroceryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A grocer is a bulk seller of food and products.", "label": "Grocery [Member]", "terseLabel": "Grocery [Member]" } } }, "localname": "GroceryMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails": { "order": 0.0, "parentTag": "us-gaap_ProceedsFromIssuanceOfCommonStock", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gross proceeds from the additional capital contribution to the entity.", "label": "Gross Proceeds from Issuance of Common Stock", "verboseLabel": "Gross proceeds" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_IncreaseDecreaseInLeaseLiability": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period lease liability.", "label": "Increase (Decrease) in Lease liability", "negatedLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiability", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_IncreaseDecreaseInPrepaidExpenseAndVendorDeposits": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and vendor deposits.", "label": "Increase (Decrease) in Prepaid Expense and Vendor Deposits", "negatedLabel": "Prepaid expenses and vendor deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndVendorDeposits", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_IssuanceOfCommonStockInConnectionWithCashlessExerciseOfSeriesWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with cashless exercise of Series A warrants.", "label": "Issuance Of Common Stock In Connection With Cashless Exercise Of Series A Warrants", "verboseLabel": "Issuance of common stock in connection with series E preferred stock conversion" } } }, "localname": "IssuanceOfCommonStockInConnectionWithCashlessExerciseOfSeriesWarrants", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_LiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIQUIDITY [Abstract]" } } }, "localname": "LiquidityAbstract", "nsuri": "http://healthiercmc.com/20230331", "xbrltype": "stringItemType" }, "hcmc_LiquidityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of liquidity.", "label": "Liquidity [Text Block]", "terseLabel": "LIQUIDITY" } } }, "localname": "LiquidityTextBlock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "hcmc_LossContingenciesInvestmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of investment under litigation.", "label": "Loss Contingencies, Investment Amount", "terseLabel": "Invested amount" } } }, "localname": "LossContingenciesInvestmentAmount", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_MedicalCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical costs claimed by Plaintiffs.", "label": "Medical Costs [Member]" } } }, "localname": "MedicalCostsMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_MotherEarthsStorehouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An organic and natural health food grocery store company.", "label": "Mother Earth's Storehouse [Member]", "terseLabel": "Mother Earth's Storehouse [Member]" } } }, "localname": "MotherEarthsStorehouseMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "hcmc_NotesReceivableExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The extension term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Notes Receivable, Extension Term", "terseLabel": "Extension term" } } }, "localname": "NotesReceivableExtensionTerm", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "hcmc_NotesReceivablePaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The payment term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Notes Receivable Payment Term", "terseLabel": "Payment term" } } }, "localname": "NotesReceivablePaymentTerm", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "hcmc_NumberOfAppealsFiledInPatentInfringement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of appeals filed in patent infringement during the period.", "label": "Number of Appeals Filed in Patent Infringement", "terseLabel": "Number of appeals filed in patent infringement" } } }, "localname": "NumberOfAppealsFiledInPatentInfringement", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "hcmc_NumberOfUsersApproached": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of users approached by the entity.", "label": "Number of Users Approached", "terseLabel": "Number of users approached" } } }, "localname": "NumberOfUsersApproached", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "hcmc_OfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs are those expenditures made to pay for the accounting, legal and underwriting activities associated with the issuance of securities to investors.", "label": "Offering Costs", "terseLabel": "Offering costs" } } }, "localname": "OfferingCosts", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_OfficersAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Persons with designation of chief executive officer, chief operating officer, chief financial officer and a director of the company.", "label": "Officers and Director [Member]" } } }, "localname": "OfficersAndDirectorMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_OnlineAndECommerceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the online stores and other e-commerce platforms that sell vape products.", "label": "Online and E-commerce [Member]", "verboseLabel": "Online/e-Commerce [Member]" } } }, "localname": "OnlineAndECommerceMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_OtherDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to other debt.", "label": "Other Debt [Member]", "terseLabel": "Other Debt [Member]" } } }, "localname": "OtherDebtMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "hcmc_ParadiseHealthNutritionSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A company offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items.", "label": "Paradise Health & Nutrition's [Member]", "terseLabel": "Paradise Health & Nutrition's [Member]" } } }, "localname": "ParadiseHealthNutritionSMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "hcmc_PatentInfringementLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The patent infringement litigation.", "label": "Patent Infringement Litigation [Member]", "terseLabel": "Patent Infringement Litigation [Member]" } } }, "localname": "PatentInfringementLitigationMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_PercentageOfForfeitedFromCurrentAmendedAwardAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of forfeited from current amended award agreement.", "label": "Percentage of Forfeited from Current Amended Award Agreement", "terseLabel": "Percentage of forfeited from current amended award agreement" } } }, "localname": "PercentageOfForfeitedFromCurrentAmendedAwardAgreement", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "hcmc_PercentageOfStatedValueOfPreferredStockWillBePaidToPurchaserUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of stated value of preferred stock will be paid to purchaser upon conversion.", "label": "Percentage of Stated Value of Preferred Stock will be Paid to Purchaser upon Conversion", "terseLabel": "Percentage of stated value of preferred stock will be paid to purchaser upon conversion" } } }, "localname": "PercentageOfStatedValueOfPreferredStockWillBePaidToPurchaserUponConversion", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "hcmc_PhilipMorrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the name of an entity.", "label": "Philip Morris [Member]" } } }, "localname": "PhilipMorrisMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_PreferredStockRedemptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time after closing when a holder may require the redemption of all or a portion of the stated value of the Company's Preferred Stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Preferred Stock, Redemption Period", "terseLabel": "Redemption period" } } }, "localname": "PreferredStockRedemptionPeriod", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "durationItemType" }, "hcmc_PrepaidExpenseAndVendorDepositsCurrent": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of vendor deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Vendor Deposits, Current", "terseLabel": "Prepaid expenses and vendor deposits" } } }, "localname": "PrepaidExpenseAndVendorDepositsCurrent", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hcmc_PresidentAndChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Person with designation of president and chief operating officer.", "label": "President and Chief Operating Officer [Member]", "terseLabel": "President and Chief Operating Officer [Member]" } } }, "localname": "PresidentAndChiefOperatingOfficerMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_ProceedsFromBalloonPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the balloon payment.", "label": "Proceeds from Balloon Payment", "terseLabel": "Balloon payment" } } }, "localname": "ProceedsFromBalloonPayment", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_PromissoryNotesAndSecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory notes a signed document containing a written promise to pay a stated sum to a specified person or the bearer at a specified date or on demand and Secured note is a type of loan that is backed by the borrower's assets.", "label": "Promissory Notes and Secured Notes [Member]" } } }, "localname": "PromissoryNotesAndSecuredNotesMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "hcmc_PromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory notes a signed document containing a written promise to pay a stated sum to a specified person or the bearer at a specified date or on demand.", "label": "Promissory Notes [Member]", "terseLabel": "Promissory Note [Member]" } } }, "localname": "PromissoryNotesMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/DebtDetails", "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "hcmc_RetailGroceryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A grocery retailer primarily sells food. Grocery stores also offer non-perishable foods that are packaged in bottles, boxes, and cans; some also have bakeries, butchers, delis, and fresh produce.", "label": "Retail Grocery [Member]", "terseLabel": "Retail Grocery [Member]" } } }, "localname": "RetailGroceryMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_RetailVaporMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A retail vapor outlet specializing in the selling of electronic cigarette products.", "label": "Retail Vapor [Member]", "terseLabel": "Retail Vapor [Member]" } } }, "localname": "RetailVaporMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_RightsOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Offering [Abstract]", "terseLabel": "Rights Offering [Abstract]" } } }, "localname": "RightsOfferingAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "stringItemType" }, "hcmc_ScheduleOfAccountsNotesReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of notes receivable.", "label": "Schedule Of Accounts Notes Receivable [Text Block]", "verboseLabel": "Summary of Amended Notes" } } }, "localname": "ScheduleOfAccountsNotesReceivableTextBlock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "hcmc_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents and cash and cash equivalents restricted as to withdrawal or usage.", "label": "Schedule of Cash and Cash Equivalents and Restricted Cash [Table Text Block]", "terseLabel": "Cash and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "hcmc_SellersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dean's Natural Food Market of Shrewsbury, Inc., a New Jersey corporation, Green's Natural Foods, Inc., a Delaware corporation, Dean's Natural Food Market of Chester, LLC, a New Jersey limited liability company, Dean's Natural Food Market of Basking Ridge, LLC, a New Jersey limited liability company, and Dean's Natural Food Market, Inc., a New Jersey corporation (collectively, the \"Sellers\").", "label": "Sellers [Member]", "terseLabel": "Sellers [Member]" } } }, "localname": "SellersMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "hcmc_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series D Convertible Preferred Stock [Member]", "terseLabel": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "hcmc_SeriesEConvertiblePreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series E Convertible Preferred Stock [Abstract]", "terseLabel": "Series E Convertible Preferred Stock [Abstract]" } } }, "localname": "SeriesEConvertiblePreferredStockAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "hcmc_SeriesEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series E Convertible Preferred Stock [Member]", "terseLabel": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsIncreaseInVestingPercentageFromItsOriginalAwardsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase in grants from its original award agreement, made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Grants, Increase in Vesting Percentage from its Original Awards In Period", "terseLabel": "Percentage of increase in restricted stock grants from its original award agreement to officers" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsIncreaseInVestingPercentageFromItsOriginalAwardsInPeriod", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "hcmc_SpinOffPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for spin-off.", "label": "Spin-Off [Policy Text Block]", "terseLabel": "Spin-Off" } } }, "localname": "SpinOffPolicyTextBlock", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/OrganizationPolicies" ], "xbrltype": "textBlockItemType" }, "hcmc_StockIssuedDuringPeriodSharesNewIssuesRightsOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued in connection with Rights Offering during the period.", "label": "Stock Issued During Period, Shares, New Issues, Rights Offering", "terseLabel": "Issuance of common stock in connection with the Rights Offering, net of offering expenses (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesRightsOffering", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_StockIssuedDuringPeriodValueNewIssuesRightsOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period in connection with Rights Offering.", "label": "Stock Issued During Period, Value, New Issues, Rights Offering", "terseLabel": "Issuance of common stock in connection with the Rights Offering, net of offering expenses" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesRightsOffering", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hcmc_SubsequentEventAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Event [Abstract]", "terseLabel": "Subsequent Event [Abstract]" } } }, "localname": "SubsequentEventAbstract", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hcmc_TemporaryEquityConversionOfConvertiblePreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of convertible preferred stock converted during the period.", "label": "Temporary Equity, Conversion of Convertible Preferred Stock, Shares", "negatedLabel": "Conversion of series E convertible preferred stock (in shares)" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockShares", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_TemporaryEquityConversionOfConvertiblePreferredStockValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of convertible preferred stock converted during the period.", "label": "Temporary Equity, Conversion of Convertible Preferred Stock, Value", "negatedLabel": "Conversion of series E convertible preferred stock" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockValue", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hcmc_TemporaryEquityConvertiblePreferredStockRedeemedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of convertible preferred stock redeemed during the period.", "label": "Temporary Equity, Convertible Preferred Stock Redeemed, Shares", "negatedLabel": "Series E convertible preferred stock redeemed (in shares)" } } }, "localname": "TemporaryEquityConvertiblePreferredStockRedeemedShares", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_TemporaryEquityConvertiblePreferredStockRedeemedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of convertible preferred stock redeemed during the period.", "label": "Temporary Equity, Convertible Preferred Stock Redeemed, Value", "negatedLabel": "Series E convertible preferred stock redeemed" } } }, "localname": "TemporaryEquityConvertiblePreferredStockRedeemedValue", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hcmc_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Series E Convertible Preferred stock in connection with the Securities Purchase Agreement, net of offering costs (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_TermLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "On August 18, 2020, the Company agreed to a term loan and security agreement (the \"Loan\") with Sabby Healthcare Master Fund, LTD and Sabby Volatility Warrant Master Fund, LTD (\"collectively, the Lender\").", "label": "Term Loan and Security Agreement [Member]", "terseLabel": "Loan and Security Agreement [Member]" } } }, "localname": "TermLoanAndSecurityAgreementMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_TwoThousandAndFifteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fifteen equity incentive plan is an arrangement where employees own a percentage of their company's shares so that they make money when the company makes a profit.", "label": "Two Thousand and Fifteen Equity Incentive Plan [Member]", "terseLabel": "2015 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndFifteenEquityIncentivePlanMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_VapeStoresDisposalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Includes equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities, additions or improvements to assets held under a lease arrangement, and long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Vape Stores' Disposal [Member]", "terseLabel": "Vape Stores' Disposal [Member]" } } }, "localname": "VapeStoresDisposalsMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "hcmc_VaporLoyaltyRewardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to product of the vapor loyalty rewards.", "label": "Vapor Loyalty Rewards [Member]", "terseLabel": "Vapor Loyalty Rewards [Member]" } } }, "localname": "VaporLoyaltyRewardsMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_VaporMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to a substance diffused or suspended in the air, especially one normally liquid or solid.", "label": "Vapor [Member]", "terseLabel": "Vapor [Member]" } } }, "localname": "VaporMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_WeightedAverageDiscountedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average discounted interest rate.", "label": "Weighted Average Discounted Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "WeightedAverageDiscountedInterestRate", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "percentItemType" }, "hcmc_WholesaleGroceryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A person that is a dealer primarily engaged in the full-line wholesale distribution and resale of grocery and related nonfood items.", "label": "Wholesale Grocery [Member]", "terseLabel": "Wholesale Grocery [Member]" } } }, "localname": "WholesaleGroceryMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_WholesaleVaporMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A person that is a dealer primarily engaged in the full-line wholesale distribution of vape products.", "label": "Wholesale Vapor [Member]", "terseLabel": "Wholesale Vapor [Member]" } } }, "localname": "WholesaleVaporMember", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of working capital (deficit) as of the balance sheet date. Working capital represents the money available to meet current, short-term obligations.", "label": "Working Capital (Deficit)", "terseLabel": "Working capital" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://healthiercmc.com/20230331", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "verboseLabel": "Board Member [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [ "r511", "r560" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r172", "r207", "r218", "r219", "r220", "r221", "r222", "r224", "r227", "r264", "r265", "r266", "r267", "r269", "r270", "r272", "r274", "r275", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r172", "r207", "r218", "r219", "r220", "r221", "r222", "r224", "r227", "r264", "r265", "r266", "r267", "r269", "r270", "r272", "r274", "r275", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r170", "r171", "r280", "r309", "r450", "r452" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r260", "r261", "r262", "r263", "r346", "r418", "r428", "r446", "r447", "r462", "r475", "r479", "r526", "r563", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r260", "r261", "r262", "r263", "r346", "r418", "r428", "r446", "r447", "r462", "r475", "r479", "r526", "r563", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "label": "Officers [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r228", "r420", "r463", "r478", "r521", "r522", "r529", "r569" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r228", "r420", "r463", "r478", "r521", "r522", "r529", "r569" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r260", "r261", "r262", "r263", "r339", "r346", "r371", "r372", "r373", "r417", "r418", "r428", "r446", "r447", "r462", "r475", "r479", "r517", "r526", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r260", "r261", "r262", "r263", "r339", "r346", "r371", "r372", "r373", "r417", "r418", "r428", "r446", "r447", "r462", "r475", "r479", "r517", "r526", "r564", "r565", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r170", "r171", "r280", "r309", "r451", "r452" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r173", "r174", "r175", "r183", "r184", "r200", "r392", "r393", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Reclassification, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r134", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r200", "r236", "r237", "r379", "r391", "r392", "r393", "r394", "r405", "r409", "r410", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r134", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r200", "r236", "r237", "r379", "r391", "r392", "r393", "r394", "r405", "r409", "r410", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r511", "r560" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r232", "r233" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r66", "r141" ], "calculation": { "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r8", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r375", "r376", "r377", "r498", "r499", "r500", "r558" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r42", "r57", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from computation of diluted loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r125", "r145", "r169", "r215", "r220", "r226", "r234", "r264", "r265", "r267", "r268", "r269", "r271", "r273", "r275", "r276", "r386", "r388", "r396", "r477", "r524", "r525", "r561" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r138", "r152", "r169", "r234", "r264", "r265", "r267", "r268", "r269", "r271", "r273", "r275", "r276", "r386", "r388", "r396", "r477", "r524", "r525", "r561" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r382", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r92", "r93", "r382", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Abstract]", "terseLabel": "Pro Forma Information [Abstract]" } } }, "localname": "BusinessAcquisitionProFormaInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Supplemental Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r380", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r380", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Sales" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACQUISITIONS [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r102", "r103", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Cash Consideration paid", "verboseLabel": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r385", "r492" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Change in contingent consideration", "verboseLabel": "Remeasurement" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r101", "r104" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Contingent consideration", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r106", "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "ACQUISITION" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/Acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]", "terseLabel": "Finite-Lived Intangible Assets [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r94", "r95" ], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r94", "r95" ], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r95" ], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r94", "r95" ], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]", "terseLabel": "Purchase Price Allocation [Abstract]" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r95" ], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Acquisitions [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r439", "r440", "r477", "r489" ], "calculation": { "http://healthiercmc.com/role/ConcentrationsDetails": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r39", "r44", "r46" ], "calculation": { "http://healthiercmc.com/role/ConcentrationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND RESTRICTED CASH - END OF PERIOD", "periodStartLabel": "CASH AND RESTRICTED CASH - BEGINNING OF PERIOD", "totalLabel": "Total cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash and Restricted Cash [Abstract]" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r39", "r108" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET DECREASE IN CASH AND RESTRICTED CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Contract Liabilities Activity [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r147", "r148", "r149", "r169", "r192", "r193", "r196", "r198", "r203", "r204", "r234", "r264", "r267", "r268", "r269", "r275", "r276", "r306", "r307", "r311", "r315", "r322", "r396", "r448", "r487", "r495", "r508" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r118", "r131" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES (SEE NOTE 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r69", "r257", "r258", "r442", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r498", "r499", "r558" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 346,441,632,384 and 339,741,632,384 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Hardware & Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "CONCENTRATIONS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONTRACT LIABILITIES [Abstract]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Net Changes in Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r324", "r325", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance as of March 31,", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Abstract]" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r324", "r325", "r336" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of convertible preferred stock that was converted to other securities.", "label": "Convertible Preferred Stock Converted to Other Securities", "negatedLabel": "Series E convertible preferred stock redeemed" } } }, "localname": "ConvertiblePreferredStockConvertedToOtherSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r306", "r307", "r311" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r53", "r219", "r220", "r221", "r222", "r227", "r510" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r25", "r420" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DEBT [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r74", "r166", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r293", "r300", "r301", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r113", "r114", "r123", "r172", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r404", "r457", "r458", "r459", "r460", "r461", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r110", "r111", "r277", "r404", "r458", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r17", "r172", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r404", "r457", "r458", "r459", "r460", "r461", "r496" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r17", "r81", "r85", "r86", "r87", "r109", "r110", "r111", "r122", "r172", "r277", "r278", "r279", "r280", "r281", "r283", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r302", "r404", "r457", "r458", "r459", "r460", "r461", "r496" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Increment percentage on salary each subsequent year" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r42", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r42", "r64" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r153" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivative liabilities, warrants" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r335", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregated Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r159", "r178", "r179", "r181", "r182", "r183", "r189", "r192", "r196", "r197", "r198", "r200", "r393", "r394", "r425", "r427", "r453" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "NET LOSS PER SHARE-BASIC (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r159", "r178", "r179", "r181", "r182", "r183", "r192", "r196", "r197", "r198", "r200", "r393", "r394", "r425", "r427", "r453" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "NET LOSS PER SHARE-DILUTED (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation Expense Recognized [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r80", "r133", "r156", "r157", "r158", "r173", "r174", "r175", "r177", "r184", "r187", "r202", "r235", "r323", "r375", "r376", "r377", "r378", "r379", "r392", "r397", "r398", "r399", "r400", "r401", "r402", "r410", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesRestrictedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock [Abstract]" } } }, "localname": "EquitySecuritiesRestrictedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r291", "r340", "r341", "r342", "r343", "r344", "r345", "r395", "r414", "r415", "r416", "r458", "r459", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r291", "r340", "r341", "r342", "r343", "r344", "r345", "r395", "r416", "r458", "r459", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Market Value - Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r291", "r340", "r341", "r342", "r343", "r344", "r345", "r414", "r415", "r416", "r458", "r459", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful lives", "terseLabel": "Amortization period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r143", "r252" ], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r62" ], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "2023 (remaining nine months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r62" ], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r62" ], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r62" ], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r250", "r251", "r252", "r253", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Future Annual Estimated Amortization Expense [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r60", "r422" ], "calculation": { "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r60", "r421" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net of accumulated amortization", "totalLabel": "Net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/IntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails", "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r26", "r55", "r486" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Loss (gain) on investment", "terseLabel": "(Loss) gain on investment" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r42", "r72", "r73" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on extinguishment of debt", "negatedLabel": "Net gain on debt settlements", "terseLabel": "Gain on debt settlements" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r142", "r240", "r423", "r456", "r477", "r514", "r515" ], "calculation": { "http://healthiercmc.com/role/AcquisitionDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r24", "r169", "r215", "r219", "r225", "r227", "r234", "r264", "r265", "r267", "r268", "r269", "r271", "r273", "r275", "r276", "r396", "r455", "r524" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r493", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income tax" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r41" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r41" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r492" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r419", "r492" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r41" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "terseLabel": "Changes in operating assets, inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r492" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r492" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r41" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Convertible Preferred Stock [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r28", "r297", "r305", "r460", "r461" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Accrued interest on loan" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r120" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r161", "r163", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternetDomainNamesMember": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.", "label": "Internet Domain Names [Member]", "terseLabel": "Website [Member]" } } }, "localname": "InternetDomainNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r150", "r449", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r239" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Write-down of obsolete and slow-moving inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r169", "r234", "r264", "r265", "r267", "r268", "r269", "r271", "r273", "r275", "r276", "r387", "r388", "r389", "r396", "r454", "r524", "r561", "r562" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r115", "r129", "r477", "r497", "r513", "r559" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r139", "r169", "r234", "r264", "r265", "r267", "r268", "r269", "r271", "r273", "r275", "r276", "r387", "r388", "r389", "r396", "r477", "r524", "r561", "r562" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r2", "r113" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Attorney fees paid" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "NOTES RECEIVABLE AND OTHER INCOME" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Current portion of loan payment" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r4", "r114", "r127", "r290", "r304", "r458", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, by Current and Noncurrent [Abstract]", "terseLabel": "Debt [Abstract]" } } }, "localname": "LongTermDebtByCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r17" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loan payable, net of current portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r70", "r71", "r259", "r260", "r261", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r70", "r71", "r259", "r260", "r261", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r518", "r519", "r520" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency, Information about Litigation Matters [Abstract]", "terseLabel": "Legal Proceedings [Abstract]" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r70", "r71", "r259", "r260", "r261", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of lawsuits" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r162" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r162" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r39", "r40", "r43" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r23", "r43", "r119", "r132", "r137", "r154", "r155", "r158", "r169", "r176", "r178", "r179", "r181", "r182", "r186", "r187", "r194", "r215", "r219", "r225", "r227", "r234", "r264", "r265", "r267", "r268", "r269", "r271", "r273", "r275", "r276", "r394", "r396", "r455", "r524" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r178", "r179", "r181", "r182", "r189", "r190", "r195", "r198", "r215", "r219", "r225", "r227", "r455" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashMergerRelatedCosts": { "auth_ref": [ "r42" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.", "label": "Acquisition non cash expense" } } }, "localname": "NoncashMergerRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Non-Compete Agreement [Member]", "verboseLabel": "Non-Compete [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r232", "r233", "r424" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.", "label": "Notes receivable" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Note receivable" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankNoncurrent": { "auth_ref": [ "r4", "r114", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount due within more than 12 month, or the operating cycle if longer, on all notes payable to banks paid on an installment. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Notes Payable to Bank, Noncurrent", "terseLabel": "Promissory note" } } }, "localname": "NotesPayableToBankNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStores": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of stores.", "label": "Number of Stores", "terseLabel": "Number of stores" } } }, "localname": "NumberOfStores", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r215", "r219", "r225", "r227", "r455" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total loss", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r407" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r407" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r406" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset - operating lease, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r493" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r222", "r227" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r151", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r144" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherMachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.", "label": "Other Machinery and Equipment [Member]", "verboseLabel": "Other [Member]" } } }, "localname": "OtherMachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r36" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.", "label": "Payment of induced conversions of Preferred Stock", "negatedLabel": "Payment of induced conversions of preferred stock" } } }, "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock": { "auth_ref": [ "r36" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for reacquisition of callable preferred stock.", "label": "Payments for Repurchase of Redeemable Preferred Stock", "negatedLabel": "Payment for series E preferred stock redemption" } } }, "localname": "PaymentsForRepurchaseOfRedeemablePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r38" ], "calculation": { "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails": { "order": 1.0, "parentTag": "us-gaap_ProceedsFromIssuanceOfCommonStock", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Direct financing costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r32", "r384" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedLabel": "Acquisition of Mother Earth's Storehouse", "terseLabel": "Cash purchase price" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r33" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireNotesReceivable": { "auth_ref": [ "r31" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Payments to Acquire Notes Receivable", "negatedLabel": "Issuance of note receivable" } } }, "localname": "PaymentsToAcquireNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r33" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConversionsInducements": { "auth_ref": [ "r201" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.", "label": "Preferred Stock Conversions, Inducements", "negatedLabel": "Induced conversions of Preferred Stock" } } }, "localname": "PreferredStockConversionsInducements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionRatio": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.", "label": "Conversion rate" } } }, "localname": "PreferredStockConvertibleConversionRatio", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "pureItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r6", "r81", "r82", "r495", "r527" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Liquidation preference (in dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r167", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock, Liquidation Preference, Value", "verboseLabel": "Series D convertible preferred stock, aggregate liquidation preference" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r306" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, stated value (in dollars per share)", "verboseLabel": "Series D convertible preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r79", "r81", "r83" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Conversion price (in dollars per share)" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Series D convertible preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6", "r306" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Number of preferred shares sold and issued (in shares)", "verboseLabel": "Series D convertible preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Series D convertible preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesSubscribedButUnissuedValue": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription received from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.", "label": "Aggregate subscription price" } } }, "localname": "PreferredStockSharesSubscribedButUnissuedValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Series D convertible preferred stock, $1,000 par value per share, 5,000 shares authorized; 800 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $0.8 million" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prior Period Adjustment [Abstract]", "terseLabel": "Reclassification [Abstract]" } } }, "localname": "PriorPeriodAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r34" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from Rights Offering", "totalLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r34" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r35", "r496" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r35" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from loan and security agreement" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfNotesReceivable": { "auth_ref": [ "r30" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.", "label": "Collection of note receivable", "terseLabel": "Proceeds" } } }, "localname": "ProceedsFromSaleOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r34", "r91" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT, AND EQUIPMENT [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r68", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY, PLANT, AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r65", "r140" ], "calculation": { "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r67", "r130", "r426", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant, and equipment, net of accumulated depreciation", "totalLabel": "Total property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r160", "r238" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r110", "r404" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "terseLabel": "Interest rate" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReceivableWithImputedInterestFaceAmount": { "auth_ref": [ "r110", "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The principal amount of the receivable or note before consideration of the discount or premium.", "label": "Receivable with Imputed Interest, Face Amount", "terseLabel": "Loan amount" } } }, "localname": "ReceivableWithImputedInterestFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableWithImputedInterestNetAmount": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The receivable or note face amount less the unamortized discount or premium.", "label": "Remaining balance" } } }, "localname": "ReceivableWithImputedInterestNetAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES RECEIVABLE AND OTHER INCOME [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesWithImputedInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables with Imputed Interest [Abstract]" } } }, "localname": "ReceivablesWithImputedInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification [Line Items]" } } }, "localname": "ReclassificationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationTable": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification [Table]" } } }, "localname": "ReclassificationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r37", "r496" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Principal payment on the line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r37" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedLabel": "Principal payments on loan payable" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r489", "r494" ], "calculation": { "http://healthiercmc.com/role/ConcentrationsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r441", "r490", "r494" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r88", "r128", "r433", "r438", "r477" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r133", "r173", "r174", "r175", "r177", "r184", "r187", "r235", "r375", "r376", "r377", "r378", "r379", "r392", "r429", "r431" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DISAGGREGATION OF REVENUES [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r206", "r207", "r218", "r223", "r224", "r228", "r229", "r230", "r334", "r335", "r420" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "SALES, NET", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "SEGMENT INFORMATION AND DISAGGREGATION OF REVENUES" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SALES" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Line of Credit [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r408", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATIONS [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Base salary" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Common Share Equivalent Excluded from Calculation of Dilutive Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Change in Fair Value of Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r92", "r93", "r382" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails", "http://healthiercmc.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Purchase Price Allocation for Mother Earth's Storehouse, Inc." } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Breakdown of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r58", "r59", "r421" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Intangible Assets, Net" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r50", "r51", "r52", "r56" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r75", "r77", "r78", "r81", "r82", "r84", "r85", "r86", "r87", "r88", "r147", "r148", "r149", "r203", "r306", "r307", "r309", "r311", "r315", "r320", "r322", "r462", "r487", "r495" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Future Annual Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r255", "r256", "r456", "r569" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]", "terseLabel": "Segment Information [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r41" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/StockholdersEquityStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Common stock available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vesting on February 1, 2024 [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Last Day of Each Calendar Quarter Thereafter Through September 30, 2025 [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Stock vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Common stock at a price per share (in dollars per share)", "terseLabel": "Subscription price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r116", "r117", "r124", "r491" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Investment" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r47", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/BasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r136", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r254", "r255", "r256", "r456", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SegmentInformationAndDisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r147", "r148", "r149", "r169", "r192", "r193", "r196", "r198", "r203", "r204", "r234", "r264", "r267", "r268", "r269", "r275", "r276", "r306", "r307", "r311", "r315", "r322", "r396", "r448", "r487", "r495", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r80", "r133", "r156", "r157", "r158", "r173", "r174", "r175", "r177", "r184", "r187", "r202", "r235", "r323", "r375", "r376", "r377", "r378", "r379", "r392", "r397", "r398", "r399", "r400", "r401", "r402", "r410", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r173", "r174", "r175", "r202", "r420" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r20", "r80", "r81", "r88", "r294" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of series E convertible preferred stock (in shares)", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r80", "r88" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock shares issued from offering (in shares)", "terseLabel": "Issuance of common stock in connection with cashless exercise of Series A warrants (in shares)", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r6", "r7", "r80", "r88" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedLabel": "Cancellation of awarded stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r80", "r88" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Issuance of awarded stock for officers and board member (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r6", "r7", "r80", "r88", "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r21", "r80", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of series E convertible preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r80", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Indebtedness aggregate amount", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementAndRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r6", "r7", "r80", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures", "negatedLabel": "Cancellation of awarded stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r6", "r7", "r80", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Issuance of awarded stock for officers and board member" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r21", "r80", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock redeemed (in shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock redeemed" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized repurchase of common stock" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r54", "r477", "r497", "r513", "r559" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r89", "r168", "r307", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r323", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r403", "r412" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r403", "r412" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r403", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r403", "r412" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity [Abstract]", "verboseLabel": "CONVERTIBLE PREFERRED STOCK" } } }, "localname": "TemporaryEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets", "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r264", "r267", "r268", "r269", "r275", "r276" ], "calculation": { "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Series E redeemable convertible preferred stock, $1,000 par value per share, 14,722 shares authorized, 13,497 shares and 14,722 share issued and outstanding as of March 31, 2023 and December 31, 2022; aggregate liquidation preference of $13.5 million and $14.7 million as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r19", "r169", "r234", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Series E convertible preferred stock, aggregate liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r1", "r76" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Series E convertible preferred stock, par value (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Series E convertible preferred stock, authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Series E convertible preferred stock, issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Series E convertible preferred stock, outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Series E Convertible Preferred stock in connection with the Securities Purchase Agreement, net of offering costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.", "label": "Total Cash in excess of FDIC limits of $250,000" } } }, "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/ConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/IntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks [Member]" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/AcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r191", "r198" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-DILUTED (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r189", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthiercmc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=122038299&loc=d3e42851-122695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 68 0000844856-23-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000844856-23-000016-xbrl.zip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